43 CFR 3815.8 - Notation required in application for patent; conditions required in patent.

Code of Federal Regulations, 2013 CFR

2013-10-01

... patent; conditions required in patent. 3815.8 Section 3815.8 Public Lands: Interior Regulations Relating... Notation required in application for patent; conditions required in patent. (a) Every application for patent for any minerals located subject to this Act must bear on its face, before being executed by the...

43 CFR 3863.1-1 - Application for patent.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Application for patent. 3863.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-1 Application for patent. ...

43 CFR 3863.1-1 - Application for patent.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Application for patent. 3863.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-1 Application for patent. ...

43 CFR 3863.1-1 - Application for patent.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Application for patent. 3863.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-1 Application for patent. ...

43 CFR 3863.1-1 - Application for patent.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Application for patent. 3863.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-1 Application for patent. ...

43 CFR 3862.1-1 - Application for patent.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Application for patent. 3862.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.1-1 Application for patent. (a) At the time the proof of posting is...

43 CFR 3862.1-1 - Application for patent.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Application for patent. 3862.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.1-1 Application for patent. (a) At the time the proof of posting is...

43 CFR 3862.1-1 - Application for patent.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Application for patent. 3862.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.1-1 Application for patent. (a) At the time the proof of posting is...

37 CFR 1.33 - Correspondence respecting patent applications, patent reexamination proceedings, and other...

Code of Federal Regulations, 2014 CFR

2014-07-01

... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Correspondence respecting patent applications, patent reexamination proceedings, and other proceedings. 1.33 Section 1.33 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF...

37 CFR 1.33 - Correspondence respecting patent applications, patent reexamination proceedings, and other...

Code of Federal Regulations, 2013 CFR

2013-07-01

... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Correspondence respecting patent applications, patent reexamination proceedings, and other proceedings. 1.33 Section 1.33 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF...

43 CFR 3864.1-1 - Application for patent.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Application for patent. 3864.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1-1 Application for patent. (a) Land entered as a millsite must be shown to be nonmineral...

43 CFR 3864.1-1 - Application for patent.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Application for patent. 3864.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1-1 Application for patent. (a) Land entered as a millsite must be shown to be nonmineral...

43 CFR 3864.1-1 - Application for patent.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Application for patent. 3864.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1-1 Application for patent. (a) Land entered as a millsite must be shown to be nonmineral...

43 CFR 3864.1-1 - Application for patent.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Application for patent. 3864.1-1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1-1 Application for patent. (a) Land entered as a millsite must be shown to be nonmineral...

Trends in worldwide nanotechnology patent applications: 1991 to 2008

NASA Astrophysics Data System (ADS)

Dang, Yan; Zhang, Yulei; Fan, Li; Chen, Hsinchun; Roco, Mihail C.

2010-03-01

Nanotechnology patent applications published during 1991-2008 have been examined using the "title-abstract" keyword search on esp@cenet "worldwide" database. The longitudinal evolution of the number of patent applications, their topics, and their respective patent families have been evaluated for 15 national patent offices covering 98% of the total global activity. The patent offices of the United States (USA), People's Republic of China (PRC), Japan, and South Korea have published the largest number of nanotechnology patent applications, and experienced significant but different growth rates after 2000. In most repositories, the largest numbers of nanotechnology patent applications originated from their own countries/regions, indicating a significant "home advantage." The top applicant institutions are from different sectors in different countries (e.g., from industry in the US and Canada patent offices, and from academe or government agencies at the PRC office). As compared to 2000, the year before the establishment of the US National Nanotechnology Initiative (NNI), numerous new invention topics appeared in 2008, in all 15 patent repositories. This is more pronounced in the USA and PRC. Patent families have increased among the 15 patent offices, particularly after 2005. Overlapping patent applications increased from none in 1991 to about 4% in 2000 and to about 27% in 2008. The largest share of equivalent nanotechnology patent applications (1,258) between two repositories was identified between the US and Japan patent offices.

Trends in worldwide nanotechnology patent applications: 1991 to 2008.

PubMed

Dang, Yan; Zhang, Yulei; Fan, Li; Chen, Hsinchun; Roco, Mihail C

2010-03-01

Nanotechnology patent applications published during 1991-2008 have been examined using the "title-abstract" keyword search on esp@cenet "worldwide" database. The longitudinal evolution of the number of patent applications, their topics, and their respective patent families have been evaluated for 15 national patent offices covering 98% of the total global activity. The patent offices of the United States (USA), People's Republic of China (PRC), Japan, and South Korea have published the largest number of nanotechnology patent applications, and experienced significant but different growth rates after 2000. In most repositories, the largest numbers of nanotechnology patent applications originated from their own countries/regions, indicating a significant "home advantage." The top applicant institutions are from different sectors in different countries (e.g., from industry in the US and Canada patent offices, and from academe or government agencies at the PRC office). As compared to 2000, the year before the establishment of the US National Nanotechnology Initiative (NNI), numerous new invention topics appeared in 2008, in all 15 patent repositories. This is more pronounced in the USA and PRC. Patent families have increased among the 15 patent offices, particularly after 2005. Overlapping patent applications increased from none in 1991 to about 4% in 2000 and to about 27% in 2008. The largest share of equivalent nanotechnology patent applications (1,258) between two repositories was identified between the US and Japan patent offices.

43 CFR 3862.1 - Lode claim patent applications: General.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Lode claim patent applications: General... LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.1 Lode claim patent applications: General. ...

43 CFR 3862.1 - Lode claim patent applications: General.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Lode claim patent applications: General... LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.1 Lode claim patent applications: General. ...

43 CFR 3862.1 - Lode claim patent applications: General.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Lode claim patent applications: General... LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.1 Lode claim patent applications: General. ...

43 CFR 3862.1 - Lode claim patent applications: General.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Lode claim patent applications: General... LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.1 Lode claim patent applications: General. ...

37 CFR 1.215 - Patent application publication.

Code of Federal Regulations, 2012 CFR

2012-07-01

... 37 Patents, Trademarks, and Copyrights 1 2012-07-01 2012-07-01 false Patent application publication. 1.215 Section 1.215 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Publication...

37 CFR 1.215 - Patent application publication.

Code of Federal Regulations, 2014 CFR

2014-07-01

... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Patent application publication. 1.215 Section 1.215 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Publication...

37 CFR 1.215 - Patent application publication.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent application publication. 1.215 Section 1.215 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Publication...

Trends in worldwide nanotechnology patent applications: 1991 to 2008

PubMed Central

Zhang, Yulei; Fan, Li; Chen, Hsinchun; Roco, Mihail C.

2009-01-01

Nanotechnology patent applications published during 1991–2008 have been examined using the “title–abstract” keyword search on esp@cenet “worldwide” database. The longitudinal evolution of the number of patent applications, their topics, and their respective patent families have been evaluated for 15 national patent offices covering 98% of the total global activity. The patent offices of the United States (USA), People’s Republic of China (PRC), Japan, and South Korea have published the largest number of nanotechnology patent applications, and experienced significant but different growth rates after 2000. In most repositories, the largest numbers of nanotechnology patent applications originated from their own countries/regions, indicating a significant “home advantage.” The top applicant institutions are from different sectors in different countries (e.g., from industry in the US and Canada patent offices, and from academe or government agencies at the PRC office). As compared to 2000, the year before the establishment of the US National Nanotechnology Initiative (NNI), numerous new invention topics appeared in 2008, in all 15 patent repositories. This is more pronounced in the USA and PRC. Patent families have increased among the 15 patent offices, particularly after 2005. Overlapping patent applications increased from none in 1991 to about 4% in 2000 and to about 27% in 2008. The largest share of equivalent nanotechnology patent applications (1,258) between two repositories was identified between the US and Japan patent offices. PMID:21170123

37 CFR 1.41 - Applicant for patent.

Code of Federal Regulations, 2011 CFR

2011-07-01

... 37 Patents, Trademarks, and Copyrights 1 2011-07-01 2011-07-01 false Applicant for patent. 1.41 Section 1.41 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for A...

37 CFR 1.41 - Applicant for patent.

Code of Federal Regulations, 2012 CFR

2012-07-01

... 37 Patents, Trademarks, and Copyrights 1 2012-07-01 2012-07-01 false Applicant for patent. 1.41 Section 1.41 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for A...

37 CFR 1.42 - Applicant for patent.

Code of Federal Regulations, 2014 CFR

2014-07-01

... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Applicant for patent. 1.42 Section 1.42 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for A...

37 CFR 1.42 - Applicant for patent.

Code of Federal Regulations, 2013 CFR

2013-07-01

... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Applicant for patent. 1.42 Section 1.42 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for A...

37 CFR 1.14 - Patent applications preserved in confidence.

Code of Federal Regulations, 2010 CFR

2010-07-01

... section. (1) Records associated with patent applications (see paragraph (g) for international applications... invention registration, a U.S. patent application publication, or an international patent application publication of an international application that was published in accordance with PCT Article 21(2). An...

37 CFR 1.81 - Drawings required in patent application.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Drawings required in patent..., DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions The Drawings § 1.81 Drawings required in patent application. (a) The applicant for a patent is required to furnish...

Trends in genetic patent applications: the commercialization of academic intellectual property.

PubMed

Kers, Jannigje G; Van Burg, Elco; Stoop, Tom; Cornel, Martina C

2014-10-01

We studied trends in genetic patent applications in order to identify the trends in the commercialization of research findings in genetics. To define genetic patent applications, the European version (ECLA) of the International Patent Classification (IPC) codes was used. Genetic patent applications data from the PATSTAT database from 1990 until 2009 were analyzed for time trends and regional distribution. Overall, the number of patent applications has been growing. In 2009, 152 000 patent applications were submitted under the Patent Cooperation Treaty (PCT) and within the EP (European Patent) system of the European Patent Office (EPO). The number of genetic patent applications increased until a peak was reached in the year 2000, with >8000 applications, after which it declined by almost 50%. Continents show different patterns over time, with the global peak in 2000 mainly explained by the USA and Europe, while Asia shows a stable number of >1000 per year. Nine countries together account for 98.9% of the total number of genetic patent applications. In The Netherlands, 26.7% of the genetic patent applications originate from public research institutions. After the year 2000, the number of genetic patent applications dropped significantly. Academic leadership and policy as well as patent regulations seem to have an important role in the trend differences. The ongoing investment in genetic research in the past decade is not reflected by an increase of patent applications.

37 CFR 1.178 - Original patent; continuing duty of applicant.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Original patent; continuing... Provisions Reissues § 1.178 Original patent; continuing duty of applicant. (a) The application for reissue of... upon reissue of the patent. Until a reissue application is granted, the original patent shall remain in...

Trends in genetic patent applications: the commercialization of academic intellectual property

PubMed Central

Kers, Jannigje G; Van Burg, Elco; Stoop, Tom; Cornel, Martina C

2014-01-01

We studied trends in genetic patent applications in order to identify the trends in the commercialization of research findings in genetics. To define genetic patent applications, the European version (ECLA) of the International Patent Classification (IPC) codes was used. Genetic patent applications data from the PATSTAT database from 1990 until 2009 were analyzed for time trends and regional distribution. Overall, the number of patent applications has been growing. In 2009, 152 000 patent applications were submitted under the Patent Cooperation Treaty (PCT) and within the EP (European Patent) system of the European Patent Office (EPO). The number of genetic patent applications increased until a peak was reached in the year 2000, with >8000 applications, after which it declined by almost 50%. Continents show different patterns over time, with the global peak in 2000 mainly explained by the USA and Europe, while Asia shows a stable number of >1000 per year. Nine countries together account for 98.9% of the total number of genetic patent applications. In The Netherlands, 26.7% of the genetic patent applications originate from public research institutions. After the year 2000, the number of genetic patent applications dropped significantly. Academic leadership and policy as well as patent regulations seem to have an important role in the trend differences. The ongoing investment in genetic research in the past decade is not reflected by an increase of patent applications. PMID:24448546

Patent prosecution at the European Patent Office: what is new for life sciences applicants?

PubMed

Lidén, Camilla; Setréus, Ellen

2011-06-01

During the last couple of years, the European Patent Office (EPO) has gradually implemented the so-called 'Raising the Bar' initiative, which is aimed at improving the quality of European patents and, in combination with speeding up the procedure for grant, reducing uncertainty for third parties. As a part of this initiative, a series of changes to the implementing regulations of the European Patent Convention (EPC) were introduced last year. Applicants now need to be sure of their position with regard to supportive experimental data and a thorough argumentation at an earlier stage in the prosecution of a patent application. When evaluating the criteria of inventive step (Art 56 EPC) and sufficiency of disclosure (Art 83 EPC), the EPO frequently refers to two decisions issued by the Boards of Appeal. These decisions are also used to determine whether it is appropriate to further support a disclosed technical effect or a scope of protection with experimental data produced after the date of filing of the patent application. In view of recent case law, it is evident that applicants cannot rely on post-filed experimental data as the only evidence for a technical effect or a certain scope of protection claimed in the application.

76 FR 11206 - Proposed Collection; Patent Examiner Employment Application

Federal Register 2010, 2011, 2012, 2013, 2014

2011-03-01

... the Workforce Employment Division, Office of Human Resources, United States Patent and Trademark... rapidly review applications for employment of entry-level patent examiners. The Office of Human Resources... supplied by an applicant seeking a patent examiner position with the USPTO assists the Human Resources...

37 CFR 1.14 - Patent applications preserved in confidence.

Code of Federal Regulations, 2013 CFR

2013-07-01

... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Patent applications preserved in confidence. 1.14 Section 1.14 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions...

37 CFR 1.14 - Patent applications preserved in confidence.

Code of Federal Regulations, 2014 CFR

2014-07-01

... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Patent applications preserved in confidence. 1.14 Section 1.14 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions...

37 CFR 1.14 - Patent applications preserved in confidence.

Code of Federal Regulations, 2012 CFR

2012-07-01

... 37 Patents, Trademarks, and Copyrights 1 2012-07-01 2012-07-01 false Patent applications preserved in confidence. 1.14 Section 1.14 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions...

37 CFR 1.14 - Patent applications preserved in confidence.

Code of Federal Regulations, 2011 CFR

2011-07-01

... 37 Patents, Trademarks, and Copyrights 1 2011-07-01 2011-07-01 false Patent applications preserved in confidence. 1.14 Section 1.14 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions...

The shadow of inequitable conduct in the US patent application.

PubMed

Chang, Bao-Chi; Wang, Shyh-Jen

2016-05-03

Inequitable conduct regarding any single claim can render the entire patent unenforceable and further damage other related patents and applications in the assignee's patent portfolio. The adverse impact of inequitable conduct significantly became a litigation strategy. The US Federal Circuit (CAFC) observed that inequitable conduct as a patent litigation strategy had become a plague and thus tightened the standard for finding inequitable conduct in a case with full court judges. However, under the shadow of previous adverse impact of inequitable conduct, patent applicants may still submit many marginal related references. This study demonstrates that an applicant even prepared an information disclosure statement (IDS) as many as 50 pages. Actually, under the new standard, inequitable conduct would not further produce significant impact in the US patent system. Thus, a patent applicant need not submit marginal references but should distinguish the prior art from the current application, especially for those listed in the IDS, to avoid the novelty rejection.

37 CFR 1.81 - Drawings required in patent application.

Code of Federal Regulations, 2013 CFR

2013-07-01

... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Drawings required in patent application. 1.81 Section 1.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions The Drawings...

37 CFR 1.81 - Drawings required in patent application.

Code of Federal Regulations, 2012 CFR

2012-07-01

... 37 Patents, Trademarks, and Copyrights 1 2012-07-01 2012-07-01 false Drawings required in patent application. 1.81 Section 1.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions The Drawings...

37 CFR 1.81 - Drawings required in patent application.

Code of Federal Regulations, 2014 CFR

2014-07-01

... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Drawings required in patent application. 1.81 Section 1.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions The Drawings...

Patenting of university and non-university public research organisations in Germany: evidence from patent applications for medical research results.

PubMed

Tinnemann, Peter; Ozbay, Jonas; Saint, Victoria A; Willich, Stefan N

2010-11-18

Patents are one of the most important forms of intellectual property. They grant a time-limited exclusivity on the use of an invention allowing the recuperation of research costs. The use of patents is fiercely debated for medical innovation and especially controversial for publicly funded research, where the patent holder is an institution accountable to public interest. Despite this controversy, for the situation in Germany almost no empirical information exists. The purpose of this study is to examine the amount, types and trends of patent applications for health products submitted by German public research organisations. We conducted a systematic search for patent documents using the publicly accessible database search interface of the German Patent and Trademark Office. We defined keywords and search criteria and developed search patterns for the database request. We retrieved documents with application date between 1988 and 2006 and processed the collected data stepwise to compile the most relevant documents in patent families for further analysis. We developed a rationale and present individual steps of a systematic method to request and process patent data from a publicly accessible database. We retrieved and processed 10194 patent documents. Out of these, we identified 1772 relevant patent families, applied for by 193 different universities and non-university public research organisations. 827 (47%) of these patent families contained granted patents. The number of patent applications submitted by universities and university-affiliated institutions more than tripled since the introduction of legal reforms in 2002, constituting almost half of all patent applications and accounting for most of the post-reform increase. Patenting of most non-university public research organisations remained stable. We search, process and analyse patent applications from publicly accessible databases. Internationally mounting evidence questions the viability of policies to

Patenting of University and Non-University Public Research Organisations in Germany: Evidence from Patent Applications for Medical Research Results

PubMed Central

Tinnemann, Peter; Özbay, Jonas; Saint, Victoria A.; Willich, Stefan N.

2010-01-01

Background Patents are one of the most important forms of intellectual property. They grant a time-limited exclusivity on the use of an invention allowing the recuperation of research costs. The use of patents is fiercely debated for medical innovation and especially controversial for publicly funded research, where the patent holder is an institution accountable to public interest. Despite this controversy, for the situation in Germany almost no empirical information exists. The purpose of this study is to examine the amount, types and trends of patent applications for health products submitted by German public research organisations. Methods/Principal Findings We conducted a systematic search for patent documents using the publicly accessible database search interface of the German Patent and Trademark Office. We defined keywords and search criteria and developed search patterns for the database request. We retrieved documents with application date between 1988 and 2006 and processed the collected data stepwise to compile the most relevant documents in patent families for further analysis. We developed a rationale and present individual steps of a systematic method to request and process patent data from a publicly accessible database. We retrieved and processed 10194 patent documents. Out of these, we identified 1772 relevant patent families, applied for by 193 different universities and non-university public research organisations. 827 (47%) of these patent families contained granted patents. The number of patent applications submitted by universities and university-affiliated institutions more than tripled since the introduction of legal reforms in 2002, constituting almost half of all patent applications and accounting for most of the post-reform increase. Patenting of most non-university public research organisations remained stable. Conclusions We search, process and analyse patent applications from publicly accessible databases. Internationally mounting

The development of synthetic biology: a patent analysis.

PubMed

van Doren, Davy; Koenigstein, Stefan; Reiss, Thomas

2013-12-01

In the past decades, synthetic biology has gained interest regarding research and development efforts within the biotechnology domain. However, it is unclear to what extent synthetic biology has matured already into being commercially exploitable. By means of a patent analysis, this study shows that there is an increasing trend regarding synthetic biology related patent applications. The majority of retrieved patents relates to innovations facilitating the realisation of synthetic biology through improved understanding of biological systems. In addition, there is increased activity concerning the development of synthetic biology based applications. When looking at potential application areas, the majority of synthetic biology patents seems most relevant for the medical, energy and industrial sector. Furthermore, the analysis shows that most activity has been carried out by the USA, with Japan and a number of European countries considerably trailing behind. In addition, both universities and companies are major patent applicant actor types. The results presented here form a starting point for follow-up studies concerning the identification of drivers explaining the observed patent application trends in synthetic biology.

75 FR 30773 - United States Patent Applicant Survey

Federal Register 2010, 2011, 2012, 2013, 2014

2010-06-02

... DEPARTMENT OF COMMERCE Patent and Trademark Office United States Patent Applicant Survey ACTION..., information from a survey of the inventor community is included when formulating application filing forecasts. In addition to using the survey as part of a comprehensive approach to forecasting, the USPTO is also...

37 CFR 1.730 - Applicant for extension of patent term; signature requirements.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Applicant for extension of patent term; signature requirements. 1.730 Section 1.730 Patents, Trademarks, and Copyrights UNITED... for extension of patent term; signature requirements. (a) Any application for extension of a patent...

Biotechnological Patents Applications of the Deuterium Oxide in Human Health.

PubMed

da S Mariano, Reysla M; Bila, Wendell C; Trindade, Maria Jaciara F; Lamounier, Joel A; Galdino, Alexsandro S

2017-01-01

Deuterium oxide is a molecule that has been used for decades in several studies related to human health. Currently, studies on D2O have mobilized a "Race for Patenting" worldwide. Several patents have been registered from biomedical and technological studies of D2O showing the potential of this stable isotope in industry and health care ecosystems. Most of the patents related to the applications of the deuterium oxide in human health have been summarized in this review. The following patents databases were consulted: European Patent Office (Espacenet), the United States Patent and Trademark Office (USPTO), the United States Latin America Patents (LATIPAT), Patent scope -Search International and National Patent Collections (WIPO), Google Patents and Free Patents Online. With this review, the information was collected on recent publications including 22 patents related to deuterium oxide and its applications in different areas. This review showed that deuterium oxide is a promising component in different areas, including biotechnology, chemistry and medicine. In addition, the knowledge of this compound was covered, reinforcing its importance in the field of biotechnology and human health. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

The role of patent and non-patent databases in patent research in universities

NASA Astrophysics Data System (ADS)

Tolstaya, A. M.; Suslina, I. V.; Tolstaya, P. M.

2017-01-01

This studies deal with the description and systematization of the popular patent retrieval resources. The importance of the non-patent information when conducting patent research for the intellectual property created in educational and scientific activity of the university is highlighted. The differences in the patent and non-patent information are found out. Based on the databases` analysis the authors conducted the patent research on "Wireless endoscopic capsules" (development of the NRNU MEPhI). This study can be used to facilitate the university work on the new product development in order to improve the efficiency of the process of the commercialization of the intellectual activity results, including the entering the international market.

Patents of drugs extracted from Brazilian medicinal plants.

PubMed

Balbani, Aracy P S; Silva, Dulce H S; Montovani, Jair C

2009-04-01

Plants synthesise a vast repertoire of chemicals with various biological activities. Brazilian enormous botanical diversity facilitates the development of novel ethical drugs for the treatment of diseases in humans. To present therapeutic patent applications comprising Brazilian native plants published in the 2003-2008 period in light of legal aspects of patentability of biodiversity and public health concerns. Therapeutic patent applications related to Brazilian medicinal plants available at both the European Patent Office and the Brazilian National Institute of Industrial Property databases were reviewed. Twenty-five patents are presented, most of which concern inflammatory, allergic, parasitic, infectious or digestive diseases, including extracts from Carapa guianensis, Copaifera genus, Cordia verbenacea, Erythrina mulungu, Physalis angulata and other pharmaceutical compositions with antileishmanial, antimalarial or trypanocidal activity. Brazilian research centres and universities are responsible for most of these inventions.

Pharmaceutical patent applications in freeze-drying.

PubMed

Ekenlebie, Edmond; Einfalt, Tomaž; Karytinos, Arianna Irò; Ingham, Andrew

2016-09-01

Injectable products are often the formulation of choice for new therapeutics; however, formulation in liquids often enhances degradation through hydrolysis. Thus, freeze-drying (lyophilization) is regularly used in pharmaceutical manufacture to reduce water activity. Here we examine its contribution to 'state of the art' and look at its future potential uses. A comprehensive search of patent databases was conducted to characterize the international patent landscape and trends in the use of freeze-drying. A total of 914 disclosures related to freeze-drying, lyophilization or drying of solid systems in pressures and temperatures equivalent to those of freeze-drying were considered over the period of 1992-2014. Current applications of sublimation technology were contrasted across two periods those with patents due to expire (1992-1993) and those currently filed. The number of freeze-drying technology patents has stabilized after initial activity across the biotechnology sector in 2011 and 2012. Alongside an increasing trend for patent submissions, freeze-drying submissions have slowed since 2002 and is indicative of a level of maturity.

Patome: a database server for biological sequence annotation and analysis in issued patents and published patent applications.

PubMed

Lee, Byungwook; Kim, Taehyung; Kim, Seon-Kyu; Lee, Kwang H; Lee, Doheon

2007-01-01

With the advent of automated and high-throughput techniques, the number of patent applications containing biological sequences has been increasing rapidly. However, they have attracted relatively little attention compared to other sequence resources. We have built a database server called Patome, which contains biological sequence data disclosed in patents and published applications, as well as their analysis information. The analysis is divided into two steps. The first is an annotation step in which the disclosed sequences were annotated with RefSeq database. The second is an association step where the sequences were linked to Entrez Gene, OMIM and GO databases, and their results were saved as a gene-patent table. From the analysis, we found that 55% of human genes were associated with patenting. The gene-patent table can be used to identify whether a particular gene or disease is related to patenting. Patome is available at http://www.patome.org/; the information is updated bimonthly.

Patome: a database server for biological sequence annotation and analysis in issued patents and published patent applications

PubMed Central

Lee, Byungwook; Kim, Taehyung; Kim, Seon-Kyu; Lee, Kwang H.; Lee, Doheon

2007-01-01

With the advent of automated and high-throughput techniques, the number of patent applications containing biological sequences has been increasing rapidly. However, they have attracted relatively little attention compared to other sequence resources. We have built a database server called Patome, which contains biological sequence data disclosed in patents and published applications, as well as their analysis information. The analysis is divided into two steps. The first is an annotation step in which the disclosed sequences were annotated with RefSeq database. The second is an association step where the sequences were linked to Entrez Gene, OMIM and GO databases, and their results were saved as a gene–patent table. From the analysis, we found that 55% of human genes were associated with patenting. The gene–patent table can be used to identify whether a particular gene or disease is related to patenting. Patome is available at ; the information is updated bimonthly. PMID:17085479

The lone inventor: low success rates and common errors associated with pro-se patent applications.

PubMed

Gaudry, Kate S

2012-01-01

A pro-se patent applicant is an inventor who chooses to represent himself while pursuing ("prosecuting") a patent application. To the author's knowledge, this paper is the first empirical study addressing how applications filed by pro-se inventors fare compared to applications in which inventors were represented by patent attorneys or agents. The prosecution history of 500 patent applications filed at the United States Patent and Trademark Office were analyzed: inventors were represented by a patent professional for 250 of the applications ("represented applications") but not in the other 250 ("pro-se applications"). 76% of the pro-se applications became abandoned (not issuing as a patent), as compared to 35% of the represented applications. Further, among applications that issued as patents, pro-se patents' claims appear to be narrower and therefore of less value than claims in the represented patent set. Case-specific data suggests that a substantial portion of pro-se applicants unintentionally abandon their applications, terminate the examination process relatively early, and/or fail to take advantage of interview opportunities that may resolve issues stalling allowance of the application.

25 CFR 152.4 - Application for patent in fee.

Code of Federal Regulations, 2012 CFR

2012-04-01

... 25 Indians 1 2012-04-01 2011-04-01 true Application for patent in fee. 152.4 Section 152.4 Indians BUREAU OF INDIAN AFFAIRS, DEPARTMENT OF THE INTERIOR LAND AND WATER ISSUANCE OF PATENTS IN FEE, CERTIFICATES OF COMPETENCY, REMOVAL OF RESTRICTIONS, AND SALE OF CERTAIN INDIAN LANDS Issuing Patents in Fee...

25 CFR 152.4 - Application for patent in fee.

Code of Federal Regulations, 2011 CFR

2011-04-01

... 25 Indians 1 2011-04-01 2011-04-01 false Application for patent in fee. 152.4 Section 152.4 Indians BUREAU OF INDIAN AFFAIRS, DEPARTMENT OF THE INTERIOR LAND AND WATER ISSUANCE OF PATENTS IN FEE, CERTIFICATES OF COMPETENCY, REMOVAL OF RESTRICTIONS, AND SALE OF CERTAIN INDIAN LANDS Issuing Patents in Fee...

25 CFR 152.4 - Application for patent in fee.

Code of Federal Regulations, 2014 CFR

2014-04-01

... 25 Indians 1 2014-04-01 2014-04-01 false Application for patent in fee. 152.4 Section 152.4 Indians BUREAU OF INDIAN AFFAIRS, DEPARTMENT OF THE INTERIOR LAND AND WATER ISSUANCE OF PATENTS IN FEE, CERTIFICATES OF COMPETENCY, REMOVAL OF RESTRICTIONS, AND SALE OF CERTAIN INDIAN LANDS Issuing Patents in Fee...

25 CFR 152.4 - Application for patent in fee.

Code of Federal Regulations, 2013 CFR

2013-04-01

... 25 Indians 1 2013-04-01 2013-04-01 false Application for patent in fee. 152.4 Section 152.4 Indians BUREAU OF INDIAN AFFAIRS, DEPARTMENT OF THE INTERIOR LAND AND WATER ISSUANCE OF PATENTS IN FEE, CERTIFICATES OF COMPETENCY, REMOVAL OF RESTRICTIONS, AND SALE OF CERTAIN INDIAN LANDS Issuing Patents in Fee...

A Review on Recent Patents and Applications of Inorganic Material Binding Peptides.

PubMed

Thota, Veeranjaneyulu; Perry, Carole C

2017-01-01

Although the popularity of using combinatorial display techniques for recognising unique peptides having high affinity for inorganic (nano) particles has grown rapidly, there are no systematic reviews showcasing current developments or patents on binding peptides specific to these materials. In this review, we summarize and discuss recent progress in patents on material binding peptides specifically exploring inorganic nano surfaces such as metals, metal oxides, minerals, carbonbased materials, polymer based materials, magnetic materials and semiconductors. We consider both the peptide display strategies used and the exploitation of the identified peptides in the generation of advanced nanomaterials. In order to get a clear picture on the number of patents and literature present to date relevant to inorganic material binding biomolecules and their applications, a thorough online search was conducted using national and worldwide databases. The literature search include standard bibliographic databases while patents included EPO Espacenet, WIPO patent scope, USPTO, Google patent search, Patent lens, etc. along with commercial databases such as Derwent and Patbase. Both English and American spellings were included in the searches. The initial number of patents found related to material binders were 981. After reading and excluding irrelevant patents such as organic binding peptides, works published before 2001, repeated patents, documents not in English etc., 51 highly relevant patents published from 2001 onwards were selected and analysed. These patents were further separated into six categories based on their target inorganic material and combinatorial library used. They include relevant patents on metal, metal oxide or combination binding peptides (19), magnetic and semiconductor binding peptides (8), carbon based (3), mineral (5), polymer (8) and other binders (9). Further, how these material specific binders have been used to synthesize simple to complex bio- or

Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?

PubMed

Mueller, Lisa L; Taketsuma Costa, Silvia Moreira

2014-01-01

Pharmaceutical manufacturers who seek new markets for expansion are particularly attracted to Brazil given its potential for growth and the expectation that it will be the fifth largest drug market by 2015. Given the significance of Brazil in the marketplace, strong patent protection for pharmaceutical products and processes is critical. In April 2013, a new workflow came into effect in Brazil which allows the National Sanitary Vigilance Agency (ANVISA), a government agency whose function is to protect public health, to examine and reject any patent application that claims a pharmaceutical product or process before any examination of the application by the Brazilian Patent Office. If a patent application is rejected by ANVISA, the application is returned to the Brazilian Patent Office and filed away, without any further examination, for an unknown period of time. Therefore, the examination of pharmaceutical product and process applications under this new workflow is problematic for local and global pharmaceutical manufacturers for multiple reasons.

The Lone Inventor: Low Success Rates and Common Errors Associated with Pro-Se Patent Applications

PubMed Central

Gaudry, Kate S.

2012-01-01

A pro-se patent applicant is an inventor who chooses to represent himself while pursuing (“prosecuting”) a patent application. To the author's knowledge, this paper is the first empirical study addressing how applications filed by pro-se inventors fare compared to applications in which inventors were represented by patent attorneys or agents. The prosecution history of 500 patent applications filed at the United States Patent and Trademark Office were analyzed: inventors were represented by a patent professional for 250 of the applications (“represented applications”) but not in the other 250 (“pro-se applications”). 76% of the pro-se applications became abandoned (not issuing as a patent), as compared to 35% of the represented applications. Further, among applications that issued as patents, pro-se patents' claims appear to be narrower and therefore of less value than claims in the represented patent set. Case-specific data suggests that a substantial portion of pro-se applicants unintentionally abandon their applications, terminate the examination process relatively early, and/or fail to take advantage of interview opportunities that may resolve issues stalling allowance of the application. PMID:22470439

37 CFR 1.17 - Patent application and reexamination processing fees.

Code of Federal Regulations, 2011 CFR

2011-07-01

... decision on petition refusing to accept delayed payment of maintenance fee in an expired patent. § 1.741(b... and record payment of a maintenance fee filed prior to expiration of a patent. § 1.550(c)—for patent... application from issue. § 1.314—to defer issuance of a patent. (i) Processing fee for taking action under one...

Candida vaccines development from point view of US patent application.

PubMed

Wang, Shyh-Jen

2011-11-01

Candidiasis is the fourth most common bloodstream infection in hospitalized patients in the United States. Moreover, the mortality rate from Candida infections remains high, even after treatment with antifungal therapy. Vaccination would be a promising strategy for prevention of invasive fungal infections. In order to examine the main trends in anticandidal vaccine patenting activity, we conducted an analysis for anticandidal vaccine patents. We find 190 issued patent and 940 patent application documents containing the keywords Candida and vaccine within claims in the USA. Candida vaccines development, as evidenced by the numbers of issued patents, has decreased since the year 2002. Furthermore, the number of patent applications in Candida vaccines may indicate the strength of engaged resources were also in the status of stagnation during 2005-2007 and even a decline in 2008. Academic and nonprofit research institutions not only account for a large share of Candida vaccines patents but also apply for patents continually. Based on this analysis, the strength of Candida vaccines resources seems to remain stagnant in recent years due to patent prosecution or technical barrier in the filed of Candida vaccines. Therefore, we consider that Candida vaccines technology to still be under development and the researchers are still looking for scientific breakthrough in the filed.

25 CFR 152.4 - Application for patent in fee.

Code of Federal Regulations, 2010 CFR

2010-04-01

..., CERTIFICATES OF COMPETENCY, REMOVAL OF RESTRICTIONS, AND SALE OF CERTAIN INDIAN LANDS Issuing Patents in Fee, Certificates of Competency Or Orders Removing Restrictions § 152.4 Application for patent in fee. Any Indian 21...

37 CFR 1.5 - Identification of patent, patent application, or patent-related proceeding.

Code of Federal Regulations, 2010 CFR

2010-07-01

... UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions General Information and Correspondence § 1.5 Identification of patent, patent... benefit of the date of deposit with the United States Postal Service. If the returned correspondence is...

37 CFR 1.41 - Applicant for patent.

Code of Federal Regulations, 2010 CFR

2010-07-01

... COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for A... inventor or inventors. (1) The inventorship of a nonprovisional application is that inventorship set forth... nonprovisional application, the inventorship is that inventorship set forth in the application papers filed...

A patent landscape on application of microorganisms in construction industry.

PubMed

Dapurkar, Dipti; Telang, Manasi

2017-07-01

Construction biotechnology includes research and development of construction materials and processes that make use of various microbes. The present technology landscape gives a perspective on how microbes have been used in construction industry as cement and concrete additives by analyzing patents filed in this technology arena. All patents related to the technology of interest published globally to date have been reviewed. The earliest patent filing in this technology domain was recorded in the year 1958 and the patenting activity reached its peak around mid to late 1990s. The early technology was mainly focused on microbial polysaccharides and other metabolic products as additives. Year 2002 onwards, biomineralization has taken precedence over the other technologies with consistent patent filings indicating a shift in innovation focus. Japan has been the global leader with highest number of patents filed on application of microbes in construction industry. Southeast University, China has topped the patent assignee list with maximum number of filings followed by Kajima Corp. and Shin-Etsu Chemical Co., Ltd. Most patent applications have claimed microbe based bio-products. Construction-related microbial technologies are mainly based on activity of different microorganisms such as urease-producing, acidogenic, halophilic, alkaliphilic, nitrate and iron-reducing bacteria. Sporosarcina pasteurii has been the most widely used microbe for biomineralization.

Exploration of Global Trend on Biomedical Application of Polyhydroxyalkanoate (PHA): A Patent Survey.

PubMed

Ponnaiah, Paulraj; Vnoothenei, Nagiah; Chandramohan, Muruganandham; Thevarkattil, Mohamed Javad Pazhayakath

2018-01-30

Polyhydroxyalkanoates are bio-based, biodegradable naturally occurring polymers produced by a wide range of organisms, from bacteria to higher mammals. The properties and biocompatibility of PHA make it possible for a wide spectrum of applications. In this context, we analyze the potential applications of PHA in biomedical science by exploring the global trend through the patent survey. The survey suggests that PHA is an attractive candidate in such a way that their applications are widely distributed in the medical industry, drug delivery system, dental material, tissue engineering, packaging material as well as other useful products. In our present study, we explored patents associated with various biomedical applications of polyhydroxyalkanoates. Patent databases of European Patent Office, United States Patent and Trademark Office and World Intellectual Property Organization were mined. We developed an intensive exploration approach to eliminate overlapping patents and sort out significant patents. We demarcated the keywords and search criterions and established search patterns for the database request. We retrieved documents within the recent 6 years, 2010 to 2016 and sort out the collected data stepwise to gather the most appropriate documents in patent families for further scrutiny. By this approach, we retrieved 23,368 patent documents from all the three databases and the patent titles were further analyzed for the relevance of polyhydroxyalkanoates in biomedical applications. This ensued in the documentation of approximately 226 significant patents associated with biomedical applications of polyhydroxyalkanoates and the information was classified into six major groups. Polyhydroxyalkanoates has been patented in such a way that their applications are widely distributed in the medical industry, drug delivery system, dental material, tissue engineering, packaging material as well as other useful products. There are many avenues through which PHA & PHB could be

Specification Patent Management for Web Application Platform Ecosystem

NASA Astrophysics Data System (ADS)

Fukami, Yoshiaki; Isshiki, Masao; Takeda, Hideaki; Ohmukai, Ikki; Kokuryo, Jiro

Diversified usage of web applications has encouraged disintegration of web platform into management of identification and applications. Users make use of various kinds of data linked to their identity with multiple applications on certain social web platforms such as Facebook or MySpace. There has emerged competition among web application platforms. Platformers can design relationship with developers by controlling patent of their own specification and adopt open technologies developed external organizations. Platformers choose a way to open according to feature of the specification and their position. Patent management of specification come to be a key success factor to build competitive web application platforms. Each way to attract external developers such as standardization, open source has not discussed and analyzed all together.

37 CFR 1.17 - Patent application and reexamination processing fees.

Code of Federal Regulations, 2010 CFR

2010-07-01

... reexamination processing fees. 1.17 Section 1.17 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND... and Payment of Money § 1.17 Patent application and reexamination processing fees. (a) Extension fees... the inventors or a person not the inventor. § 1.59—for expungement of information. § 1.103(a)—to...

75 FR 71072 - Extension of the Patent Application Backlog Reduction Stimulus Plan

Federal Register 2010, 2011, 2012, 2013, 2014

2010-11-22

... DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No.: PTO-P-2010-0087] Extension of the Patent Application Backlog Reduction Stimulus Plan AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent and Trademark Office (USPTO...

37 CFR 5.3 - Prosecution of application under secrecy orders; withholding patent.

Code of Federal Regulations, 2011 CFR

2011-07-01

... 37 Patents, Trademarks, and Copyrights 1 2011-07-01 2011-07-01 false Prosecution of application under secrecy orders; withholding patent. 5.3 Section 5.3 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL SECRECY OF CERTAIN INVENTIONS AND...

37 CFR 5.3 - Prosecution of application under secrecy orders; withholding patent.

Code of Federal Regulations, 2012 CFR

2012-07-01

... 37 Patents, Trademarks, and Copyrights 1 2012-07-01 2012-07-01 false Prosecution of application under secrecy orders; withholding patent. 5.3 Section 5.3 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL SECRECY OF CERTAIN INVENTIONS AND...

37 CFR 5.3 - Prosecution of application under secrecy orders; withholding patent.

Code of Federal Regulations, 2013 CFR

2013-07-01

... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Prosecution of application under secrecy orders; withholding patent. 5.3 Section 5.3 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL SECRECY OF CERTAIN INVENTIONS AND...

37 CFR 5.3 - Prosecution of application under secrecy orders; withholding patent.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Prosecution of application under secrecy orders; withholding patent. 5.3 Section 5.3 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL SECRECY OF CERTAIN INVENTIONS AND...

37 CFR 5.3 - Prosecution of application under secrecy orders; withholding patent.

Code of Federal Regulations, 2014 CFR

2014-07-01

... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Prosecution of application under secrecy orders; withholding patent. 5.3 Section 5.3 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL SECRECY OF CERTAIN INVENTIONS AND...

75 FR 5041 - Extension of the Patent Application Backlog Reduction Stimulus Plan

Federal Register 2010, 2011, 2012, 2013, 2014

2010-02-01

... DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No.: PTO-P-2010-0003] Extension of the Patent Application Backlog Reduction Stimulus Plan AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent and Trademark Office (USPTO) published a notice...

[Application of ultrasound counter currentextraction in patent of traditional Chinese medicine].

PubMed

Miao, Yan-ni; Wu, Bin; Yue, Xue-lian

2015-07-01

The patent information of ultrasound countercurrent extraction used in traditional Chinese medicine was analyzed in this paper by the samples from Derwent World Patent Database (DWPI) and the Chinese Patent Abstracts Database (CNABS). The application of ultrasound countercurrent was discussed with the patent applicant,the amount of the annual distribution, and the pharmaceutical raw materials and other aspects. While the technical parameters published in the patent was deeply analyzed, such as material crushing, extraction solvent, extraction time and temperature, extraction equipment and ultrasonic frequency. Thought above research, various technical parameters of ultrasound countercurrent extraction used in traditional Chinese was summarize. The analysis conclusion of the paper can be used in discovering the technical advantages, optimizing extraction conditions, and providing a reference to extraction technological innovation of traditional Chinese medicine.

37 CFR 1.17 - Patent application and reexamination processing fees.

Code of Federal Regulations, 2012 CFR

2012-07-01

... maintenance fee in an expired patent. § 1.741(b)—to accord a filing date to an application under § 1.740 for...—for review of decision refusing to accept and record payment of a maintenance fee filed prior to... publication. § 1.313—to withdraw an application from issue. § 1.314—to defer issuance of a patent. (i...

22 CFR 92.72 - Services in connection with patents and patent applications.

Code of Federal Regulations, 2010 CFR

2010-04-01

... depends on who is making the application, the type of invention, and the circumstances of the case... this section regarding authentication of the authority of a foreign official. A notary or other... United States Patent Office.) (c) Authentication of authority of foreign official—(1) Necessity for...

Patent Family Databases.

ERIC Educational Resources Information Center

Simmons, Edlyn S.

1985-01-01

Reports on retrieval of patent information online and includes definition of patent family, basic and equivalent patents, "parents and children" applications, designated states, patent family databases--International Patent Documentation Center, World Patents Index, APIPAT (American Petroleum Institute), CLAIMS (IFI/Plenum). A table…

75 FR 23227 - Initial Patent Applications

Federal Register 2010, 2011, 2012, 2013, 2014

2010-05-03

... subject line of the message. Fax: 571-273-0112, marked to the attention of Susan K. Fawcett. Mail: Susan K... FURTHER INFORMATION CONTACT: Requests for additional information should be directed to the attention of... Compact Disk-Read Only Memory (CD-ROM) or Compact Disk-Recordables (CD-R) to submit patent applications...

Patenting the Life Sciences at the European Patent Office

PubMed Central

Gates, Christina

2014-01-01

The European patent system is very much like those of the United States and other major countries. Patent applications can be filed as a first filing, as a priority application, or as a national phase of a Patent Cooperation Treaty application. The applications are searched, rigorously examined, and ultimately granted, with the time periods varying somewhat depending on the application type. The object of this article is to highlight some of the differences between the U.S. and European systems, particularly as they relate to life sciences. PMID:25342060

Patent Citation Networks

NASA Astrophysics Data System (ADS)

Strandburg, Katherine; Tobochnik, Jan; Csardi, Gabor

2005-03-01

Patent applications contain citations which are similar to but different from those found in published scientific papers. In particular, patent citations are governed by legal rules. Moreover, a large fraction of citations are made not by the patent inventor, but by a patent examiner during the application procedure. Using a patent database, which contains the patent citations, assignees and inventors, we have applied network analysis and built network models. Our work includes determining the structure of the patent citation network and comparing it to existing results for scientific citation networks; identifying differences between various technological fields and comparing the observed differences to expectations based on anecdotal evidence about patenting practice; and developing models to explain the results.

37 CFR 1.130 - Affidavit or declaration to disqualify commonly owned patent or published application as prior art.

Code of Federal Regulations, 2010 CFR

2010-07-01

... disqualify commonly owned patent or published application as prior art. 1.130 Section 1.130 Patents... or declaration to disqualify commonly owned patent or published application as prior art. (a) When... patent or published application are not identical but are not patentably distinct, and the inventions are...

48 CFR 52.227-10 - Filing of Patent Applications-Classified Subject Matter.

Code of Federal Regulations, 2012 CFR

2012-10-01

... application to the United States Patent Office, but the Contractor shall not be denied the right to file the... States Patent Office, the Contractor shall by separate letter identify by agency and number the contract... 48 Federal Acquisition Regulations System 2 2012-10-01 2012-10-01 false Filing of Patent...

48 CFR 52.227-10 - Filing of Patent Applications-Classified Subject Matter.

Code of Federal Regulations, 2013 CFR

2013-10-01

... application to the United States Patent Office, but the Contractor shall not be denied the right to file the... States Patent Office, the Contractor shall by separate letter identify by agency and number the contract... 48 Federal Acquisition Regulations System 2 2013-10-01 2013-10-01 false Filing of Patent...

48 CFR 52.227-10 - Filing of Patent Applications-Classified Subject Matter.

Code of Federal Regulations, 2011 CFR

2011-10-01

... application to the United States Patent Office, but the Contractor shall not be denied the right to file the... States Patent Office, the Contractor shall by separate letter identify by agency and number the contract... 48 Federal Acquisition Regulations System 2 2011-10-01 2011-10-01 false Filing of Patent...

48 CFR 52.227-10 - Filing of Patent Applications-Classified Subject Matter.

Code of Federal Regulations, 2010 CFR

2010-10-01

... application to the United States Patent Office, but the Contractor shall not be denied the right to file the... States Patent Office, the Contractor shall by separate letter identify by agency and number the contract... 48 Federal Acquisition Regulations System 2 2010-10-01 2010-10-01 false Filing of Patent...

48 CFR 52.227-10 - Filing of Patent Applications-Classified Subject Matter.

Code of Federal Regulations, 2014 CFR

2014-10-01

... application to the United States Patent Office, but the Contractor shall not be denied the right to file the... States Patent Office, the Contractor shall by separate letter identify by agency and number the contract... 48 Federal Acquisition Regulations System 2 2014-10-01 2014-10-01 false Filing of Patent...

77 FR 65537 - Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence...

Federal Register 2010, 2011, 2012, 2013, 2014

2012-10-29

... DEPARTMENT OF COMMERCE Patent and Trademark Office Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ACTION: Proposed collection; comment request... Patent applications that contain nucleotide and/or amino acid sequence disclosures must include a copy of...

75 FR 36063 - Expansion and Extension of the Patent Application Backlog Reduction Stimulus Plan

Federal Register 2010, 2011, 2012, 2013, 2014

2010-06-24

... DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No.: PTO-P-2010-0048] Expansion and Extension of the Patent Application Backlog Reduction Stimulus Plan AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Notice. SUMMARY: The United States Patent and Trademark...

37 CFR 1.130 - Affidavit or declaration to disqualify commonly owned patent or published application as prior art.

Code of Federal Regulations, 2011 CFR

2011-07-01

... disqualify commonly owned patent or published application as prior art. 1.130 Section 1.130 Patents... or declaration to disqualify commonly owned patent or published application as prior art. (a) When.... patent or U.S. patent application publication which is not prior art under 35 U.S.C. 102(b), and the...

Patenting the life sciences at the European Patent Office.

PubMed

Gates, Christina

2014-10-23

The European patent system is very much like those of the United States and other major countries. Patent applications can be filed as a first filing, as a priority application, or as a national phase of a Patent Cooperation Treaty application. The applications are searched, rigorously examined, and ultimately granted, with the time periods varying somewhat depending on the application type. The object of this article is to highlight some of the differences between the U.S. and European systems, particularly as they relate to life sciences. Copyright © 2014 Cold Spring Harbor Laboratory Press; all rights reserved.

Searching bioremediation patents through Cooperative Patent Classification (CPC).

PubMed

Prasad, Rajendra

2016-03-01

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing with new patent applications. As patent databases maintained by them went online for free access to public as also for global search of prior art by examiners, the need arose for a common platform and uniform structure of patent databases. The diversity of different classification, however, posed problems of integrating and searching relevant patents across patent jurisdictions. To address this problem of comparability of data from different sources and searching patents, WIPO in the recent past developed what is known as International Patent Classification (IPC) system which most countries readily adopted to code their patents with IPC codes along with their own codes. The Cooperative Patent Classification (CPC) is the latest patent classification system based on IPC/European Classification (ECLA) system, developed by the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) which is likely to become a global standard. This paper discusses this new classification system with reference to patents on bioremediation.

Albert Einstein and Mościcki's Patent Application

NASA Astrophysics Data System (ADS)

Gołab-Meyer, Zofia

2006-04-01

Much was said and written during the 2005 World Year of Physics about Einstein's work in the Bern, Switzerland, Patent Office (Fig. 1). He took the post (Technical Expert 3rd Class) there after completing his studies at the Zurich Polytechnic (later called ETH) in 1900 and being unsuccessful in his attempts to obtain a university position. However, little seems to be known of the patent applications he examined during his five years at the office in Bern. This paper discusses one of those applications—one that was submitted by a rather remarkable individual.

37 CFR 1.31 - Applicant may be represented by one or more patent practitioners or joint inventors.

Code of Federal Regulations, 2010 CFR

2010-07-01

... PATENT CASES National Processing Provisions Prosecution of Application and Appointment of Attorney Or Agent § 1.31 Applicant may be represented by one or more patent practitioners or joint inventors. An... by one or more patent practitioners or joint inventors. 1.31 Section 1.31 Patents, Trademarks, and...

The "real world" barriers and solutions to Candida vaccine patent prosecutions: an analysis of U.S. Patent and Trademark Office actions on related applications.

PubMed

Wang, Shyh-Jen

2012-10-01

The US Patent and Trademark Office (USPTO) adopts recent patent courts' opinions (such as KSR In re Fisher and Ariad v. Lilly) in patent examinations, which would certainly create barriers to biotech patent prosecution. To identify the barriers to Candida vaccine patent prosecution, we analyzed 99 US-granted patents from January 2001 to May 2012 related to Candida vaccines. The rejections were based on factors that included obviousness, novelty, indefiniteness, double patenting, enablement, written description and utility. Based on this investigation, we find that some of these rejections were actually avoidable, and then further provide workable solutions to avoid some of the barriers, especially those related to patentability. These principles recited in this study should also be applicable to other fields of vaccines and immunotherapeutics.

Patently Obvious: The Place for Patents in Information Literacy in the Sciences

ERIC Educational Resources Information Center

MacMillan, Don

2005-01-01

Patents are an underutilized source of scientific information, particularly in the life and health sciences. Patents and patent applications usually contain the first disclosure of new technologies and processes and serve to link theory with practice, providing "real world" examples of the application of scientific research. Increasingly,…

22 CFR 92.72 - Services in connection with patents and patent applications.

Code of Federal Regulations, 2011 CFR

2011-04-01

... United States Patent Office.) (c) Authentication of authority of foreign official—(1) Necessity for... United States Patent Office must be legibly written or printed in permanent ink. (Rule 52, Rules of Practice of the United States Patent Office.) Consular certificates of authentication executed in...

22 CFR 92.72 - Services in connection with patents and patent applications.

Code of Federal Regulations, 2013 CFR

2013-04-01

... United States Patent Office.) (c) Authentication of authority of foreign official—(1) Necessity for... United States Patent Office must be legibly written or printed in permanent ink. (Rule 52, Rules of Practice of the United States Patent Office.) Consular certificates of authentication executed in...

22 CFR 92.72 - Services in connection with patents and patent applications.

Code of Federal Regulations, 2014 CFR

2014-04-01

... United States Patent Office.) (c) Authentication of authority of foreign official—(1) Necessity for... United States Patent Office must be legibly written or printed in permanent ink. (Rule 52, Rules of Practice of the United States Patent Office.) Consular certificates of authentication executed in...

22 CFR 92.72 - Services in connection with patents and patent applications.

Code of Federal Regulations, 2012 CFR

2012-04-01

... United States Patent Office.) (c) Authentication of authority of foreign official—(1) Necessity for... United States Patent Office must be legibly written or printed in permanent ink. (Rule 52, Rules of Practice of the United States Patent Office.) Consular certificates of authentication executed in...

37 CFR 1.821 - Nucleotide and/or amino acid sequence disclosures in patent applications.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Nucleotide and/or amino acid... Biotechnology Invention Disclosures Application Disclosures Containing Nucleotide And/or Amino Acid Sequences § 1.821 Nucleotide and/or amino acid sequence disclosures in patent applications. (a) Nucleotide and...

37 CFR 1.821 - Nucleotide and/or amino acid sequence disclosures in patent applications.

Code of Federal Regulations, 2011 CFR

2011-07-01

... 37 Patents, Trademarks, and Copyrights 1 2011-07-01 2011-07-01 false Nucleotide and/or amino acid... Biotechnology Invention Disclosures Application Disclosures Containing Nucleotide And/or Amino Acid Sequences § 1.821 Nucleotide and/or amino acid sequence disclosures in patent applications. (a) Nucleotide and...

The evolution of gene patents viewed from the United States Patent Office.

PubMed

Mossinghoff, Gerald J

2003-01-01

In my remarks here, I have necessarily limited myself to general principles of patent law that are applicable to a consideration of gene-related inventions. Were I still Commissioner of Patents and Trademarks, I would not let electrical engineers anywhere near the examination of applications for patents for gene-related inventions, just as I would not let the USPTO's many Ph.D.s in microbiology or genetics near the examination of complex applications on computer architecture or programming. The same should hold true for attorneys who prosecute patent applications. That is why the U.S. patent system works so well. There can be no discrimination in the system by the field of technology--a principle enshrined in Article 27 of the World Trade Organization's Trade-Related Aspects of Intellectual Property. But we quite properly depend upon specialists to apply across-the-board general principles to very specialized technological fields of endeavor. This works very well in a system in which in the U.S., "everything under the sun made by humans" is patentable.

Nanotechnology patenting trends through an environmental lens: analysis of materials and applications

NASA Astrophysics Data System (ADS)

Leitch, Megan E.; Casman, Elizabeth; Lowry, Gregory V.

2012-12-01

Many international groups study environmental health and safety (EHS) concerns surrounding the use of engineered nanomaterials (ENMs). These researchers frequently use the "Project on Emerging Nanotechnologies" (PEN) inventory of nano-enabled consumer products to prioritize types of ENMs to study because estimates of life-cycle ENM releases to the environment can be extrapolated from the database. An alternative "snapshot" of nanomaterials likely to enter commerce can be determined from the patent literature. The goal of this research was to provide an overview of nanotechnology intellectual property trends, complementary to the PEN consumer product database, to help identify potentially "risky" nanomaterials for study by the nano-EHS community. Ten years of nanotechnology patents were examined to determine the types of nano-functional materials being patented, the chemical compositions of the ENMs, and the products in which they are likely to appear. Patenting trends indicated different distributions of nano-enabled products and materials compared to the PEN database. Recent nanotechnology patenting is dominated by electrical and information technology applications rather than the hygienic and anti-fouling applications shown by PEN. There is an increasing emphasis on patenting of nano-scale layers, coatings, and other surface modifications rather than traditional nanoparticles, and there is widespread use of nano-functional semiconductor, ceramic, magnetic, and biological materials that are currently less studied by EHS professionals. These commonly patented products and the nano-functional materials they contain may warrant life-cycle evaluations to determine the potential for environmental exposure and toxicity. The patent and consumer product lists contribute different and complementary insights into the emerging nanotechnology industry and its potential for introducing nanomaterials into the environment.

Basics of US patents and the patent system.

PubMed

Elliott, George

2007-08-24

The patent system plays an important role in stimulating the economy and advancing the quality of life in the United States. It serves as an incentive for innovation by giving inventors an exclusive right to their inventions for a limited period of time. It also increases and hastens the publication of useful knowledge by requiring inventors to disclose their invention to the public. Patents are particularly important in the pharmaceutical and biotechnology industries because they provide a mechanism by which the extremely high product development costs may be recouped. The United States Patent and Trademark Office acts as a gatekeeper in the patent system to prevent patents that do not meet the legal requirements from being thrust on the public. The legal requirements for obtaining a patent are discussed, particularly as they relate to pharmaceutical and biotechnological inventions. The process of examining an application for a patent is briefly described, along with some of the burdens faced by examiners when deciding the patentability of therapy-related inventions.

37 CFR 1.81 - Drawings required in patent application.

Code of Federal Regulations, 2011 CFR

2011-07-01

... to be patented; this drawing, or a high quality copy thereof, must be filed with the application... the original disclosure thereof for the purpose of interpretation of the scope of any claim. [43 FR...

75 FR 33584 - Request for Comments on Proposed Changes to Restriction Practice in Patent Applications

Federal Register 2010, 2011, 2012, 2013, 2014

2010-06-14

... DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No.: PTO-P-2010-0030] Request for Comments on Proposed Changes to Restriction Practice in Patent Applications AGENCY: United States Patent and Trademark Office, Commerce. ACTION: Request for comments. SUMMARY: In situations in...

Facilitated patent haemostasis after transradial catheterisation to reduce radial artery occlusion

PubMed Central

Edris, Ahmad; Gordin, Jonathan; Sallam, Tamer; Wachsner, Robin; Meymandi, Sheba; Traina, Mahmoud

2016-01-01

Aims This study sought to evaluate the feasibility of a rapid deflation technique (RDT) after transradial catheterisation to achieve patent haemostasis and to assess whether this could reduce radial artery occlusion (RAO). Ensuring patent haemostasis is the most important factor in reducing RAO. The use of larger sheath sizes and antiplatelet and antithrombotic agents limits achieving patent haemostasis immediately after transradial intervention. Methods and results A feasibility assessment was first performed in 105 patients to assess whether RDT could be performed safely and consistently achieve patent haemostasis after transradial catheterisation. Prospective data were then collected on 201 patients who underwent either rapid or standard deflation technique and had RAO assessment at 24 hours. Acute coronary syndrome was the indication for transradial catheterisation in 62.7% of patients. Baseline patent haemostasis increased from 40% to 95% after RDT. RAO at 24 hours was seen in two (2.0%) patients in the RDT group and 15 (14.9%) in the standard deflation group (OR 0.117; 95% CI: 0.026 to 0.526, p=0.005). Other independent predictors of RAO included body surface area (OR 0.022; 95% CI: 0.002 to 0.273, p=0.003) and male sex (OR 0.298; 95% CI: 0.108 to 0.824, p=0.020). No significant difference was found in safety outcomes: need to re-inflate compression band (2% versus 1.8%) or haematoma (0% versus 0.9%). Conclusions Rapid deflation of the compression band after transradial catheterisation is a safe and effective method of achieving patent haemostasis that reduces RAO. PMID:26603985

Facilitated patent haemostasis after transradial catheterisation to reduce radial artery occlusion.

PubMed

Edris, Ahmad; Gordin, Jonathan; Sallam, Tamer; Wachsner, Robin; Meymandi, Sheba; Traina, Mahmoud

2015-11-01

This study sought to evaluate the feasibility of a rapid deflation technique (RDT) after transradial catheterisation to achieve patent haemostasis and to assess whether this could reduce radial artery occlusion (RAO). Ensuring patent haemostasis is the most important factor in reducing RAO. The use of larger sheath sizes and antiplatelet and antithrombotic agents limits achieving patent haemostasis immediately after transradial intervention. A feasibility assessment was first performed in 105 patients to assess whether RDT could be performed safely and consistently achieve patent haemostasis after transradial catheterisation. Prospective data were then collected on 201 patients who underwent either rapid or standard deflation technique and had RAO assessment at 24 hours. Acute coronary syndrome was the indication for transradial catheterisation in 62.7% of patients. Baseline patent haemostasis increased from 40% to 95% after RDT. RAO at 24 hours was seen in two (2.0%) patients in the RDT group and 15 (14.9%) in the standard deflation group (OR 0.117; 95% CI: 0.026 to 0.526, p=0.005). Other independent predictors of RAO included body surface area (OR 0.022; 95% CI: 0.002 to 0.273, p=0.003) and male sex (OR 0.298; 95% CI: 0.108 to 0.824, p=0.020). No significant difference was found in safety outcomes: need to re-inflate compression band (2% versus 1.8%) or haematoma (0% versus 0.9%). Rapid deflation of the compression band after transradial catheterisation is a safe and effective method of achieving patent haemostasis that reduces RAO.

[Development strategy of Paris based on combination of domestic patent and current resource application and development].

PubMed

Zhao, Fei-Ya; Tao, Ai-En; Xia, Cong-Long

2018-01-01

Paris is a commonly used traditional Chinese medicine (TCM), and has antitumor, antibacterial, sedative, analgesic and hemostatic effects. It has been used as an ingredient of 81 Chinese patent medicines, with a wide application and large market demand. Based on the data retrieved from state Intellectual Property Office patent database, a comprehensive analysis was made on Paris patents, so as to explore the current features of Paris patents in the aspects of domestic patent output, development trend, technology field distribution, time dimension, technology growth rate and patent applicant, and reveal the development trend of China's Paris industry. In addition, based on the current Paris resource application and development, a sustainable, multi-channel and multi-level industrial development approach was built. According to the results, studies of Paris in China are at the rapid development period, with a good development trend. However, because wild Paris resources tend to be exhausted, the studies for artificial cultivation technology should be strengthened to promote the industrial development. Copyright© by the Chinese Pharmaceutical Association.

Overview of Flaxseed Patent Applications for the Reduction of Cholesterol Levels.

PubMed

Ribas, Simone A; Grando, Rafaela L; Zago, Lilia; Carvajal, Elvira; Fierro, Iolanda M

2016-01-01

Flaxseed is becoming an increasingly widely used food ingredient. The rising interest of the food industry in this nutraceutical is primarily because of functional nutrients, such as alpha-linolenic acid and lignans, which have health benefits due to their lipid-lowering properties. The objective of this study was to provide an overview of the patenting of flaxseed products with cholesterol-lowering effects. Patent applications filed by country of origin were retrieved from the Derwent Innovations Index®database. A total of 307 patent documents were identified, of which 184 claim the use of flaxseed or parts of the flax plant in the product formulation, for their lipid-lowering effect when consumed by humans. A few of the patent applications contain claims for new products based on flaxseed in isolation, including the preparation of foods designed to inhibit the production of cholesterol. Most of the claims were for flaxseed in the form of oil and in association with other lipid-lowering compounds, mainly for the food industry, in the form of dietary supplements or baked products designed to raise their high-density lipoprotein content, and for treating heart problems. China and the United States are the leading countries of flax-related applications. These results may have important implications for the production of functional food products that meet specific societal demands. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Ontology-based content analysis of US patent applications from 2001-2010.

PubMed

Weber, Lutz; Böhme, Timo; Irmer, Matthias

2013-01-01

Ontology-based semantic text analysis methods allow to automatically extract knowledge relationships and data from text documents. In this review, we have applied these technologies for the systematic analysis of pharmaceutical patents. Hierarchical concepts from the knowledge domains of chemical compounds, diseases and proteins were used to annotate full-text US patent applications that deal with pharmacological activities of chemical compounds and filed in the years 2001-2010. Compounds claimed in these applications have been classified into their respective compound classes to review the distribution of scaffold types or general compound classes such as natural products in a time-dependent manner. Similarly, the target proteins and claimed utility of the compounds have been classified and the most relevant were extracted. The method presented allows the discovery of the main areas of innovation as well as emerging fields of patenting activities - providing a broad statistical basis for competitor analysis and decision-making efforts.

Patent first, ask questions later: morality and biotechnology in patent law.

PubMed

Bagley, Margo A

2003-12-01

This Article explores the U.S. "patent first, ask questions later" approach to determining what subject matter should receive patent protection. Under this approach, the U.S. Patent and Trademark Office (USPTO or the Agency) issues patents on "anything under the sun made by man," and to the extent a patent's subject matter is sufficiently controversial, Congress acts retrospectively in assessing whether patents should issue on such interventions. This practice has important ramifications for morally controversial biotechnology patents specifically, and for American society generally. For many years a judicially created "moral utility" doctrine served as a type of gatekeeper of patent subject matter eligibility. The doctrine allowed both the USTPO and courts to deny patents on morally controversial subject matter under the fiction that such inventions were not "useful." The gate, however, is currently untended. A combination of the demise of the moral utility doctrine, along with expansive judicial interpretations of the scope of patent-eligible subject matter, has resulted in virtually no basis on which the USTPO or courts can deny patent protection to morally controversial, but otherwise patentable, subject matter. This is so despite position statements by the Agency to the contrary. Biotechnology is an area in which many morally controversial inventions are generated. Congress has been in react-mode following the issuance of a stream of morally controversial biotech patents, including patents on transgenic animals, surgical methods, and methods of cloning humans. With no statutory limits on patent eligibility, and with myriad concerns complicating congressional action following a patent's issuance, it is not Congress, the representative of the people, determining patent eligibility. Instead, it is patent applicants, scientific inventors, who are deciding matters of high public policy through the contents of the applications they file with the USTPO. This Article

Patents on Phytochemicals: Methodologies of Extraction, Application in Food and Pharmaceutical Industry.

PubMed

Ordaz-Trinidad, Nancy; Dorantes-Alvarez, Lidia; Salas-Benito, Juan

2015-01-01

Patents on phytochemicals are being registered worldwide. Such phytochemicals provide benefits to human health, and include terpenoids, phenolic compounds, alkaloids, lignin, and fiber. This review has the purpose to provide a comprehensive overview of patents published in the last five years about extraction of phytochemicals and their application in the food and pharmaceutical industry. Forty eight pa- tents were analyzed and classified in four topics of interest; 1) Extraction, 2) Functional foods, 3) Biological activity, and 4) Prevention of diseases. Extraction yield of phytochemicals is the critical step. The techniques to extract phytochemicals include enzymat- ic hydrolysis, nano-particulate precipitation, salts formation and combination of solvents; however, the use of ultrasound and microwave is increasing. Patents concerning functional foods include pediatric formulations, sport drink, and compo- sitions that produce beneficial effects. Biological activity of plant extracts tested in animals or cell cultures, as antioxidant, anti-inflammatory, anticancer activity, reduction of obesity and diabetes are presented in this review. Application of phy- tochemicals in the prevention and treatment of health disorders, such as diabetes, gastritis, enteritis, topical inflammation, macular degeneration, gingivitis, prostatic hyperplasia, urinary impairments. Patents revised include 30% methodologies for extraction of phytochemicals, 16% application of phytochem- icals in food matrixes to obtain functional foods, 18% biological activity of extracts or compounds and 36% application in the prevention and treatment of illness, which reveals a great interest to protect intellectual property concerning applica- tion of phytochemicals formulations for human health.

International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.

PubMed

McDonald, Rebecca; Danielsson Glende, Øyvind; Dale, Ola; Strang, John

2018-02-01

Non-injectable naloxone formulations are being developed for opioid overdose reversal, but only limited data have been published in the peer-reviewed domain. Through examination of a hitherto-unsearched database, we expand public knowledge of non-injectable formulations, tracing their development and novelty, with the aim to describe and compare their pharmacokinetic properties. (i) The PatentScope database of the World Intellectual Property Organization was searched for relevant English-language patent applications; (ii) Pharmacokinetic data were extracted, collated and analysed; (iii) PubMed was searched using Boolean search query '(nasal OR intranasal OR nose OR buccal OR sublingual) AND naloxone AND pharmacokinetics'. Five hundred and twenty-two PatentScope and 56 PubMed records were identified: three published international patent applications and five peer-reviewed papers were eligible. Pharmacokinetic data were available for intranasal, sublingual, and reference routes. Highly concentrated formulations (10-40 mg mL -1 ) had been developed and tested. Sublingual bioavailability was very low (1%; relative to intravenous). Non-concentrated intranasal spray (1 mg mL -1 ; 1 mL per nostril) had low bioavailability (11%). Concentrated intranasal formulations (≥10 mg mL -1 ) had bioavailability of 21-42% (relative to intravenous) and 26-57% (relative to intramuscular), with peak concentrations (dose-adjusted C max  = 0.8-1.7 ng mL -1 ) reached in 19-30 min (t max ). Exploratory analysis identified intranasal bioavailability as associated positively with dose and negatively with volume. We find consistent direction of development of intranasal sprays to high-concentration, low-volume formulations with bioavailability in the 20-60% range. These have potential to deliver a therapeutic dose in 0.1 mL volume. [McDonald R, Danielsson Glende Ø, Dale O, Strang J. International patent applications for non-injectable naloxone for opioid overdose reversal

[Global patent overview of Ginkgo biloba preparation].

PubMed

Cheng, Xin-Min; Lei, Hai-Min; Liu, Wei

2013-09-01

With related global patent data as analysis samples, worldwide patent overview of Ginkgo biloba preparation is analyzed in application, applicant, technical distribution and so on. This research shows that the most important areas of G. biloba preparation are Europe and China. The European applicants start earliest along with developing smoothly, moreover, their patents have best quality. The Chinese applicants start late along with the fastest growing, and have already certain research capabilities, moreover, their patents' quality needs to be improved. This research result provides reference for development of G. biloba preparation. The author suggest that Chinese applicants learn techniques and layout experiences of other's patents fully to enhance the level of new drug development and patent protection.

Can patents prohibit research? On the social epistemology of patenting and licensing in science.

PubMed

Biddle, Justin B

2014-03-01

A topic of growing importance within philosophy of science is the epistemic implications of the organization of research. This paper identifies a promising approach to social epistemology--nonideal systems design--and uses it to examine one important aspect of the organization of research, namely the system of patenting and licensing and its role in structuring the production and dissemination of knowledge. The primary justification of patenting in science and technology is consequentialist in nature. Patenting should incentivize research and thereby promote the development of knowledge, which in turn facilitates social progress. Some have disputed this argument, maintaining that patenting actually inhibits knowledge production. In this paper, I make a stronger argument; in some areas of research in the US--in particular, research on GM seeds--patents and patent licenses can be, and are in fact being, used to prohibit some research. I discuss three potential solutions to this problem: voluntary agreements, eliminating patents, and a research exemption. I argue against eliminating patents, and I show that while voluntary agreements and a research exemption could be helpful, they do not sufficiently address the problems of access that are discussed here. More extensive changes in the organization of research are necessary.

US photovoltaic patents, 1951--1987

NASA Astrophysics Data System (ADS)

1988-09-01

This document contains 2195 U.S. patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials as well as manufacturing and support functions. The patent entries in this document were issued from 1951 through 1987; no patents were found in 1950. The entries were located by searching USPA, the data base of the U.S. Patent Office. The final search retrieved all patents under the class Batteries, Thermoelectric and Photoelectric, and the subclasses Photoelectric, Testing, and Applications. The search also located patents that contained the words photovoltaic(s) or solar cell(s) and their derivatives. A manual search of the patents in the Solar Energy Research Institute (SERI) patent file augmented the data base search. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors, and subjects only peripherally concerned with photovoltaics. Some patents on these three subjects were included when it appeared that those inventions might be of use in terrwstrial PV power technologies.

43 CFR 2562.7 - Patent.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Patent. 2562.7 Section 2562.7 Public Lands... Patent. The application and proofs filed therewith will be carefully examined and, if all be found regular, the application will be allowed and patent issued upon payment for the land at the rate of $2.50...

43 CFR 2562.7 - Patent.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Patent. 2562.7 Section 2562.7 Public Lands... Patent. The application and proofs filed therewith will be carefully examined and, if all be found regular, the application will be allowed and patent issued upon payment for the land at the rate of $2.50...

43 CFR 2562.7 - Patent.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Patent. 2562.7 Section 2562.7 Public Lands... Patent. The application and proofs filed therewith will be carefully examined and, if all be found regular, the application will be allowed and patent issued upon payment for the land at the rate of $2.50...

43 CFR 2562.7 - Patent.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Patent. 2562.7 Section 2562.7 Public Lands... Patent. The application and proofs filed therewith will be carefully examined and, if all be found regular, the application will be allowed and patent issued upon payment for the land at the rate of $2.50...

US photovoltaic patents: 1991-1993

NASA Astrophysics Data System (ADS)

Pohle, L.

1995-03-01

This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials as well as manufacturing and support functions. The patent entries in this document were issued from 1991 to 1993. The entries were located by searching USPA, the database of the US Patent Office. The final search retrieved all patents under the class 'Batteries, Thermoelectric and Photoelectric' and the subclasses 'Photoelectric,' 'Testing,' and 'Applications.' The search also located patents that contained the words 'photovoltaic(s)' or 'solar cell(s)' and their derivatives. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors, and subjects only peripherally concerned with photovoltaic. Some patents on these three subjects were included when ft appeared that those inventions might be of use in terrestrial PV power technologies.

Considerations on patent valuation based on patent classification and citation in biotechnological field

NASA Astrophysics Data System (ADS)

Mihara, Kenji

Regarding innovation measurement utilizing patent information, a number of researchers are making great efforts to measure a "patent value (patent quality)." For patent valuation, patent classification and citation are often utilized as patent information. Also, biotechnological field is attracting attention from the viewpoint of application to environmental or medical study, and considerable researches on patent valuation are ongoing in this technical field. However, it is not enough recognized that researchers cannot be too careful when they deal with classification information in the biotech field because patent classification structure in this field is not well-established. And also, it is not known enough that citation patterns of both academic papers and patent documents are so complicated that the patterns cannot be easily generalized. In this article, the issues above were verified from a position based on working experiences of biotech patent examiner at Japan Patent Office, and considerations and implications were given on what patent valuation should be.

The political contradictions of incremental innovation: lessons from pharmaceutical patent examination in Brazil.

PubMed

Shadlen, Kenneth C

2011-01-01

Neodevelopmental patent regimes aim to facilitate local actors’ access to knowledge and also encourage incremental innovations. The case of pharmaceutical patent examination in Brazil illustrates political contradictions between these objectives. Brazil’s patent law includes the Ministry of Health in the examination of pharmaceutical patent applications. Though widely celebrated as a health-oriented policy, the Brazilian experience has become fraught with tensions and subject to decreasing levels of both stability and enforcement. I show how one pillar of the neodevelopmental regime, the array of initiatives to encourage incremental innovations, has fostered the acquisition of innovative capabilities in the Brazilian pharmaceutical sector, and how these new capabilities have altered actors’ policy preferences and thus contributed to the erosion of the coalition in support of the other pillar of the neodevelopmental regime, the health-oriented approach to examining pharmaceutical patents. The analysis of capability-derived preference formation points to an endogenous process of coalitional change.

US photovoltaic patents: 1991--1993

DOE Office of Scientific and Technical Information (OSTI.GOV)

Pohle, L

1995-03-01

This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials as well as manufacturing and support functions. The patent entries in this document were issued from 1991 to 1993. The entries were located by searching USPA, the database of the US Patent Office. The final search retrieved all patents under the class ``Batteries, Thermoelectric and Photoelectric`` and the subclasses ``Photoelectric,`` ``Testing,`` and ``Applications.`` The search also located patents that contained the words ``photovoltaic(s)`` or ``solar cell(s)`` and their derivatives. After the initial list was compiled, most of the patents on the following subjects weremore » excluded: space photovoltaic technology, use of the photovoltaic effect for detectors, and subjects only peripherally concerned with photovoltaic. Some patents on these three subjects were included when ft appeared that those inventions might be of use in terrestrial PV power technologies.« less

78 FR 67339 - Initial Patent Applications

Federal Register 2010, 2011, 2012, 2013, 2014

2013-11-12

... collection; Extension of Comment Period. SUMMARY: The United States Patent and Trademark Office (USPTO), as... Information Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450... to take this opportunity to comment on the revision of a continuing information collection. DATES...

A user-friendly tool for medical-related patent retrieval.

PubMed

Pasche, Emilie; Gobeill, Julien; Teodoro, Douglas; Gaudinat, Arnaud; Vishnyakova, Dina; Lovis, Christian; Ruch, Patrick

2012-01-01

Health-related information retrieval is complicated by the variety of nomenclatures available to name entities, since different communities of users will use different ways to name a same entity. We present in this report the development and evaluation of a user-friendly interactive Web application aiming at facilitating health-related patent search. Our tool, called TWINC, relies on a search engine tuned during several patent retrieval competitions, enhanced with intelligent interaction modules, such as chemical query, normalization and expansion. While the functionality of related article search showed promising performances, the ad hoc search results in fairly contrasted results. Nonetheless, TWINC performed well during the PatOlympics competition and was appreciated by intellectual property experts. This result should be balanced by the limited evaluation sample. We can also assume that it can be customized to be applied in corporate search environments to process domain and company-specific vocabularies, including non-English literature and patents reports.

43 CFR 3862.8 - Patents for mining claims.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Patents for mining claims. 3862.8 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8 Patents for mining claims. ...

43 CFR 3862.8 - Patents for mining claims.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Patents for mining claims. 3862.8 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8 Patents for mining claims. ...

43 CFR 3862.8 - Patents for mining claims.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Patents for mining claims. 3862.8 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8 Patents for mining claims. ...

43 CFR 3862.8 - Patents for mining claims.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Patents for mining claims. 3862.8 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8 Patents for mining claims. ...

Patent border wars: defining the boundary between scientific discoveries and patentable inventions.

PubMed

Holman, Christopher M

2007-12-01

Drawing an appropriate boundary between unpatentable natural phenomena and patentable inventions is crucial in preventing the patent laws from unduly restricting access to fundamental scientific discoveries. Some would argue that, particularly in the U.S., patents are being issued that purport to claim a novel product or process but that, in effect, encompass any practical application of a fundamental biological principle. Examples include gene patents, which Congress is considering banning, and patents relating to biological correlations and pathways, such as the patents at issue in the headline-grabbing LabCorp v. Metabolite and Ariad v. Eli Lilly litigations. In view of the mounting concern, it seems likely that Congress and/or the courts will address the issue, and perhaps substantially shift the boundary.

Digital pathology: A systematic evaluation of the patent landscape.

PubMed

Cucoranu, Ioan C; Parwani, Anil V; Vepa, Suryanarayana; Weinstein, Ronald S; Pantanowitz, Liron

2014-01-01

Digital pathology is a relatively new field. Inventors of technology in this field typically file for patents to protect their intellectual property. An understanding of the patent landscape is crucial for companies wishing to secure patent protection and market dominance for their products. To our knowledge, there has been no prior systematic review of patents related to digital pathology. Therefore, the aim of this study was to systematically identify and evaluate United States patents and patent applications related to digital pathology. Issued patents and patent applications related to digital pathology published in the United States Patent and Trademark Office (USPTO) database (www.uspto.gov) (through January 2014) were searched using the Google Patents search engine (Google Inc., Mountain View, California, USA). Keywords and phrases related to digital pathology, whole-slide imaging (WSI), image analysis, and telepathology were used to query the USPTO database. Data were downloaded and analyzed using the Papers application (Mekentosj BV, Aalsmeer, Netherlands). A total of 588 United States patents that pertain to digital pathology were identified. In addition, 228 patent applications were identified, including 155 that were pending, 65 abandoned, and eight rejected. Of the 588 patents granted, 348 (59.18%) were specific to pathology, while 240 (40.82%) included more general patents also usable outside of pathology. There were 70 (21.12%) patents specific to pathology and 57 (23.75%) more general patents that had expired. Over 120 unique entities (individual inventors, academic institutions, and private companies) applied for pathology specific patents. Patents dealt largely with telepathology and image analysis. WSI related patents addressed image acquisition (scanning and focus), quality (z-stacks), management (storage, retrieval, and transmission of WSI files), and viewing (graphical user interface (GUI), workflow, slide navigation and remote control). An

Digital pathology: A systematic evaluation of the patent landscape

PubMed Central

Cucoranu, Ioan C.; Parwani, Anil V.; Vepa, Suryanarayana; Weinstein, Ronald S.; Pantanowitz, Liron

2014-01-01

Introduction: Digital pathology is a relatively new field. Inventors of technology in this field typically file for patents to protect their intellectual property. An understanding of the patent landscape is crucial for companies wishing to secure patent protection and market dominance for their products. To our knowledge, there has been no prior systematic review of patents related to digital pathology. Therefore, the aim of this study was to systematically identify and evaluate United States patents and patent applications related to digital pathology. Materials and Methods: Issued patents and patent applications related to digital pathology published in the United States Patent and Trademark Office (USPTO) database (www.uspto.gov) (through January 2014) were searched using the Google Patents search engine (Google Inc., Mountain View, California, USA). Keywords and phrases related to digital pathology, whole-slide imaging (WSI), image analysis, and telepathology were used to query the USPTO database. Data were downloaded and analyzed using the Papers application (Mekentosj BV, Aalsmeer, Netherlands). Results: A total of 588 United States patents that pertain to digital pathology were identified. In addition, 228 patent applications were identified, including 155 that were pending, 65 abandoned, and eight rejected. Of the 588 patents granted, 348 (59.18%) were specific to pathology, while 240 (40.82%) included more general patents also usable outside of pathology. There were 70 (21.12%) patents specific to pathology and 57 (23.75%) more general patents that had expired. Over 120 unique entities (individual inventors, academic institutions, and private companies) applied for pathology specific patents. Patents dealt largely with telepathology and image analysis. WSI related patents addressed image acquisition (scanning and focus), quality (z-stacks), management (storage, retrieval, and transmission of WSI files), and viewing (graphical user interface (GUI

Herbal drug patenting in India: IP potential.

PubMed

Sahoo, Niharika; Manchikanti, Padmavati; Dey, Satya Hari

2011-09-01

Herbal drugs are gaining worldwide prominence due to their distinct advantages. Developing countries have started exploring the ethnopharmacological approach of drug discovery and have begun to file patents on herbal drugs. The expansion of R&D in Indian herbal research organizations and presence of manufacturing units at non-Indian sites is an indication of the capability to develop new products and processes. The present study attempts to identify innovations in the Indian herbal drug sector by analyzing the patenting trends in India, US and EU. Based on key word and IPC based search at the IPO, USPTO, Esp@cenet and WIPO databases, patent applications and grant in herbal drugs by Indian applicants/assignees was collected for the last ten years (from 1st January 2001 to 31st October 2010). From this collection patents related to human therapeutic use only were selected. Analysis was performed to identify filing trends, major applicants/assignees, disease area and major plant species used for various treatments. There is a gradual increase in patent filing through the years. In India, individual inventors have maximum applications and grants. CSIR, among research organizations and Hindustan Unilever, Avesthagen, Piramal Life Science, Sahajanand Biotech and Indus Biotech among the companies have the maximum granted patents in India, US and EU respectively. Diabetes, cancer and inflammatory disorders are the major areas for patenting in India and abroad. Recent patents are on new herbal formulations for treatment of AIDS, hepatitis, skin disorders and gastrointestinal disorders. A majority of the herbal patents applications and grants in India are with individual inventors. Claim analysis indicates that these patents include novel multi-herb compositions with synergistic action. Indian research organizations are more active than companies in filing for patents. CSIR has maximum numbers of applications not only in India but also in the US and EU. Patents by research

Patent Law for Computer Scientists

NASA Astrophysics Data System (ADS)

Closa, Daniel; Gardiner, Alex; Giemsa, Falk; Machek, Jörg

More than five centuries ago the first patent statute was passed by the Venetian senate. It already had most of the features of modern patent law, recognizing the public interest in innovation and granting exclusive right in exchange for a full disclosure. Some 350 years later the industrial revolution led to globalisation. The wish to protect intellectual property on a more international level evolved and supranational treaties were negotiated. Patent laws are still different in many countries, however, and inventors are sometimes at a loss to understand which basic requirements should be satisfied if an invention is to be granted a patent. This is particularly true for inventions implemented on a computer. While roughly a third of all applications (and granted patents) relate, in one way or another, to a computer, applications where the innovation mainly resides in software or in a business method are treated differently by the major patent offices. The procedures at the USPTO, JPO and EPO and, in particular, the differences in the treatment of applications centring on software are briefly explained. In later sections of this book, a wealth of examples will be presented. The methodology behind the treatment of these examples is explained.

Patent prosecution strategies for stem cell related applications.

PubMed

Kumar, Rajeev; Yeh, Jenny J; Fernandez, Dennis; Hansen, Nels

2007-09-01

Stem cell research and the intellectual property derived from it, because of its potential to completely transform health care, demand an especially high level of consideration from business and patent prosecution perspectives. As with other revolutionary technologies, ordinary risks are amplified (e.g., litigation), and ordinarily irrelevant considerations may become important (e.g., heightened level of both domestic and foreign legislative risk). In the first part of this article, general strategies for patent prosecutors such as several prosecution considerations and methods for accelerating patent prosecution process are presented. In the second part, patent prosecution challenges of stem cell-related patents and possible solutions are discussed. In the final part, ethical and public policy issues particular to stem cell-related and other biotechnological inventions are summarized.

43 CFR 3862.8-1 - Land descriptions in patents.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Land descriptions in patents. 3862.8-1... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8-1 Land descriptions in patents. The land description in a patent for...

43 CFR 3862.8-1 - Land descriptions in patents.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Land descriptions in patents. 3862.8-1... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8-1 Land descriptions in patents. The land description in a patent for...

43 CFR 3862.8-1 - Land descriptions in patents.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Land descriptions in patents. 3862.8-1... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8-1 Land descriptions in patents. The land description in a patent for...

43 CFR 3862.8-1 - Land descriptions in patents.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Land descriptions in patents. 3862.8-1... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Lode Mining Claim Patent Applications § 3862.8-1 Land descriptions in patents. The land description in a patent for...

Effect of the economic crisis on the production of immunology patents managed through the Patent Cooperation Treaty agreement from 2004-2011.

PubMed

Campos, Elena; Campos, Adolfo

2015-07-01

To determine the evolution of patents in immunology, as a result of research and innovation in the years 2004-2011. The search for patents published internationally in immunology was made by using the SCOPUSTM database. SCOPUS gives information about over 23 million patents. The extracted data from patents were: inventors and applicants; their nationalities; sections, classes and subclasses of the International Patent Classification. 89 countries. Data have been obtained from the database SCOPUS. It has been used for the international patent classification. Patents by country, Productive sectors, Productive areas. A total of 17,281 patents were applied for immunology during 2004-2011 of which 16,811 were from 30 Organisation for Economic Cooperation and Development countries, and 5326 from 28 countries in the European Union. These patents were granted in 89 countries and 13,699 of them were submitted by researchers from only one country. Private entities applied for 62.45% of all patents, universities 17.48%, hospitals 3.40% and public research organisations and private applicants applied for the rest. The university that made more applications was the University of California with 315 and the company was Genentech Inc. (US) with 302. The reduction in the number of applications of international patents in all disciplines of science also affected the area of immunology. Collaboration in immunology between universities, companies and hospitals is hard because their interests are different. It is shown in patent applications that the majority of patents in immunology are applied for by only one entity. Patents in immunology are developed, mainly, in aspects such as medical preparations, peptides, mutation or genetic engineering, therapeutic activity of chemical compounds and analysing materials by determining their chemical or physical properties.

43 CFR 3864.1 - Millsite patents: General.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Millsite patents: General. 3864.1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1 Millsite patents: General. ...

43 CFR 3864.1 - Millsite patents: General.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Millsite patents: General. 3864.1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1 Millsite patents: General. ...

43 CFR 3864.1 - Millsite patents: General.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Millsite patents: General. 3864.1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1 Millsite patents: General. ...

43 CFR 3864.1 - Millsite patents: General.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Millsite patents: General. 3864.1 Section... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Millsite Patents § 3864.1 Millsite patents: General. ...

Evaluation of Brazilian biotechnology patent activity from 1975 to 2010.

PubMed

Dias, F; Delfim, F; Drummond, I; Carmo, A O; Barroca, T M; Horta, C C; Kalapothakis, E

2012-08-01

The analysis of patent activity is one methodology used for technological monitoring. In this paper, the activity of biotechnology-related patents in Brazil were analyzed through 30 International Patent Classification (IPC) codes published by the Organization for Economic Cooperation and Development (OECD). We developed a program to analyse the dynamics of the major patent applicants, countries and IPC codes extracted from the Brazilian Patent Office (INPI) database. We also identified Brazilian patent applicants who tried to expand protection abroad via the Patent Cooperation Treaty (PCT). We had access to all patents published online at the INPI from 1975 to July 2010, including 9,791 biotechnology patent applications in Brazil, and 163 PCTs published online at World Intellectual Property Organization (WIPO) from 1997 to December 2010. To our knowledge, there are no other online reports of biotechnology patents previous to the years analyzed here. Most of the biotechnology patents filed in the INPI (10.9%) concerned measuring or testing processes involving nucleic acids. The second and third places belonged to patents involving agro-technologies (recombinant DNA technology for plant cells and new flowering plants, i.e. angiosperms, or processes for obtaining them, and reproduction of flowering plants by tissue culture techniques). The majority of patents (87.2%) were filed by nonresidents, with USA being responsible for 51.7% of all biotechnology patents deposited in Brazil. Analyzing the resident applicants per region, we found a hub in the southeast region of Brazil. Among the resident applicants for biotechnology patents filed in the INPI, 43.5% were from São Paulo, 18.3% were from Rio de Janeiro, and 9.7% were from Minas Gerais. Pfizer, Novartis, and Sanofi were the largest applicants in Brazil, with 339, 288, and 245 biotechnology patents filed, respectively. For residents, the largest applicant was the governmental institution FIOCRUZ (Oswaldo Cruz

Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents.

PubMed

Perez-Santos, Martin; Anaya-Ruiz, Maricruz; Bandala, Cindy

2017-01-01

Data mining publications and patent data can provide decision support for scientists, inventors and industry in the field of cancer research. The main objective of this article it to identify trends of research and patent generation productivity originating from Latin American countries in the field of cancer. Publications were collected from the Scopus, Web of Science, PubMed database; and patents were collected from Latipat Espacenet databases. Data from January 1, 2000 until December 31, 2014 were searched for documents with specific words in cancer as a ''topic'' and a list of 20 Latin American countries as affiliation country. A total of 12,989 items published and 244 patent applications including "cancer" were retrieved. Brazil, Mexico, Argentina, Chile and Peru were highest contributors in cancer research, while Brazil, Mexico, Cuba and Argentina were highest contributors in cancer patent applications. The analysis of the data from this study provides an overview of research and patent activity in Latin America in the cancer field, which can be useful to help health policy makers and people in academia to shape up cancer research in the future. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Therapeutic and cosmetic applications of mangiferin: a patent review.

PubMed

Telang, Manasi; Dhulap, Sivakami; Mandhare, Anita; Hirwani, Rajkumar

2013-12-01

Mangiferin, a natural C-glucoside xanthone [2-C-β-D-glucopyranosyl-1, 3, 6, 7-tetrahydroxyxanthone], is abundantly present in young leaves and stem bark of the mango tree. The xanthonoid structure of mangiferin with C-glycosyl linkage and polyhydroxy components contributes to its free radical-scavenging ability, leading to a potent antioxidant effect as well as multiple biological activities. An extensive search was carried out to collect patent information on mangiferin and its derivatives using various patent databases spanning all priority years to date. The patents claiming therapeutic and cosmetic applications of mangiferin and its derivatives were analyzed in detail. The technology areas covered in this article include metabolic disorders, cosmeceuticals, multiple uses of the same compound, miscellaneous uses, infectious diseases, inflammation, cancer and autoimmune disorders, and neurological disorders. Mangiferin has the potential to modulate multiple molecular targets including nuclear factor-kappa B (NF-κB) signaling and cyclooxygenase-2 (COX-2) protein expression. Mangiferin exhibits antioxidant, antidiabetic, antihyperuricemic, antiviral, anticancer and antiinflammatory activities. The molecular structure of mangiferin fulfils the four Lipinski's requisites reported to favor high bioavailability by oral administration. There is no evidence of adverse side effects of mangiferin so far. Mangiferin could thus be a promising candidate for development of a multipotent drug.

The ethics of patenting human embryonic stem cells.

PubMed

Chapman, Audrey R

2009-09-01

Just as human embryonic stem cell research has generated controversy about the uses of human embryos for research and therapeutic applications, human embryonic stem cell patents raise fundamental ethical issues. The United States Patent and Trademark Office has granted foundational patents, including a composition of matter (or product) patent to the Wisconsin Alumni Research Foundation (WARF), the University of Wisconsin-Madison's intellectual property office. In contrast, the European Patent Office rejected the same WARF patent application for ethical reasons. This article assesses the appropriateness of these patents placing the discussion in the context of the deontological and consequentialist ethical issues related to human embryonic stem cell patenting. It advocates for a patent system that explicitly takes ethical factors into account and explores options for new types of intellectual property arrangements consistent with ethical concerns.

Patents and nanomedicine.

PubMed

Bawa, Raj

2007-06-01

Big pharma's business model, which relies on a few blockbusters to generate profits, is clearly broken. Patent expiration on numerous blockbusters in recent years is already altering the drug landscape. Drug companies are also facing other challenges that necessitate development and implementation of novel R&D strategies, including those that focus on nanotechnology and miniaturization. Clearly, there is enormous excitement and expectation regarding nanomedicine's potential impact. However, securing valid and defensible patent protection will be critical. Although early forecasts for nanomedicine commercialization are encouraging, there are numerous bottlenecks as well. One of the major hurdles is an emerging thicket of patent claims, resulting primarily from patent proliferation as well as continued issuance of surprisingly broad patents by the US Patent and Trademark Office (PTO). Adding to this confusion is the fact that the US National Nanotechnology Initiative's widely cited definition of nanotechnology is inaccurate and irrelevant from a nanomedicine perspective. It is also the cause of the inadequate patent classification system that was recently unveiled by the PTO. All of this is creating a chaotic, tangled patent landscape in various sectors of nanomedicine where the competing players are unsure of the validity and enforceability of numerous issued patents. If this trend continues, it could stifle competition and limit access to some inventions. Therefore, reforms are urgently needed at the PTO to address problems ranging from poor patent quality and questionable examination practices to inadequate search capabilities, rising attrition, poor employee morale and a skyrocketing patent application backlog. Only a robust patent system will stimulate the development of commercially viable nanomedicine products that can drastically improve a patient's quality of life and reduce healthcare costs.

43 CFR 2542.4 - Patent.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Patent. 2542.4 Section 2542.4 Public Lands..., Contiguous to Spanish or Mexican Grants § 2542.4 Patent. (a) Upon submission of satisfactory proof of... there be no protest, contest or other objection against the application, patent will then be issued by...

43 CFR 2542.4 - Patent.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Patent. 2542.4 Section 2542.4 Public Lands..., Contiguous to Spanish or Mexican Grants § 2542.4 Patent. (a) Upon submission of satisfactory proof of... there be no protest, contest or other objection against the application, patent will then be issued by...

43 CFR 2542.4 - Patent.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Patent. 2542.4 Section 2542.4 Public Lands..., Contiguous to Spanish or Mexican Grants § 2542.4 Patent. (a) Upon submission of satisfactory proof of... there be no protest, contest or other objection against the application, patent will then be issued by...

43 CFR 2542.4 - Patent.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Patent. 2542.4 Section 2542.4 Public Lands..., Contiguous to Spanish or Mexican Grants § 2542.4 Patent. (a) Upon submission of satisfactory proof of... there be no protest, contest or other objection against the application, patent will then be issued by...

Effect of the economic crisis on the production of immunology patents managed through the Patent Cooperation Treaty agreement from 2004–2011

PubMed Central

Campos, Elena

2015-01-01

Objectives To determine the evolution of patents in immunology, as a result of research and innovation in the years 2004–2011. Design The search for patents published internationally in immunology was made by using the SCOPUSTM database. SCOPUS gives information about over 23 million patents. The extracted data from patents were: inventors and applicants; their nationalities; sections, classes and subclasses of the International Patent Classification. Participants 89 countries Setting Data have been obtained from the database SCOPUS. It has been used for the international patent classification. Main outcome measures Patents by country, Productive sectors, Productive areas Results A total of 17,281 patents were applied for immunology during 2004–2011 of which 16,811 were from 30 Organisation for Economic Cooperation and Development countries, and 5326 from 28 countries in the European Union. These patents were granted in 89 countries and 13,699 of them were submitted by researchers from only one country. Private entities applied for 62.45% of all patents, universities 17.48%, hospitals 3.40% and public research organisations and private applicants applied for the rest. The university that made more applications was the University of California with 315 and the company was Genentech Inc. (US) with 302. The reduction in the number of applications of international patents in all disciplines of science also affected the area of immunology. Conclusions Collaboration in immunology between universities, companies and hospitals is hard because their interests are different. It is shown in patent applications that the majority of patents in immunology are applied for by only one entity. Patents in immunology are developed, mainly, in aspects such as medical preparations, peptides, mutation or genetic engineering, therapeutic activity of chemical compounds and analysing materials by determining their chemical or physical properties. PMID:28008369

Trends in the human embryonic stem cell patent field.

PubMed

Karlsson, Ulrika; Hyllner, Johan; Runeberg, Kristina

2007-01-01

The successful derivation of human embryonic stem (hES) cell lines in late 1990s marks the birth of a new era in biomedical research. In the USA, this landmark invention is protected by granted composition-of-matter patents. In addition to these patents, several others have been granted on further development of hES cell research, such as on differentiated cell types and in vitro and in vivo use aspects. In Europe, there is presently no consensus pertaining to the patentability of hES cells, and all patent applications pending at the European patent office are therefore awaiting a principal decision by the Enlarged Board of Appeal. The authors argue that it will be of importance to the stem cell industry that patents are granted on inventions downstream in the value chain, e.g on specialised cell types derived from hES cells and different drug discovery applications. Patents and patent applications on such inventions for the three germ layers ectoderm/neuro, endoderm/hepato and mesoderm/cardio have been examined. The number of patents increased in the period 2001 to 2006 for all three lineages with ectoderm/neuro as the most patent intensive field. There where 9-13 times more US patent applications filed related to the three lineages compared to in Europe.

THE OTHER PATENT AGENCY: CONGRESSIONAL REGULATION OF THE ITC

PubMed Central

Kumar, Sapna

2009-01-01

The United States International Trade Commission has recently experienced a dramatic increase in patent infringement investigations under § 337 of the Tariff Act of 1930. In fact, the number of patent enforcement actions submitted to the ITC has nearly doubled in the last five years. Patent holders are selecting this forum because of its speedy proceedings and its ability to award broad exclusion orders. This rise in ITC patent litigation, however, has revealed weaknesses in the structure of § 337. In broadening the provision to facilitate the enforcement of patent rights, Congress failed to consider the impact of this change on technological innovation and on the coherence of the patent system. In particular, Congress did not clarify the relationship between § 337 and the Patent Act, thereby jeopardizing the uniformity of the patent system. Nor did it consider the effect that patent-related exclusion orders would have on innovation and on strategic behavior. This Article recommends that Congress harmonize ITC patent law with the Patent Act and related federal precedent, or alternatively, abolish § 337. PMID:20671808

43 CFR 2541.3 - Patents.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Patents. 2541.3 Section 2541.3 Public... § 2541.3 Patents. (a) Any applicant who satisfied all requirements for a claim of class 1 or class 2... will receive a patent conveying title to all other minerals except: (1) Any minerals which, at the time...

43 CFR 2541.3 - Patents.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Patents. 2541.3 Section 2541.3 Public... § 2541.3 Patents. (a) Any applicant who satisfied all requirements for a claim of class 1 or class 2... will receive a patent conveying title to all other minerals except: (1) Any minerals which, at the time...

43 CFR 2541.3 - Patents.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Patents. 2541.3 Section 2541.3 Public... § 2541.3 Patents. (a) Any applicant who satisfied all requirements for a claim of class 1 or class 2... will receive a patent conveying title to all other minerals except: (1) Any minerals which, at the time...

43 CFR 2541.3 - Patents.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Patents. 2541.3 Section 2541.3 Public... § 2541.3 Patents. (a) Any applicant who satisfied all requirements for a claim of class 1 or class 2... will receive a patent conveying title to all other minerals except: (1) Any minerals which, at the time...

Modern evaluation of patents

NASA Astrophysics Data System (ADS)

Ignat, V.

2016-08-01

The number of patents is not so important as the market value. The market value is especially important for licensing of patents, make-or-buy decisions for technology procurement, corporate finance. Patents can be used as collateral for financing. Patents and credit approvals: without patents only 46% and with patents 54%. The value share of knowledge-based components to industrial products already reached 50% and it is still rising. OECD called these developments under the slogan "knowledge economy”. German Norm-DIN 77100 provides a working method for monetary evaluation of a patent. The value of a patent arises from its use. A patent can be used to protect or to earn licensing revenues. An evaluation expertise is required in areas, such as marketing, finance, R & D and strategic planning. As an indicator of the value of a patent is often used the number of citations. The number of a patent citation refers to its meaning and value. Other indicators would be: size of the patent family, validity of the patent, result of objections against patent application, number and quality of claims. The analysis of 9.000 patents resulted that only 7.2% worth over 10 million euro and 68% below 1 million euro. The cost method: it is considered the cost that would be incurred for the development and patenting of a similar invention. The market method: are used the prices that have been achieved in comparable with recently transactions. The Income method: the potential reward is measured, which can arise from a patent. The evaluation will be in the following areas: legal status, technology, market conditions, finance and strategy. Each question relates to a different parameter of a value.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 06)

NASA Technical Reports Server (NTRS)

1975-01-01

Patents and applications for patent introduced into the NASA scientific and technical information system are cited. Each entry consists of a citation, an abstract, and a key illustration selected from the patent or application for patent. The patent and application for patent citations are indexed according to subject, inventor, source, number, and accession number.

Patent life of antiretroviral drugs approved in the US from 1987 to 2007.

PubMed

Rodriguez-Monguio, Rosa; Seoane-Vazquez, Enrique

2009-06-01

This study analyzes the effective patent life of antiretroviral (ARV) new molecular entities (NMEs) approved for marketing in the United States (US) between 1987 and 2007. The study includes all NMEs approved during the study period with at least one patent listed in the Orange Book (OB). Drugs discontinued from the market were excluded from the analysis. Data sources are the US Food and Drug Administration (FDA) and the US Patent and Trademark Office. A comparison between the effective patent life of ARV NMEs and NMEs from other therapeutic classes was performed. The first and last patents were used to estimate the minimum and maximum effective patent life of NMEs. Group differences were assessed using group comparison t-tests, Chi-Square and Fishers' exact tests. The FDA approved 547 NMEs during the study period; 153 NMEs did not have a patent listed in the OB or were discontinued from the US market. The patent analysis included 22 ARV NMEs and 372 other NMEs. ARV MNEs had a range from 1 to 15 patents listed in the OB. The FDA new drug application (NDA) review time was shorter for ARVs (5.8+/-2.3 months) than for other NMEs (23.6+/-18.7 months). ARV NMEs had an average of 13.2+/-3.8 years of effective patent life for the first patent versus 11.0+/-4.2 years for other NMEs. ARV NMEs had an average of 17.5+/-3.6 years of effective patent life for the last patent versus the 14.8+/-4.8 years for other NMEs. The effective patent life listed for the last patent of seven ARV NMEs (31.8%) exceeded 20 years. Shortening the drug approval process increased the effective patent life of ARVs and facilitated faster entry of new drugs into the market. ARVs had an average of 2-3 more years of effective patent life than other therapeutic classes and, therefore, a longer period without generic competition.

How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?

PubMed

Sampat, Bhaven N; Amin, Tahir

2013-08-01

The 1995 Trade Related Intellectual Property Rights (TRIPS) agreement required developing countries to grant product patents in pharmaceuticals. Developing countries have since explored various measures to ameliorate potential negative effects of the new laws on public health. A prominent example is India, whose post-TRIPS patent laws include a provision, section 3(d), that restricts patents on incremental pharmaceutical innovations. Its critics and supporters alike suggest that this provision makes Indian patent law very different from that in other jurisdictions. Yet there are concerns that given resource constraints facing the Indian patent office, this novel feature of Indian patent laws on the books may not have an effect on Indian patent prosecution in practice. We test this by examining the prosecution outcomes of 2,803 applications filed in both India and Europe, coded by whether they include claims that trigger 3(d) considerations. We find that having the 3(d) provision on the books does not translate into very different patent outcomes in practice in India, relative to Europe, a jurisdiction without this provision.

Review of patents and application of spray drying in pharmaceutical, food and flavor industry.

PubMed

Patel, Bhavesh B; Patel, Jayvadan K; Chakraborty, Subhashis

2014-04-01

Spray drying has always remained an energetic field of innovation in pharmaceutical, food and flavor industry since last couple of decades. The current communication embodies an in-depth application of spray drying in pulmonary drug delivery for production of uniform and respirable size particles suitable for nebulizers, dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI). The review also highlights spray drying application in the manufacturing of mucoadhesive formulation suitable for nasal cavities to improve the drug absorption and bioavailability. Recent research works and patents filed by various researchers on spray drying technology for solubility enhancement have also been accentuated. Benefits of spray drying in production of dry flavorings to meet a product with maximum yield and least flavor loss are also discussed. The use of spray drying in production of various food products like milk or soymilk powder, tomato pulp, dry fruit juice etc, and in encapsulation of vegetable oil or fish oil and dry creamer has been discussed. Current review also highlights the application of spray drying in the biotechnology field like production of dry influenza or measles vaccine as well as application in ceramic industry. Spray drying based patents issued by the U.S. Patent and Trademark Office in the area of drug delivery have also been included in the current review to emphasize importance of spray drying in the recent research scenario.

Protecting new ideas and inventions in nanomedicine with patents.

PubMed

Bawa, Raj; Bawa, S R; Maebius, Stephen B; Flynn, Ted; Wei, Chiming

2005-06-01

New paradigms are shrinking our world. Tiny is in and patents are essential for success in nanomedicine. In fact, patents are already shaping this nascent and rapidly evolving field. For the past decade a swarm of patent applications pertaining to nanomedicine has been arriving at the US Patent and Trademark Office (PTO). As companies develop products and processes and begin to seek commercial applications for their inventions, securing valid and defensible patent protection will be vital to their long-term survival. As we enter the "golden era" of medicine, or nanomedicine, in the next decade with the field maturing and the promised breakthroughs accruing, patents will generate licensing revenue, provide leverage in deals and mergers, and reduce the likelihood of infringement. Because development of nanobiotechnology- and nanomedicine-related products is extremely research intensive, without the market exclusivity offered by a US patent, development of these products and their commercial viability in the marketplace will be significantly hampered. In this article, we highlight critical issues relating to patenting nanomedicine products. Effects of the "nanopatent land grab" that is underway in nanomedicine by "patent prospectors" are examined as startups and corporations compete to lock up broad patents in these critical early days. Because nanomedicine is multidisciplinary, patenting presents unique opportunities and poses numerous challenges. Although patents are being sought more actively and enforced more vigorously, the entire patent system is under greater scrutiny and strain, with the PTO continuing to struggle with evaluating nanomedicine-related patent applications.

Gene and genetic diagnostic method patent claims: a comparison under current European and US patent law

PubMed Central

Huys, Isabelle; Van Overwalle, Geertrui; Matthijs, Gert

2011-01-01

The paper focuses on the fundamental debate that is going on in Europe and the United States about whether genes and genetic diagnostic methods are to be regarded as inventions or subject matter eligible for patent protection, or whether they are discoveries or principles of nature and thus excluded from patentability. The study further explores some possible scenarios of American influences on European patent applications with respect to genetic diagnostic methods. Our analysis points out that patent eligibility for genes and genetic diagnostic methods, as discussed in the United States in the Association of Molecular Pathology versus US Patent and Trademark Office decision, is based on a different reasoning compared with the European Patent Convention. PMID:21654725

Gene and genetic diagnostic method patent claims: a comparison under current European and US patent law.

PubMed

Huys, Isabelle; Van Overwalle, Geertrui; Matthijs, Gert

2011-10-01

The paper focuses on the fundamental debate that is going on in Europe and the United States about whether genes and genetic diagnostic methods are to be regarded as inventions or subject matter eligible for patent protection, or whether they are discoveries or principles of nature and thus excluded from patentability. The study further explores some possible scenarios of American influences on European patent applications with respect to genetic diagnostic methods. Our analysis points out that patent eligibility for genes and genetic diagnostic methods, as discussed in the United States in the Association of Molecular Pathology versus US Patent and Trademark Office decision, is based on a different reasoning compared with the European Patent Convention.

Investigation of At-Risk Patent Filings

ERIC Educational Resources Information Center

Livne, O.

2003-01-01

The author presents an investigation of patent-application filings made without external financial support, or "at-risk", based on inventions disclosed to the University of California from fiscal years 1991 to 2000. The success of the at-risk patent applications filed on these invention disclosures is examined from the perspective of…

43 CFR 3863.1-2 - Proof of improvements for patent.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Proof of improvements for patent. 3863.1-2... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-2 Proof of improvements for patent. The proof of improvements must...

43 CFR 3863.1-2 - Proof of improvements for patent.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Proof of improvements for patent. 3863.1-2... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-2 Proof of improvements for patent. The proof of improvements must...

43 CFR 3863.1-2 - Proof of improvements for patent.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Proof of improvements for patent. 3863.1-2... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-2 Proof of improvements for patent. The proof of improvements must...

43 CFR 3863.1-2 - Proof of improvements for patent.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Proof of improvements for patent. 3863.1-2... MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT APPLICATIONS Placer Mining Claim Patent Applications § 3863.1-2 Proof of improvements for patent. The proof of improvements must...

Glidden's Patent Application for Barbed Wire. Teaching with Documents.

ERIC Educational Resources Information Center

National Archives and Records Administration, Washington, DC.

Life in the western United States was reshaped by a series of patents for a simple tool that helped ranchers tame the land: barbed wire. Nine patents for improvements to wire fencing were granted by the U.S. Patent Office to U.S. inventors beginning with Michael Kelly in 1868 and ending with Joseph Glidden in 1874. Vast and undefined prairies and…

75 FR 17380 - Patents Ombudsman Pilot Program

Federal Register 2010, 2011, 2012, 2013, 2014

2010-04-06

... Private Patent Application Information Retrieval (PAIR) system, or contact the various help desks for... before April 6, 2011. FOR FURTHER INFORMATION CONTACT: Mindy Fleisher, Special Programs Advisor... Ombudsman Pilot Program. SUPPLEMENTARY INFORMATION: The majority of patent applications filed with the USPTO...

Patents in Nanobiotechnology: A Cross Jurisdictional Approach.

PubMed

Manchikanti, Padmavati; Uppala, Shailaja; Bonta, Ramesh Kumar

2017-01-01

Bionanomaterials create new opportunities for advancing medical sciences and diseases treatment in relation to human health care. Innovations in the use of such nanomaterials and nanodevices can lead to significant improvements in the use of drugs/devices. The present study attempts to analyse patenting trends in different areas and compare the patentability criteria and the disclosure norms for nanobiotechnology inventions in countries such as US, EU and India in the field of diagnostics and therapeutics. Nanobiotechnology patents were identified based on the search using IPC/CPC as well as keywords conducted on Relecura (a web-based patent and portfolio analysis platform). Growth of filing/ grants and by area was analysed. Comparative analysis of the patentability criteria was done to identify challenges in prosecution of nanobiotechnology applications. US, China, followed by Europe are top patent filing countries in nanobiotechnology. Topic maps indicate medicinal preparations to be the major area of patenting. There is an increase in patenting in BRIC since 2000. The assessment of novelty, inventive step and specific disclosure norms in different jurisdictions related to nanobiotechnology inventions reveal challenges in patent prosecution. 79% of the overall nanobiotechnology patents are from the medicinal preparation area followed by a significant number in case of diagnostic and surgical applications. The upward trend in patenting indicates to the potential of inventions in the field of diagnostics. The development of objective and subjective criteria with respect to patentability indicates to elaborate patent office practice and prosecution in this area. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 09)

NASA Technical Reports Server (NTRS)

1976-01-01

There are 200 patents and applications for patent introduced into the NASA scientific and technical information system during the period January 1976 through June 1976 presented. Each entry consists of a citation, an abstract, and, in most cases, a key illustration selected from the patent or application for patent. There are 2,994 patent and application for patent citations covering the period May 1969 through June 1976 listed. Subject, inventor, source, number, and accession number indexes are set forth.

76 FR 55364 - Rules for Patent Maintenance Fees

Federal Register 2010, 2011, 2012, 2013, 2014

2011-09-07

... DEPARTMENT OF COMMERCE United States Patent and Trademark Office Rules for Patent Maintenance Fees... States Patent and Trademark Office (USPTO) charges fees for maintaining in force all utility patents based on applications filed on or after December 12, 1980. Payment of these maintenance fees is due at 3...

Gene patents: a broken incentives system.

PubMed

Huang, Yun-Han

2013-12-01

The proliferation of patents on human genes has raised important ethical questions centered on the conflict of patient rights and intellectual property rights. With the Supreme Court's June 2013 decision that altered the patent eligibility of genetic material, it is important to reexamine the ethical implications of gene patents as a concept. Such patents suggest an ownership of genetic material that may hinder access to healthcare and inhibit medical progress. The application of the current patent system to genetic material thus violates patients' rights without fulfilling the system's goal of promoting innovation, suggesting a need for a revised incentives infrastructure.

Patenting of nanopharmaceuticals in drug delivery: no small issue.

PubMed

du Toit, Lisa Claire; Pillay, Viness; Choonara, Yahya E; Pillay, Samantha; Harilall, Sheri-lee

2007-01-01

Nanotechnology is a rapidly evolving interdisciplinary field based on the manipulation of matter on a submicron scale, encompassing matter between 1 and 100 nanometers (nm). The currently registered nanotechnology patents comprise 35 countries being involved in the global distribution of these patents. Close to 3000 patents were issued in the USA since 1996 with the term 'nano' in the patents, with a considerable number having application in nanomedicine. The large majority of therapeutic patents are focused on drug delivery systems, highlighting an important application globally. Nanopharmaceutical patents are centered mainly on non-communicable diseases, with cancer receiving the greatest focus, followed by hepatitis. Drug delivery systems employing nanotechnology have the ability to allow superior drug absorption, controlled drug release and reduced side-effects, enhancing the effectiveness of existing drug delivery systems. Nanoparticle-based drug delivery systems may be among the first types of products to generate serious nanotechnology patent disputes as the multi-billion dollar pharmaceutical industry begins to adopt them. This review article aimed to locate patented nanopharmaceuticals in drug delivery online, employing pertinent key terms while searching the patent databases. Awarded and pending patents in the past 20 years pertaining to nanopharmaceutical or nano-enabled systems such as micelles, nanoemulsions, nanogels, liposomes, nanofibres, dendrimer technology and polymer therapeutics are presented in the review article, providing an overview of the diversity of the patent applications.

Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010.

PubMed

Sun, Shaoyi; Cohen, Charles J; Dehnhardt, Christoph M

2014-09-01

There has been intense interest in developing inhibitors of the sodium channel Nav1.7 because genetic studies have established very strong validation for the efficacy to alleviate both inflammatory and neuropathic pain. This review summarizes patent applications targeting Nav1.7 since 2010 until May, 2014. We have classified the patents into three categories as follows: small molecules with well-defined molecular selectivity among sodium channel isoforms; biologicals with well-defined molecular selectivity; and, small molecules that inhibit Nav1.7 with unknown molecular selectivity. Most of the review is dedicated to small molecule selective compounds.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 18)

NASA Technical Reports Server (NTRS)

1981-01-01

Abstracts are cited for 120 patents and patent applications for patents introduced into the NASA scientific system during the period of July 1980 through December 1980. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent.

NASA Patent Abstracts: A Continuing Bibliography. Supplement 54

NASA Technical Reports Server (NTRS)

1999-01-01

The NASA Patent Abstracts Bibliography is a semiannual NASA publication containing comprehensive abstracts of NASA owned inventions covered by U.S. patents and applications for patent. The citations included in the bibliography arrangement of citations were originally published in NASA's Scientific and Technical Aerospace Reports (STAR) and cover STAR announcements made since May 1969. The citations published in this issue cover the period June 1998 through December 1998. This issue includes 10 major subject divisions separated into 76 specific categories and one general category/division. Each entry consists of a STAR citation accompanied by an abstract and, when appropriate, a key illustration taken from the patent or application for patent. Entries are arranged by subject category in ascending order.

37 CFR 3.81 - Issue of patent to assignee.

Code of Federal Regulations, 2014 CFR

2014-07-01

... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Issue of patent to assignee. 3.81 Section 3.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE... of patent to assignee. (a) With payment of the issue fee: An application may issue in the name of the...

37 CFR 3.81 - Issue of patent to assignee.

Code of Federal Regulations, 2011 CFR

2011-07-01

... 37 Patents, Trademarks, and Copyrights 1 2011-07-01 2011-07-01 false Issue of patent to assignee. 3.81 Section 3.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE... of patent to assignee. (a) With payment of the issue fee: An application may issue in the name of the...

37 CFR 3.81 - Issue of patent to assignee.

Code of Federal Regulations, 2012 CFR

2012-07-01

... 37 Patents, Trademarks, and Copyrights 1 2012-07-01 2012-07-01 false Issue of patent to assignee. 3.81 Section 3.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE... of patent to assignee. (a) With payment of the issue fee: An application may issue in the name of the...

37 CFR 3.81 - Issue of patent to assignee.

Code of Federal Regulations, 2013 CFR

2013-07-01

... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Issue of patent to assignee. 3.81 Section 3.81 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE... of patent to assignee. (a) With payment of the issue fee: An application may issue in the name of the...

Pharmaceutical patents and price controls.

PubMed

Vogel, Ronald J

2002-07-01

Since 1995, every member-country of the World Trade Organization (WTO) has agreed to honor a 20-year patent-life, from the date of a pharmaceutical company's application for the patent, in the country of application. Patent protection retards competitive imitation of an invented product. This kind of protection is particularly important for pharmaceuticals, because pharmaceuticals that are not derived from biotechnology can be imitated easily and inexpensively. The economic function of a patent is to allow a period of above-normal profits for a technically and commercially successful product; these profits stimulate further investment and invention. However, direct price controls, or permutations of direct price controls on pharmaceutical compounds, can fully or partially circumvent the economic intent of patent agreements. This paper formulates an economic model that takes into account demand and cost/supply dimensions of the output and pricing of a hypothetical pharmaceutical, extrapolating about the respective effects of direct price controls and lack of price controls, and describing permutations of direct price controls in different countries. The pharmaceutical industry depends on patents to fund the development and introduction of new products. A country can indirectly circumvent the economic logic of a patent by using price controls, but it cannot shift the economic costs of such a policy to another country that does not use price controls. Instead, less money is available for research and development (R&D). Pharmaceutical price controls allow some countries to avoid the constraints of patent agreements without breaking those agreements outright. This, in turn, reduces the amount of profit available for further R&D, which is a detriment to consumers worldwide.

[INDENA SPA company's patent portfolio of Ginkgo biloba preparation].

PubMed

Wang, Nan; Guo, Kai; Cheng, Xin-min; Liu, Wei

2015-10-01

INDENA SPA Company in Italy is a multi-national company that produces and sells plant extracts. Based on its own re- search advantages in the field of Ginkgo biloba preparation, the company protects its own products market effectively through building patent portfolio around the patents of its opponent. Based on the multi-angle analysis for patent portfolio of G. biloba preparation from the aspects of application time, legal status, technical development route, and patent portfolio layout, this article provides technical reference on research and development of G. biloba preparation, and the author suggest that Chinese applicants learn techniques and layout experiences of other patents fully to enhance the level of research and patent protection level.

Japan's patent issues relating to life science therapeutic inventions.

PubMed

Tessensohn, John A

2014-09-01

Japan has made 'innovation in science and technology' as one of its central pillars to ensure high growth in its next stage of economic development and its life sciences market which hosts regenerative medicine was proclaimed to be 'the best market in the world right now.' Although life science therapeutic inventions are patentable subject matter under Japanese patent law, there are nuanced obviousness and enablement challenges under Japanese patent law that can be surmounted in view of some encouraging Japanese court developments in fostering a pro-patent applicant environment in the life sciences therapeutic patent field. Nevertheless, great care must be taken when drafting and prosecuting such patent applications in the world's second most important life sciences therapeutic market.

Analysis of Patent Databases Using VxInsight

DOE Office of Scientific and Technical Information (OSTI.GOV)

BOYACK,KEVIN W.; WYLIE,BRIAN N.; DAVIDSON,GEORGE S.

2000-12-12

We present the application of a new knowledge visualization tool, VxInsight, to the mapping and analysis of patent databases. Patent data are mined and placed in a database, relationships between the patents are identified, primarily using the citation and classification structures, then the patents are clustered using a proprietary force-directed placement algorithm. Related patents cluster together to produce a 3-D landscape view of the tens of thousands of patents. The user can navigate the landscape by zooming into or out of regions of interest. Querying the underlying database places a colored marker on each patent matching the query. Automatically generatedmore » labels, showing landscape content, update continually upon zooming. Optionally, citation links between patents may be shown on the landscape. The combination of these features enables powerful analyses of patent databases.« less

Indian pharmaceutical patent prosecution: The changing role of Section 3(d).

PubMed

Sampat, Bhaven N; Shadlen, Kenneth C

2018-01-01

India, like many developing countries, only recently began to grant pharmaceutical product patents. Indian patent law includes a provision, Section 3(d), which tries to limit grant of "secondary" pharmaceutical patents, i.e. patents on new forms of existing molecules and drugs. Previous research suggests the provision was rarely used against secondary applications in the years immediately following its enactment, and where it was, was redundant to other aspects of the patent law, raising concerns that 3(d) was being under-utilized by the Indian Patent Office. This paper uses a novel data source, the patent office's first examination reports, to examine changes in the use of the provision. We find a sharp increase over time in the use of Section 3(d), including on the main claims of patent applications, though it continues to be used in conjunction with other types of objections to patentability. More surprisingly, see a sharp increase in the use of the provision against primary patent applications, contrary to its intent, raising concerns about potential over-utilization.

Indian pharmaceutical patent prosecution: The changing role of Section 3(d)

PubMed Central

2018-01-01

India, like many developing countries, only recently began to grant pharmaceutical product patents. Indian patent law includes a provision, Section 3(d), which tries to limit grant of “secondary” pharmaceutical patents, i.e. patents on new forms of existing molecules and drugs. Previous research suggests the provision was rarely used against secondary applications in the years immediately following its enactment, and where it was, was redundant to other aspects of the patent law, raising concerns that 3(d) was being under-utilized by the Indian Patent Office. This paper uses a novel data source, the patent office’s first examination reports, to examine changes in the use of the provision. We find a sharp increase over time in the use of Section 3(d), including on the main claims of patent applications, though it continues to be used in conjunction with other types of objections to patentability. More surprisingly, see a sharp increase in the use of the provision against primary patent applications, contrary to its intent, raising concerns about potential over-utilization. PMID:29608604

Patent Administration by Office Computer - A Case at Mazda Motor Corporation

NASA Astrophysics Data System (ADS)

Kimura, Ikuo; Nakamura, Shinji

The needs of patent administration have been diversified reflecting R&D activities under the severe competition of technical development, and business has been increased in quantity year after year as seen in patent application. Under these circumstances it is necessary to develop business mechanization which assists manual operation as much as possible to enforce the patent administration. Introducing office computer (CPU 512 KB, external memory 128 MB) for exclusive use in this purpose, Patent Department of Mazda Motor Corporation has been constructing database of patent administration centered around patent application by their own company, and utilizes it for automatic preparation of business forms, preparation of various statistical materials, and real-time reference to the application procedures.

37 CFR 1.221 - Voluntary publication or republication of patent application publication.

Code of Federal Regulations, 2010 CFR

2010-07-01

... filing system requirements and be accompanied by the publication fee set forth in § 1.18(d) and the..., the Office will not publish the application and will refund the publication fee. (b) The Office will... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Voluntary publication or...

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 05)

NASA Technical Reports Server (NTRS)

1974-01-01

This bibliography is issued in two sections: Section 1 - Abstracts, and section 2 - Indexes. The abstract section cites 217 patents and applications for patent introduced into the NASA scientific and technical information system during the period of January 1974 through June 1974. Each entry consists of a citation, an abstract, and, in most cases, a key illustration selected from the patent or application for patent. The index section contains entries for 2653 patent and application for patent citations covering the period May 1969 through June 1974. The index section contains five indexes -- subject, inventor, source, number and accession number.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 08)

NASA Technical Reports Server (NTRS)

1976-01-01

This bibliography is issued in two sections; abstracts and indexes. The Abstract Section cites 180 patents and applications for patents introduced into the NASA scientific and technical information system during the period of July 1975 through December 1975. Each entry in the Abstract Section consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent. The index Section contains entries for 2,905 patents and applications for patent citations covering the period May 1969 through December 1975. The Index Section contains five indexes -- subject, inventor, source, number and accession number.

Study on the Application of Chinese Patent Drug and Chinese Formula of Rabdosia Rubescens

NASA Astrophysics Data System (ADS)

Peng, Mengfan; Liu, Baosong; Mao, Mingsan

2018-01-01

Rabdosia rubescens contais many active ingredients such as terpenoids, flavonoids, polysaccharides and organic acids. Modern research has proved that Rabdosia rubescens has the effect of heat-clearing and detoxicating, antibacterial and anticancer, promoting blood circulation to arrest pain and anti-tumor. It is used in the treatment of sore throat, rheumatoid arthritis and various kinds of cancer. The clinical application of Rabdosia rubescens is restricted in the fat-soluble components, and the solubility of water solubility is ignored. The application of prescriptions, Chinese patent drug and food therapy of Rabdosia rubescens are less and fragmented. This paper inquires relevant literature, the application of Rabdosia rubescens in prescription, Chinese patent medicine and food therapy was reviewed, in order to make Rabdosiae rubescens play a greater role in the relevant area. On the basis of make the best use of everything, to promote the innovation and development of Chinese medicine and services to the people in our country.

75 FR 15419 - Notice of Intent To Grant Exclusive License of U.S. Patent Application No. 12/432,842 Filed April...

Federal Register 2010, 2011, 2012, 2013, 2014

2010-03-29

... damaged due to extreme traffic loads or numbers, the system may be reworked and re-compacted with no loss... Exclusive License of U.S. Patent Application No. 12/432,842 Filed April 30, 2009 Entitled: ``A Soil... is made of a prospective exclusive license of the following U.S. Patent Application No. 12/432,842...

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 32)

NASA Technical Reports Server (NTRS)

1988-01-01

Abstracts are provided for 136 patents and patent applications entered into the NASA scientific and technical information system during the period July through December 1987. Each entry consists of a citation , an abstract, and in most cases, a key illustration selected from the patent or patent application.

[The Glivec® case: the first example of a global debate on the drug patent system].

PubMed

Moital, Inês; Bosch, Fèlix; Farré, Magí; Maddaleno, Mariano; Baños, Josep-E

2014-01-01

To describe the sequence of events involving the Glivec® case in India and to analyze the opinions generated in distinct settings. We performed a systematic search for articles concerning the imatinib (Glivec®) patent in India. We selected those sources that described the events, decisions of the authorities involved, and press and scientific opinions. Dates and arguments presented by the involved parties were clearly identified. Of 886 documents initially obtained, we selected 40 documents published between 2003 and 2013. Most of them were press news and commentaries. The process lasted 7 years, starting in 2006 when the Indian Patent Office rejected the patent application filed by Novartis. It ended in 2013 when the Indian Supreme Court upheld this decision. It was argued that the Indian Patent Law would facilitate access to medicines in the Third World and the final decision has received support by the general population. Although the court's final decision has been supported by several institutions, an objective analysis should also take into account the arguments of the pharmaceutical companies and other entities. The Glivec® case gave rise to an intense debate on the appropriateness of international standards on patents, their applicability and how they should be adopted in each country. This case, as well as other cases, should serve to stimulate reflection on the international patent system and to achieve scenarios in which the health of the poorest populations is protected but also balanced against intellectual property protection and innovation. Copyright © 2014 SESPAS. Published by Elsevier Espana. All rights reserved.

Osteoclast differentiation inhibitors: a patent review (2008 - 2012).

PubMed

Kim, Seong Hwan; Moon, Seong-Hee

2013-12-01

Mononuclear macrophage/monocyte-lineage hematopoietic precursors differentiate into multinucleated osteoclasts. Abnormally increased numbers and/or overactivation of osteoclasts can lead to bone loss. Therefore, pharmaceutical inhibition of osteoclast differentiation is one therapeutic strategy for mitigating the occurrence of bone loss-associated disorders and related fractures. This review surveys the patents and patent applications from 2008 to 2012 that are related to inventions of therapeutics and/or methods for inhibiting osteoclast differentiation. Over the past 20 years, the identification and validation of signaling molecules involved in osteoclast differentiation has led to a better understanding of the molecular mechanism, and to the development of new therapeutic agents for treating bone loss-associated disorders. Since 2008, 34 WO patents or patent applications have been filed that relate to inventions of therapeutics and/or methods for chemical-based, natural product-based, or biological-based inhibitors of osteoclast differentiation. Here, analysis of these patents and patent applications is presented, and summarize the disclosed osteoclast differentiation-inhibiting target molecules. This report can support further advances in the development of anti-osteoclastogenic therapeutics for bone loss-associated disorders, including osteoporosis, rheumatoid arthritis, Paget's disease, periodontal disease, osteosarcoma, and cancer bone metastasis.

77 FR 14686 - Claims for Patent and Copyright Infringement

Federal Register 2010, 2011, 2012, 2013, 2014

2012-03-13

... history of each patent, if it is available to the claimant. Indicate whether the patent has been the... corresponding foreign patents and patent applications and full copies of the same. (11) Pertinent prior art known to the claimant not contained in the USPTO file, for example, publications and foreign prior art...

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 31)

NASA Technical Reports Server (NTRS)

1987-01-01

Abstracts are provided for 85 patents and patent applications entered into the NASA scientific and technical information system during the period January 1987 through June 1987. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 24)

NASA Technical Reports Server (NTRS)

1984-01-01

Abstracts are provided for 167 patents and patent applications entered into the NASA scientific and technical information system during the period July 1983 through December 1983. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 27)

NASA Technical Reports Server (NTRS)

1985-01-01

Abstracts are provided for 92 patents and patent applications entered into the NASA scientific and technical information system during the period January 1985 through June 1985. Each entry consist of a citation, and abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 45)

NASA Technical Reports Server (NTRS)

1994-01-01

Abstracts are provided for 137 patents and patent applications entered into the NASA scientific and technical information system during the period Jan. 1994 through Jun. 1994. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography. A continuing bibliography (supplement 22). Section 1: Abstracts

NASA Technical Reports Server (NTRS)

1983-01-01

Abstracts are cited for 234 patents and patent applications introduced into the NASA scientific and technical information system during the period July 1982 through December 1982. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 35)

NASA Technical Reports Server (NTRS)

1989-01-01

Abstracts are provided for 58 patents and patent applications entered into the NASA scientific and technical information systems during the period January 1989 through June 1989. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 37)

NASA Technical Reports Server (NTRS)

1989-01-01

Abstracts are provided for 76 patents and patent applications entered into the NASA scientific and technical information systems during the period January 1990 through June 1990. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 30)

NASA Technical Reports Server (NTRS)

1987-01-01

Abstracts are provided for 105 patents and patent applications entered into the NASA scientific and technical information system during the period July 1986 through December 1986. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 38)

NASA Technical Reports Server (NTRS)

1991-01-01

Abstracts are provided for 132 patents and patent applications entered into the NASA scientific and technical information system during the period July 1990 through December 1990. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 39)

NASA Technical Reports Server (NTRS)

1991-01-01

Abstracts are provided for 154 patents and patent applications entered into the NASA scientific and technical information systems during the period Jan. 1991 through Jun. 1991. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 43)

NASA Technical Reports Server (NTRS)

1993-01-01

Abstracts are provided for 128 patents and patent applications entered into the NASA scientific and technical information system during the period Jan. 1993 through Jun. 1993. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 42)

NASA Technical Reports Server (NTRS)

1993-01-01

Abstracts are provided for 174 patents and patent applications entered into the NASA scientific and technical information system during the period July 1992 through December 1992. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 36)

NASA Technical Reports Server (NTRS)

1990-01-01

Abstracts are provided for 63 patents and patent applications entered into the NASA scientific and technical information systems during the period July 1989 through December 1989. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 40)

NASA Technical Reports Server (NTRS)

1992-01-01

Abstracts are provided for 181 patents and patent applications entered into the NASA scientific and technical information system during the period July 1991 through December 1991. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 28)

NASA Technical Reports Server (NTRS)

1986-01-01

Abstracts are provided for 109 patents and patent applications entered into the NASA Scientific and Technical Information System during the period July 1985 through December 1985. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA Patent Abstracts Bibliography: A Continuing Bibliography. Section 1: Abstracts (Supplement 48)

NASA Technical Reports Server (NTRS)

1996-01-01

Abstracts are provided for 85 patents and patent applications entered into the NASA scientific and technical information system during the period July 1995 through December 1995. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 25)

NASA Technical Reports Server (NTRS)

1984-01-01

Abstracts are provided for 102 patents and patent applications entered into the NASA scientific and technical information system during the period January 1984 through June 1984. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 33)

NASA Technical Reports Server (NTRS)

1988-01-01

Abstracts are provided for 16 patents and patent applications entered into the NASA scientific and technical information systems during the period January 1988 through June 1988. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 15)

NASA Technical Reports Server (NTRS)

1979-01-01

Abstracts are cited for 240 patents and applications for patents introduced into the NASA scientific system during the period of January 1979 through June 1979. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 26)

NASA Technical Reports Server (NTRS)

1985-01-01

Abstracts are provided for 172 patents and patent applications entered into the NASA scientific and technical information system during the period July 1984 through December 1984. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 16)

NASA Technical Reports Server (NTRS)

1980-01-01

Abstracts are cited for 138 patents and patent applications introduced into the NASA scientific and technical information system during the period July 1979 through December 1979. Each entry cib consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 23)

NASA Technical Reports Server (NTRS)

1983-01-01

Abstracts are cited for 129 patents and patent applications introduced into the NASA scientific and technical information system during the period January 1983 through June 1983. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 34)

NASA Technical Reports Server (NTRS)

1989-01-01

Abstracts are provided for 124 patents and patent applications entered into the NASA scientific and technical information systems during the period July 1988 through December 1988. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 41)

NASA Technical Reports Server (NTRS)

1992-01-01

Abstracts are provided for 131 patents and patent applications entered into the NASA scientific and technical information system during the period Jan. 1992 through Jun. 1992. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 44)

NASA Technical Reports Server (NTRS)

1994-01-01

Abstracts are provided for 131 patents and patent applications entered into the NASA scientific and technical information system during the period Jun. 1993 through Dec. 1993. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 20)

NASA Technical Reports Server (NTRS)

1982-01-01

Abstracts are cited for 165 patents and patent applications introduced into the NASA scientific and technical information system during the period July 1981 through December 1981. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or patent application.

Patent protection and licensing in microfluidics.

PubMed

Yetisen, Ali K; Volpatti, Lisa R

2014-07-07

Microfluidic devices offer control over low-volume samples in order to achieve high-throughput analysis, and reduce turnaround time and costs. Their efficient commercialisation has implications for biomedical sciences, veterinary medicine, environmental monitoring and industrial applications. In particular, market diffusion of microfluidic laboratory and point-of-care diagnostic devices can contribute to the improvement of global health. In their commercialisation, consultancy and patent protection are essential elements that complement academic publishing. The awareness of knowledge transfer strategies can help academics to create value for their research. The aim of this article is to provide a guidance to (1) overview the terminology in patent law, (2) elucidate the process of filing a patent in the US, EU, Japan and internationally, (3) discuss strategies to licence a patent, and (4) explain tactics to defend a patent in a potential infringement. Awareness of the patent law and rights allows obtaining optimised, valid and valuable patents, while accelerating implementation to market route. Striking a balance between academic publishing, consultancy to industry and patent protection can increase commercial potential, enhance economic growth and create social impact.

37 CFR 2.67 - Suspension of action by the Patent and Trademark Office.

Code of Federal Regulations, 2013 CFR

2013-07-01

... Patent and Trademark Office. 2.67 Section 2.67 Patents, Trademarks, and Copyrights UNITED STATES PATENT... Application and Action by Applicants § 2.67 Suspension of action by the Patent and Trademark Office. Action by the Patent and Trademark Office may be suspended for a reasonable time for good and sufficient cause...

37 CFR 2.67 - Suspension of action by the Patent and Trademark Office.

Code of Federal Regulations, 2012 CFR

2012-07-01

... Patent and Trademark Office. 2.67 Section 2.67 Patents, Trademarks, and Copyrights UNITED STATES PATENT... Application and Action by Applicants § 2.67 Suspension of action by the Patent and Trademark Office. Action by the Patent and Trademark Office may be suspended for a reasonable time for good and sufficient cause...

37 CFR 2.67 - Suspension of action by the Patent and Trademark Office.

Code of Federal Regulations, 2011 CFR

2011-07-01

... Patent and Trademark Office. 2.67 Section 2.67 Patents, Trademarks, and Copyrights UNITED STATES PATENT... Application and Action by Applicants § 2.67 Suspension of action by the Patent and Trademark Office. Action by the Patent and Trademark Office may be suspended for a reasonable time for good and sufficient cause...

37 CFR 2.67 - Suspension of action by the Patent and Trademark Office.

Code of Federal Regulations, 2010 CFR

2010-07-01

... Patent and Trademark Office. 2.67 Section 2.67 Patents, Trademarks, and Copyrights UNITED STATES PATENT... Application and Action by Applicants § 2.67 Suspension of action by the Patent and Trademark Office. Action by the Patent and Trademark Office may be suspended for a reasonable time for good and sufficient cause...

37 CFR 2.67 - Suspension of action by the Patent and Trademark Office.

Code of Federal Regulations, 2014 CFR

2014-07-01

... Patent and Trademark Office. 2.67 Section 2.67 Patents, Trademarks, and Copyrights UNITED STATES PATENT... Application and Action by Applicants § 2.67 Suspension of action by the Patent and Trademark Office. Action by the Patent and Trademark Office may be suspended for a reasonable time for good and sufficient cause...

Patent controversies and court cases

PubMed Central

Fialho, Arsenio M.; Chakrabarty, Ananda M.

2012-01-01

Patents are issued essentially by all countries on inventions that are deemed novel, non-obvious, clearly described and of significant utility or industrial application. The only exceptions to patenting an invention are abstract ideas, laws of nature and natural phenomena, although the exceptions vary depending on countries where moral, public order or human rights considerations are also taken into account. Although patent laws are updated over decades, the rapid progress of science creates situations that the patent laws on the book cannot address, leading to contentious legal issues. This is often true for life saving drugs, particularly drugs for cancers or HIV/AIDS, which are expensive and beyond the reach of poor people because of the proprietary positions of these patented drugs. Another contentious issue is the patent eligibility of human genes and mutations that are often thought of nature's contribution to human health and propagation and should be beyond the reach of patentability. In this review, we address some of these current legal issues and their implications for the development of diagnostic methods, therapeutic interventions and even prevention for cancer, a scourge of mankind. PMID:22954683

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 07)

NASA Technical Reports Server (NTRS)

1975-01-01

This bibliography is issued in two sections: Section 1 - Abstracts, and Section 2 - Indexes. This issue of the Abstract Section cites 158 patents and applications for patent introduced into the NASA scientific and technical information system during the period of January 1975 through June 1975. Each entry in the Abstract Section consists of a citation, an abstract, and, in most cases, a key illustration selected from the patent or application for patent. This issue of the Index Section contains entries for 2830 patent and application for patent citations covering the period May 1969 through June 1975. The index section contains five indexes -- subject, inventor, source, number and accession number.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 09)

NASA Technical Reports Server (NTRS)

1976-01-01

This bibliography is issued in two sections: Section 1 - Abstracts, and Section 2 - Indexes. This issue of the Abstract Section cites 200 patents and applications for patent introduced into the NASA scientific and technical information system during the period of January 1976 through June 1976. Each entry in the Abstract Section consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent. This issue of the Index Section contains entries for 2994 patent and application for patent citations covering the period May 1969 through June 1976. The Index Section contains five indexes -- subject, inventor, source, number and accession number.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 08)

NASA Technical Reports Server (NTRS)

1976-01-01

This bibliography is issued in two sections: Section 1 - Abstracts, and Section 2 - Indexes. This issue of the Abstract Section cites 180 patents and applications for patents introduced into the NASA scientific and technical information system during the period July 1975 through December 1975. Each entry in the Abstract Section consists of a citation, an abstract, and, in most cases, a key illustration selected from the patent or application for patent. This issue of the Index Section contains entries for 2,905 patents and applications for patent citations covering the period May 1969 through December 1975. The Index Section contains five indexes -- subject, inventor, source, number, and accession number.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 19)

NASA Technical Reports Server (NTRS)

1981-01-01

Abstracts are cited for 130 patents and patent applications introduced into the NASA scientific and technical information system during the period of January 1981 through July 1981. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 17)

NASA Technical Reports Server (NTRS)

1980-01-01

Abstracts are cited for 150 patents and applications for patents introduced into the NASA scientific and technical information system during the period January 1980 through June 1980. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent.

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 14)

NASA Technical Reports Server (NTRS)

1979-01-01

Abstracts are cited for 213 patents and applications for patent introduced into the NASA scientific and technical information system during the period of July 1978 through December 1978. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent.

37 CFR 401.14 - Standard patent rights clauses.

Code of Federal Regulations, 2011 CFR

2011-07-01

... clauses. 401.14 Section 401.14 Patents, Trademarks, and Copyrights ASSISTANT SECRETARY FOR TECHNOLOGY... performance. (3) Practical Application means to manufacture in the case of a composition or product, to... Disclosure, Election of Title and Filing of Patent Application by Contractor (1) The contractor will disclose...

37 CFR 401.14 - Standard patent rights clauses.

Code of Federal Regulations, 2010 CFR

2010-07-01

... clauses. 401.14 Section 401.14 Patents, Trademarks, and Copyrights ASSISTANT SECRETARY FOR TECHNOLOGY... performance. (3) Practical Application means to manufacture in the case of a composition or product, to... Disclosure, Election of Title and Filing of Patent Application by Contractor (1) The contractor will disclose...

Analysis of Taiwan patents for the medicinal mushroom "Niu-Chang- Chih".

PubMed

Chen, Yu-Fen; Lu, Wen-Ling; Wu, Ming-Der; Yuan, Gwo-Fang

2013-04-01

"Niu-Chang-Chih" (Antrodia cinnanomea) is a medicinal mushroom that has only been collected from the aromatic tree, Cinnamomum kanehirai, which is native to Taiwan. A total of 105 Taiwan patent applications and patents for "Niu-Chang-Chih" were collected and analyzed. Patent applications and granted patents claiming newly identified functional components from "Niu-Chang-Chih," biologically pure cultures of the mushroom strain, and cultivation of "Niu-Chang-Chih" were examined. Several applications and patents claim identified active compounds from "Niu-Chang- Chih," which provide better patent protection. These newly identified functional compounds include cyclohexanones, maleic and succinic acid derivatives, labdane diterpenoids, and benzenoids. Newly identified functional proteins include a glutathione-dependent formaldehyde dehydrogenase (GFD), a glycoprotein named ACA1, and a laccase. Newly identified functional polysaccharides include ACP1, ACP2, and ACP3. The number of patents for newly identified compounds and their uses are expected to continue growing.

Environmentally conscious patent histories

NASA Astrophysics Data System (ADS)

Crouch, Dennis D.; Crouch, Henry L.

2004-02-01

There is a need for investigators, legislators, and business leaders to understand the magnitude of innovation and discovery in the field of environmentally conscious technologies (ECTs). Knowledge of the "big picture" is important to providing a national and global account of actual environmental stewardship over the last twenty-five years. A recitation of the Environmental Protection Agency (EPA) supported Acts which have been enacted into law reveals one facet of the multifaceted dynamic of environmental consciousness. The popular discussion and debate, as well as partisan lobbying, which created the political forces leading to environmentally conscious legislation is another facet. A third facet is the corporate response to the threats and opportunities predicted by CEO"s and others through environmental scanning. This paper examines changes in environmentally conscious inventive effort by comparing data from United States Patents issued from 1976 through 2003. Patents are useful tool for measuring technological innovation because they are publicly available records of innovative activity. Although not all inventions result in patent applications, the monopoly rights granted on the invention give the inventor a strong incentive to obtain patents on any viable product or process. Among the results, we found a significant increase in patents relating to environmentally conscious products and processes during the period in question. Specifically, a dramatic increase in patent activity was seen for the decade of the 1990"s. Surprisingly, the patenting rate from 2000 to 2003 seems to have stabilized. Additionally public discussion of ECTs appears to have a positive impact on patent filings.

Co-processed excipients: a patent review.

PubMed

Garg, Nidhi; Dureja, Harish; Kaushik, Deepak

2013-04-01

The introduction of high speed tableting machines and the preference of direct compression as a method of tableting have increased the demands on the functionality of excipients mainly in terms of flowability and compressibility. Co-processed excipients, where in, excipients are combined by virtue of sub-particle level interaction have provided an attractive tool for developing high functionality excipients. The multifold advantages offered by co-processed excipients such as production of synergism in functionality of individual components, reduction of company's regulatory concern because of absence of chemical change during co-processing and improvement in physico-chemical properties have expanded their use in the pharmaceutical industry. In the recent years, there has been a spurt in the number of patents filed on co-processed excipients. Hence, the present review focuses on co-processed excipients and their application in pharmaceutical industry. The worldwide databases of European patent office (http://ep.espacenet.com) and United States patent office (www.uspto.gov) were employed to collect the patents and patent applications. The advantages, limitations, basis for the selection of excipients to be co-processed, methods of co-processing and regulatory perspective of co-processed excipients are also briefly discussed.

Software Patents.

ERIC Educational Resources Information Center

Burke, Edmund B.

1994-01-01

Outlines basic patent law information that pertains to computer software programs. Topics addressed include protection in other countries; how to obtain patents; kinds of patents; duration; classes of patentable subject matter, including machines and processes; patentability searches; experimental use prior to obtaining a patent; and patent…

Patents and patent office resources in biotechnology.

PubMed

Koniarek, J P; Coleman, K D

1988-02-01

Patents play an increasingly important role in the dissemination of information in many fast moving fields such as biotechnology and semiconductors. Quite a few new developments are introduced as patents, and only later, if at all, do they find their way into the scientific literature. In spite of this, patents lack wide acceptance as a source of information among scientists in academia and, to a lesser degree, industry. Patents share many similarities with scientific papers. They both are organized in a similar way and are carefully reviewed by experts in the field. Both can be effective and timely sources of information. Patents can be accessed through data bases, library collections, the "Official Gazette of the Patent and Trademark Office," or directly in the Patent and Trademark Office. This article is designed to serve as a guide to the type of information which can be found in patents, and alternatives for obtaining this information.

A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions?

PubMed Central

van Zimmeren, Esther; Verbeure, Birgit; Matthijs, Gert; Van Overwalle, Geertrui

2006-01-01

In genetic diagnostics, the emergence of a so-called "patent thicket" is imminent. Such an overlapping set of patent rights may have restrictive effects on further research and development of diagnostic tests, and the provision of clinical diagnostic services. Currently, two models that may facilitate access to and use of patented genetic inventions are attracting much debate in various national and international fora: patent pools and clearing houses. In this article, we explore the concept of clearing houses. Several types of clearing houses are identified. First, we describe and discuss two types that would provide access to information on the patented inventions: the information clearing house and the technology exchange clearing house. Second, three types of clearing houses are analysed that not only offer access to information but also provide an instrument to facilitate the use of the patented inventions: the open access clearing house, the standardized licences clearing house and the royalty collection clearing house. A royalty collection clearing house for genetic diagnostic testing would be the most comprehensive as it would serve several functions: identifying patents and patent claims essential to diagnostic testing, matching licensees with licensors, developing and supplying standardized licences, collecting royalties, monitoring whether users respect licensing conditions, and providing dispute resolution services such as mediation and arbitration. In this way, it might function as an effective model for users to facilitate access to and use of the patented inventions. However, it remains to be seen whether patent holders with a strong patent portfolio will be convinced by the advantages of the royalty collection clearing house and be willing to participate. PMID:16710543

Patent Reform Proposals Raise the Stakes for Researchers, Manufacturers of Biologics

PubMed Central

Kravetz, Shayna B.; Frei, Rosemary

2008-01-01

When the founding fathers provided for patents in the American Constitution, they could hardly have envisioned the 21st-century demands the U.S. Patents and Trademarks Office (PTO) face today. The PTO is an institution that is, by definition, concerned with the new—one essential element of a patent is novelty; however, it is also struggling to fit the needs of modern biotech research and development within a framework conceived by the young American government in the 18th century. In their new book Biotechnology and the Patent System (AEI Press, Washington, DC, 2007), Claude Barfield, PhD, and John Calfee, PhD, both Resident Scholars at the American Enterprise Institute, Washington, DC, discuss reforms being considered by legislators, lawyers, and members of the biotechnology industry that could modernize the patent system and make it work for all the stakeholders. The proposed reforms include changing the way patent applications are filed and pursued, limiting encumbrances that slow the application process, providing more funding to the PTO to speed consideration of applications, granting interested parties the right to intervene while a patent application is being considered, and limiting the administrative and economic burdens associated with the mushrooming numbers of patents for each product or process. PMID:25126213

Patent reform proposals raise the stakes for researchers, manufacturers of biologics.

PubMed

Kravetz, Shayna B; Frei, Rosemary

2008-03-01

When the founding fathers provided for patents in the American Constitution, they could hardly have envisioned the 21st-century demands the U.S. Patents and Trademarks Office (PTO) face today. The PTO is an institution that is, by definition, concerned with the new-one essential element of a patent is novelty; however, it is also struggling to fit the needs of modern biotech research and development within a framework conceived by the young American government in the 18th century. In their new book Biotechnology and the Patent System (AEI Press, Washington, DC, 2007), Claude Barfield, PhD, and John Calfee, PhD, both Resident Scholars at the American Enterprise Institute, Washington, DC, discuss reforms being considered by legislators, lawyers, and members of the biotechnology industry that could modernize the patent system and make it work for all the stakeholders. The proposed reforms include changing the way patent applications are filed and pursued, limiting encumbrances that slow the application process, providing more funding to the PTO to speed consideration of applications, granting interested parties the right to intervene while a patent application is being considered, and limiting the administrative and economic burdens associated with the mushrooming numbers of patents for each product or process.

37 CFR 1.18 - Patent post allowance (including issue) fees.

Code of Federal Regulations, 2010 CFR

2010-07-01

... entity $1,190.00 (d) Publication fee $300.00. (e) For filing an application for patent term adjustment... (including issue) fees. 1.18 Section 1.18 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions Fees...

Trends in Nanopharmaceutical Patents

PubMed Central

Antunes, Adelaide; Fierro, Iolanda; Guerrante, Rafaela; Mendes, Flavia; Alencar, Maria Simone de M.

2013-01-01

Investment in nanotechnology is now a given constant by governments, research centers and companies in both more developed countries and emerging markets. Due to their characteristics, such as high stability, ability to enable antigen identification on specific cells in the human body and controlling the release of drugs and, therefore, improving therapies, nanoparticles have been the subject of research and patent applications in the pharmaceutical field. According to the Organization for Economic Co-operation and Development (OCDE), patent data can be used as a source of information in order to measure science and technology activities. Thereby, this paper presents an analysis based on patent documents related to nanotechnology in the pharmaceutical sector. As a result, the analysis of patents demonstrate primarily that nanobiotechnology attracts high levels of R&D investments, including nanoparticle-based chemotherapeutic agents/drugs, monoclonal antibody nanoparticle complexes and their role in drug delivery or contrast agents with non-toxic effects. PMID:23535336

Quinoxaline derivatives: a patent review (2006--present).

PubMed

González, Mercedes; Cerecetto, Hugo

2012-11-01

Quinoxaline scaffold is included in a large number of therapeutic agents because of its physicochemical properties that make the difference between them and the carbono analogue, naphthalene. This review of patented products presents the quinoxaline heterocycle as part of the structural patent claims from a medicinal chemistry perspective. We centred our discussion in the various drug patent applications of the quinoxaline and its derivatives. The applications are based firstly in the specific enzyme target with very low development in the disease treatment. Only for cancer and antimicrobial agents they were specifically determined but little is mentioned in order to insight in the last development activities.

78 FR 2960 - Request for Comments on Preparation of Patent Applications

Federal Register 2010, 2011, 2012, 2013, 2014

2013-01-15

... with experts in industry to provide technical training for patent examiners and updates on developments... with training on topics such as obviousness under 35 U.S.C. 103 and statutory subject matter under 35 U... patent examination process. Patent examiners also receive training on 35 U.S.C. 112 to address concerns...

Patent Deployment Strategies and Patent Value in LED Industry

PubMed Central

Wu, Ming-Fu; Chang, Keng-Wei; Zhou, Wei; Hao, Juan; Yuan, Chien-Chung; Chang, Ke-Chiun

2015-01-01

This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields and markets are valued by the patent owner. Earn plan ratio defined as the ratio of the number of patent forward citations to patent family size. Earn plan ratio indicates the degree to which a patent family could be cited by later innovators and competitors. This study applies a logistic regression model in the analysis LED industry data. The results demonstrate that patent value has a positive relationship with the patent family depth, and earn plan ratio. PMID:26098313

Patent Deployment Strategies and Patent Value in LED Industry.

PubMed

Wu, Ming-Fu; Chang, Keng-Wei; Zhou, Wei; Hao, Juan; Yuan, Chien-Chung; Chang, Ke-Chiun

2015-01-01

This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields and markets are valued by the patent owner. Earn plan ratio defined as the ratio of the number of patent forward citations to patent family size. Earn plan ratio indicates the degree to which a patent family could be cited by later innovators and competitors. This study applies a logistic regression model in the analysis LED industry data. The results demonstrate that patent value has a positive relationship with the patent family depth, and earn plan ratio.

Converting STEM Doctoral Dissertations into Patent Applications: A Study of Chemistry, Physics, Mathematics, and Chemical Engineering Dissertations from CIC Institutions

ERIC Educational Resources Information Center

Butkovich, Nancy J.

2015-01-01

Doctoral candidates may request short-term embargoes on the release of their dissertations in order to apply for patents. This study examines how often inventions described in dissertations in chemical engineering, chemistry, physics, and mathematics are converted into U.S. patent applications, as well as the relationship between dissertation…

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 13)

NASA Technical Reports Server (NTRS)

1978-01-01

This bibliography is issued in two sections: Section 1 - Abstracts, and Section 2 - Indexes. This issue of the Abstract Section cites 161 patents and applications for patent introduced into the NASA scientific and technical information system during the period January 1978 through June 1978. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent or application for patent.

The stem cell patent landscape as relevant to cancer vaccines.

PubMed

Wang, Shyh-Jen

2011-10-01

Cancer vaccine targeting cancer stem cells is proposed to serve as a potent immunotherapy. Thus, it would be useful to examine the main trends in stem cell patenting activity as a guide for those seeking to develop such cancer vaccines. We found that a substantial number of stem cell patents were granted up to the end of 2010, including ~2000 issued in the US. Many of these have been filed since 2001, including 7,551 applications in the US. Stem cell development, as evidenced by the numbers of PubMed articles, has matured steadily in recent years. However, the other metrics, such as the number of patent applications, the technology-science linkage and the number of patent assignees, have been stagnant. Moreover, the ownership of stem cell patents is still quiet fragmented across multiple organizations, and the number of stem cell patent assignees from the business sector has not increased significantly. Academic and nonprofit institutions not only account for a large share of stem cell patents but also apply for patents continually. Based on this analysis, the strength of stem cell resources seems to remain stagnant in recent years due to the ban on government funding of embryonic stem cell research. Furthermore, the patent prosecution or technical barriers in the field of stem cells would be another main reason that the number of US-issued stem cell patents for each application have been in gradual decline since 2000. Therefore, we consider stem cell technology to still be under development.

34 CFR 6.1 - Publication or patenting of inventions.

Code of Federal Regulations, 2011 CFR

2011-07-01

... Education Office of the Secretary, Department of Education INVENTIONS AND PATENTS (GENERAL) § 6.1... invention to the public. Determinations to file a domestic patent application on inventions in which the... interest, and if it is practicable to do so. Department determinations not to apply for a domestic patent...

Grant Patents on Animals? An Ethical and Legal Battle Looms.

ERIC Educational Resources Information Center

Wheeler, David L.

1987-01-01

Rulings on applications for animal patents being considered by the U.S. Patent and Trademark Office could profoundly influence university patent and research income. Many animal-rights advocates have expressed philosophical objections to genetic engineering of animals. (MLW)

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 29)

NASA Technical Reports Server (NTRS)

1986-01-01

Abstracts are provided for 115 patents and patent applications entered into the NASA scientific and technical information system during the period January 1986 through June 1986. Each entry consists of a citation, an abstract, and in most cases, a key illustration selected from the patent application.

Patent protection for structural genomics-related inventions.

PubMed

Vinarov, Sara D

2003-01-01

Recently there have been some important developments with respect to the patentability of inventions in the field of structural genomics. The leaders of the European Patent Office (EPO), Japan Patent Office (JPO) and the United States Patent Office (USPTO) came together for a trilateral meeting to conduct a comparative study on protein 3-dimensional (3-D) structure related claims in an effort to come to a mutual understanding about the examination of such inventions. The three patent offices were presented with eight different cases: 1) 3-D structural data of a protein per se; 2) computer-readable storage medium encoded with structural data of a protein; 3) protein defined by its tertiary structure; 4) crystals of known proteins; 5) binding pockets and protein domains; 6) and 7) are both directed to in silico screening methods directed to a specific protein; and 8) pharmacophores. The preliminary conclusions reached at the trilateral meeting provide clarity regarding the types of inventions that may be patentable given a specific set of scientific facts in a patent application. Therefore, the guidance provided by this study will help inventors, attorneys and other patent practitioners who file for patent protection on structural genomics-based inventions both here and abroad comply with the patentability requirements of each office.

Therapeutic and cosmetic applications of Evodiamine and its derivatives--A patent review.

PubMed

Gavaraskar, Kirti; Dhulap, Sivakami; Hirwani, R R

2015-10-01

Evodiamine, ((+)-(S)-8,13,13b,14-tetrahydro-14-methylindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one) indoloquinazoline alkaloid, is the major component isolated from the fruits of Evodia rutaecarpa, family Rutaceae. Broad spectrum of pharmacological activities of Evodiamine suggests its imperative role in treating a variety of diseases influencing the function of diverse targets. A comprehensive search was carried out to collect patent information regarding Evodiamine and its derivatives using different patent databases covering priority years to till date. The patents claiming therapeutic as well as cosmetic applications of Evodiamine and its derivatives were analyzed in detail and were classified technically based on the its application such as treatment of metabolic disorders, cancer, neurological disorders, and cardiovascular disorders, etc. The analysis revealed that the use and the mode of actions of Evodiamine and its derivatives in weight management treatments are currently well established. For example the fat reducing property of this alkaloid is primarily due to its mode of actions such as prevention of muscle protein catabolism, enhancement of thermogenesis and lipid oxidation. Apart from its use for treating obesity, Evodiamine and its derivatives are also experimentally explored for their anti-cancer, anti-diabetic and anti-inflammatory properties. The possible mechanisms related to its anti-cancer activity as illustrated by different experimental studies include its potential action as modulator of specific receptors such as topoisomerase I, NF-kappa B and B-cell lymphoma 2 (Bcl2). The analysis hence highlights that, clinical studies pertaining to the anti-cancer, anti-diabetes as well as anti-inflammatory activities of the Evodiamine and its derivatives would possess important market potential for the development of Evodiamine based therapeutics. Copyright © 2015 Elsevier B.V. All rights reserved.

Nanocellulose patents trends: a comprehensive review on patents on cellulose nanocrystals, microfibrillated and bacterial cellulose.

PubMed

Charreau, Hernan; Foresti, Maria L; Vazquez, Analia

2013-01-01

Cellulose nanoparticles (i.e. cellulose elements having at least one dimension in the 1-100 nm range) have received increasing attention during the last decade. This is not only evident in academic articles, but it is also manifested by the increasing number of nanocellulose patents that are published every year. In the current review, nanocellulose patents are reviewed using specific software which provides valuable information on the annual number of patents that have been published throughout the years, main patent owners, most prolific inventors, and patents on the field that have received more citations. Patent statistics on rod-like cellulose nanoparticles extracted from plants by acid hydrolysis (nanocrystals), mechanical treatment leading to microfibrillated cellulose (MFC), and microbially produced nanofibrils (bacterial cellulose, BC) are analyzed in detail. The aim of the current review is to provide researchers with patent information which may help them in visualizing the evolution of nanocellulose technology, both as a whole and also divided among the different nanosized particles that are currently the subject of outstanding scientific attention. Then, patents are not only analyzed by their content, but also by global statistics which will reveal the moment at which different cellulose nanoparticles technologies achieved a breakthrough, the relative interest received by different nanocellulose particles throughout the years, the companies that have been most interested in this technology, the most prolific inventors, and the patents that have had more influence in further developments. It is expected that the results showing the explosion that nanocellulose technology is experiencing in current days will still bring more research on the topic and contribute to the expansion of nanocellulosics applications.

43 CFR 3863.1 - Placer mining claim patent applications: General.

Code of Federal Regulations, 2013 CFR

2013-10-01

...) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT.... (a) The proceedings to obtain patents for placer claims, including all forms of mineral deposits excepting veins of quartz or other rock in place, are similar to the proceedings prescribed for obtaining...

43 CFR 3863.1 - Placer mining claim patent applications: General.

Code of Federal Regulations, 2011 CFR

2011-10-01

...) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT.... (a) The proceedings to obtain patents for placer claims, including all forms of mineral deposits excepting veins of quartz or other rock in place, are similar to the proceedings prescribed for obtaining...

43 CFR 3863.1 - Placer mining claim patent applications: General.

Code of Federal Regulations, 2014 CFR

2014-10-01

...) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT.... (a) The proceedings to obtain patents for placer claims, including all forms of mineral deposits excepting veins of quartz or other rock in place, are similar to the proceedings prescribed for obtaining...

43 CFR 3863.1 - Placer mining claim patent applications: General.

Code of Federal Regulations, 2012 CFR

2012-10-01

...) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS MANAGEMENT (3000) MINERAL PATENT.... (a) The proceedings to obtain patents for placer claims, including all forms of mineral deposits excepting veins of quartz or other rock in place, are similar to the proceedings prescribed for obtaining...

[SCHWABE Company's patent portfolio of Ginkgo biloba preparation].

PubMed

Liu, Wei; Cheng, Xin-Min; Geng, Dong-Mei; Tan, Wei; Zou, Wen-Jun

2014-09-01

SCHWABE Company in German is the first and largest manufacturer of Ginkgo biloba preparation. The company not only has leading technology in this field, but also protects its own market effectively through the high quality of patent drafting and exactly patent layout. Based on multi-angle analysis for patent portfolio of G. biloba preparation at application time, legal status, globally layout, Chinese layout, the article provides technical reference of research and development of G. biloba, also provides valuable experience of traditonal Chinese medicine patent portfolio layout for Chinese enterprises.

37 CFR 1.821 - Nucleotide and/or amino acid sequence disclosures in patent applications.

Code of Federal Regulations, 2014 CFR

2014-07-01

...” means those amino acids other than “Xaa” and those nucleotide bases other than “n”defined in accordance... 37 Patents, Trademarks, and Copyrights 1 2014-07-01 2014-07-01 false Nucleotide and/or amino acid... Biotechnology Invention Disclosures Application Disclosures Containing Nucleotide And/or Amino Acid Sequences...

37 CFR 1.821 - Nucleotide and/or amino acid sequence disclosures in patent applications.

Code of Federal Regulations, 2013 CFR

2013-07-01

...” means those amino acids other than “Xaa” and those nucleotide bases other than “n”defined in accordance... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Nucleotide and/or amino acid... Biotechnology Invention Disclosures Application Disclosures Containing Nucleotide And/or Amino Acid Sequences...

37 CFR 1.821 - Nucleotide and/or amino acid sequence disclosures in patent applications.

Code of Federal Regulations, 2012 CFR

2012-07-01

...” means those amino acids other than “Xaa” and those nucleotide bases other than “n”defined in accordance... 37 Patents, Trademarks, and Copyrights 1 2012-07-01 2012-07-01 false Nucleotide and/or amino acid... Biotechnology Invention Disclosures Application Disclosures Containing Nucleotide And/or Amino Acid Sequences...

37 CFR 3.81 - Issue of patent to assignee.

Code of Federal Regulations, 2010 CFR

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issue of patent to assignee..., DEPARTMENT OF COMMERCE GENERAL ASSIGNMENT, RECORDING AND RIGHTS OF ASSIGNEE Issuance to Assignee § 3.81 Issue of patent to assignee. (a) With payment of the issue fee: An application may issue in the name of the...

Identification of the Key Fields and Their Key Technical Points of Oncology by Patent Analysis.

PubMed

Zhang, Ting; Chen, Juan; Jia, Xiaofeng

2015-01-01

This paper aims to identify the key fields and their key technical points of oncology by patent analysis. Patents of oncology applied from 2006 to 2012 were searched in the Thomson Innovation database. The key fields and their key technical points were determined by analyzing the Derwent Classification (DC) and the International Patent Classification (IPC), respectively. Patent applications in the top ten DC occupied 80% of all the patent applications of oncology, which were the ten fields of oncology to be analyzed. The number of patent applications in these ten fields of oncology was standardized based on patent applications of oncology from 2006 to 2012. For each field, standardization was conducted separately for each of the seven years (2006-2012) and the mean of the seven standardized values was calculated to reflect the relative amount of patent applications in that field; meanwhile, regression analysis using time (year) and the standardized values of patent applications in seven years (2006-2012) was conducted so as to evaluate the trend of patent applications in each field. Two-dimensional quadrant analysis, together with the professional knowledge of oncology, was taken into consideration in determining the key fields of oncology. The fields located in the quadrant with high relative amount or increasing trend of patent applications are identified as key ones. By using the same method, the key technical points in each key field were identified. Altogether 116,820 patents of oncology applied from 2006 to 2012 were retrieved, and four key fields with twenty-nine key technical points were identified, including "natural products and polymers" with nine key technical points, "fermentation industry" with twelve ones, "electrical medical equipment" with four ones, and "diagnosis, surgery" with four ones. The results of this study could provide guidance on the development direction of oncology, and also help researchers broaden innovative ideas and discover new

Patenting human genes: Chinese academic articles' portrayal of gene patents.

PubMed

Du, Li

2018-04-24

The patenting of human genes has been the subject of debate for decades. While China has gradually come to play an important role in the global genomics-based testing and treatment market, little is known about Chinese scholars' perspectives on patent protection for human genes. A content analysis of academic literature was conducted to identify Chinese scholars' concerns regarding gene patents, including benefits and risks of patenting human genes, attitudes that researchers hold towards gene patenting, and any legal and policy recommendations offered for the gene patent regime in China. 57.2% of articles were written by law professors, but scholars from health sciences, liberal arts, and ethics also participated in discussions on gene patent issues. While discussions of benefits and risks were relatively balanced in the articles, 63.5% of the articles favored gene patenting in general and, of the articles (n = 41) that explored gene patents in the Chinese context, 90.2% supported patent protections for human genes in China. The patentability of human genes was discussed in 33 articles, and 75.8% of these articles reached the conclusion that human genes are patentable. Chinese scholars view the patent regime as an important legal tool to protect the interests of inventors and inventions as well as the genetic resources of China. As such, many scholars support a gene patent system in China. These attitudes towards gene patents remain unchanged following the court ruling in the Myriad case in 2013, but arguments have been raised about the scope of gene patents, in particular that the increasing numbers of gene patents may negatively impact public health in China.

Metastasizing patent claims on BRCA1.

PubMed

Kepler, Thomas B; Crossman, Colin; Cook-Deegan, Robert

2010-05-01

Many patents make claims on DNA sequences; some include claims on oligonucleotides related to the primary patented gene. We used bioinformatics to quantify the reach of one such claim from patent 4,747,282 on BRCA1. We find that human chromosome 1 (which does not contain BRCA1) contains over 300,000 oligonucleotides covered by this claim, and that 80% of cDNA and mRNA sequences contributed to GenBank before the patent application was filed also contain at least one claimed oligonucleotide. Any "isolated" DNA molecules that include such 15 bp nucleotide sequences would fall under the claim as granted by the US Patent and Trademark Office. Anyone making, using, selling, or importing such a molecule for any purpose within the United States would thus be infringing the claim. This claim and others like it turn out, on examination, to be surprisingly broad, and if enforced would have substantial implications for medical practice and scientific research. Copyright 2010 Elsevier Inc. All rights reserved.

Strategies for stem cell patent applications in the light of recent court cases.

PubMed

Eyre, David E; Schlich, George W

2015-01-01

Stem cells offer the prospect of treatments for diseases and injuries that are currently beyond medical science. Although development of these potential medical marvels has been dogged by their controversial origin, technological developments and guidance from recent judicial decisions have answered and overcome many of these difficulties. In particular, the European Patent Office, United States Patent and Trademark Office, Japan Patent Office and State Intellectual Property Office of China have published guidelines covering patenting of stem cell technologies in the light of recent decisions. We now see a patent landscape where stem cell technologies and related therapies can, with very few exceptions, be protected via patents, provided the appropriate form of claim wording is used.

Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape.

PubMed

Ferreira, Raphael; David, Florian; Nielsen, Jens

2018-01-24

Clustered regularly interspaced short palindromic repeats (CRISPR) is poised to become one of the key scientific discoveries of the twenty-first century. Originating from prokaryotic and archaeal immune systems to counter phage invasions, CRISPR-based applications have been tailored for manipulating a broad range of living organisms. From the different elucidated types of CRISPR mechanisms, the type II system adapted from Streptococcus pyogenes has been the most exploited as a tool for genome engineering and gene regulation. In this review, we describe the different applications of CRISPR/Cas9 technology in the industrial biotechnology field. Next, we detail the current status of the patent landscape, highlighting its exploitation through different companies, and conclude with future perspectives of this technology.

Enabling policy planning and innovation management through patent information and co-authorship network analyses: a study of tuberculosis in Brazil.

PubMed

Vasconcellos, Alexandre Guimarães; Morel, Carlos Medicis

2012-01-01

New tools and approaches are necessary to facilitate public policy planning and foster the management of innovation in countries' public health systems. To this end, an understanding of the integrated way in which the various actors who produce scientific knowledge and inventions in technological areas of interest operate, where they are located and how they relate to one another is of great relevance. Tuberculosis has been chosen as a model for the present study as it is a current challenge for Brazilian research and innovation. Publications about tuberculosis written by Brazilian authors were accessed from international databases, analyzed, processed with text searching tools and networks of coauthors were constructed and visualized. Patent applications about tuberculosis in Brazil were retrieved from the Brazilian National Institute of Industrial Property (INPI) and the European Patent Office databases, through the use of International Patent Classification and keywords and then categorized and analyzed. Brazilian authorship of articles about tuberculosis jumped from 1% in 1995 to 5% in 2010. Article production and patent filings of national origin have been concentrated in public universities and research institutions while the participation of private industry in the filing of Brazilian patents has remained limited. The goals of national patenting efforts have still not been reached, as up to the present none of the applications filed have been granted a patent. The analysis of all this data about TB publishing and patents clearly demonstrates the importance of maintaining the continuity of Brazil's production development policies as well as government support for infrastructure projects to be employed in transforming the potential of research. This policy, which already exists for the promotion of new products and processes that, in addition to bringing diverse economic benefits to the country, will also contribute to effective dealing with public health

Enabling Policy Planning and Innovation Management through Patent Information and Co-Authorship Network Analyses: A Study of Tuberculosis in Brazil

PubMed Central

Vasconcellos, Alexandre Guimarães; Morel, Carlos Medicis

2012-01-01

Introduction New tools and approaches are necessary to facilitate public policy planning and foster the management of innovation in countries' public health systems. To this end, an understanding of the integrated way in which the various actors who produce scientific knowledge and inventions in technological areas of interest operate, where they are located and how they relate to one another is of great relevance. Tuberculosis has been chosen as a model for the present study as it is a current challenge for Brazilian research and innovation. Methodology Publications about tuberculosis written by Brazilian authors were accessed from international databases, analyzed, processed with text searching tools and networks of coauthors were constructed and visualized. Patent applications about tuberculosis in Brazil were retrieved from the Brazilian National Institute of Industrial Property (INPI) and the European Patent Office databases, through the use of International Patent Classification and keywords and then categorized and analyzed. Results/Conclusions Brazilian authorship of articles about tuberculosis jumped from 1% in 1995 to 5% in 2010. Article production and patent filings of national origin have been concentrated in public universities and research institutions while the participation of private industry in the filing of Brazilian patents has remained limited. The goals of national patenting efforts have still not been reached, as up to the present none of the applications filed have been granted a patent. The analysis of all this data about TB publishing and patents clearly demonstrates the importance of maintaining the continuity of Brazil's production development policies as well as government support for infrastructure projects to be employed in transforming the potential of research. This policy, which already exists for the promotion of new products and processes that, in addition to bringing diverse economic benefits to the country, will also contribute

Neglected knowledge in geophysics: Patents - how to find them, how to use them and how to apply for them

NASA Astrophysics Data System (ADS)

Wollny, K. G.

2013-12-01

their time, but maybe useful now, and to explore the historical background and/or timelines of inventions. Patent documents can help to avoid pitfalls and mistakes other experts might already have experienced and documented in describing the state of the art or the inspiration for their invention. It will be shown how to get access to these databases, how to use them to solve scientific problems and how to leverage search results to improve expertise, work experience or facilitate personal patent application. Patent documents resemble journal articles a lot - they contain an abstract, a description regarding the state of the art, the applicant's motivation to overcome a deficit, technical figures and claims to protect the invention. This structure is used globally for all patent documents. Besides the technical facts, they include the name of the inventor, the company applying for the patent, patent validity information and potential 'family members', which cover the same invention but often in other languages than the original patent document. To summarize, patent documents are a highly useful tool to strengthen one's knowledge in a practically orientated geophysical field and to widen the horizon to adjacent technical areas.

The therapeutic applications of antimicrobial peptides (AMPs): a patent review.

PubMed

Kang, Hee-Kyoung; Kim, Cheolmin; Seo, Chang Ho; Park, Yoonkyung

2017-01-01

Antimicrobial peptides (AMPs) are small molecules with a broad spectrum of antibiotic activities against bacteria, yeasts, fungi, and viruses and cytotoxic activity on cancer cells, in addition to anti-inflammatory and immunomodulatory activities. Therefore, AMPs have garnered interest as novel therapeutic agents. Because of the rapid increase in drug-resistant pathogenic microorganisms, AMPs from synthetic and natural sources have been developed using alternative antimicrobial strategies. This article presents a broad analysis of patents referring to the therapeutic applications of AMPs since 2009. The review focuses on the universal trends in the effective design, mechanism, and biological evolution of AMPs.

31 CFR 500.527 - Certain transactions with respect to United States patents, trademarks, and copyrights.

Code of Federal Regulations, 2010 CFR

2010-07-01

...) There are hereby authorized: (1) The filing in the United States Patent Office of applications for... States Patent Office of applications for letters patent and for trademarks registration; (4) The receipt... any instrument recordable in the United States Patent Office or the United States Copyright Office...

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 44)

NASA Technical Reports Server (NTRS)

1994-01-01

A subject index is provided for over 5500 patents and patent applications for the period May 1969 through December 1993. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 45)

NASA Technical Reports Server (NTRS)

1994-01-01

A subject index is provided for over 5600 patents and patent applications for the period May 1969 through June 1994. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 46)

NASA Technical Reports Server (NTRS)

1995-01-01

A subject index is provided for over 5600 patents and patent applications for the period May 1969 through December 1994. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 28)

NASA Technical Reports Server (NTRS)

1986-01-01

A subject index is provided for over 4800 patents and patent applications for the period May 1969 through December 1985. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. Patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 27)

NASA Technical Reports Server (NTRS)

1985-01-01

A subject index is provided for over 4300 patents and patent applications for the period May 1969 through June 1985. Additional indexes lists personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. Patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 42)

NASA Technical Reports Server (NTRS)

1993-01-01

A subject index is provided for over 4900 patents and patent applications for the period May 1969 through December 1992. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 41)

NASA Technical Reports Server (NTRS)

1992-01-01

A subject index is provided for over 5200 patents and patent applications for the period May 1969 through June 1992. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 35)

NASA Technical Reports Server (NTRS)

1989-01-01

A subject index is provided for over 4600 patents and patent applications for the period May 1969 through June 1989. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 25)

NASA Technical Reports Server (NTRS)

1984-01-01

A subject index is provided for over 4300 patents and patent applications for the period May 1969 through June 1984. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 34)

NASA Technical Reports Server (NTRS)

1989-01-01

A subject index is provided for over 4600 patents and patent applications for the period May 1969 through December 1988. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 26)

NASA Technical Reports Server (NTRS)

1985-01-01

A subject index is provided for over 4300 patents and patent applications for the period May 1969 through December 1984. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 40)

NASA Technical Reports Server (NTRS)

1992-01-01

A subject index is provided for over 5100 patents and patent applications for the period May 1969 through December 1991. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 39)

NASA Technical Reports Server (NTRS)

1991-01-01

A subject index is provided for over 5000 patents and patent applications for the period May 1969 through June 1991. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 37)

NASA Technical Reports Server (NTRS)

1989-01-01

A subject index is provided for over 4600 patents and patent applications for the period May 1969 through June 1990. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 36)

NASA Technical Reports Server (NTRS)

1990-01-01

A subject index is provided for over 4600 patents and patent applications for the period May 1969 through December 1989. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 43)

NASA Technical Reports Server (NTRS)

1993-01-01

A subject index is provided for over 5400 patents and patent applications for the period May 1969 through June 1993. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 38)

NASA Technical Reports Server (NTRS)

1991-01-01

A subject index is provided for over 4900 patents and patent applications for the period May 1969 through December 1990. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA Patent Abstracts Bibliography: A Continuing Bibliography. Section 2: Indexes (supplement 32)

NASA Technical Reports Server (NTRS)

1988-01-01

A subject index is provided for over 4700 patents and patent applications for the period May 1969 through December 1987. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 30)

NASA Technical Reports Server (NTRS)

1987-01-01

A subject index is provided for over 4500 patents and patent applications for the period May 1969 through December 1986. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA accession numbers.

Declaration of patent applications as financial interests: a survey of practice among authors of papers on molecular biology in Nature.

PubMed

Mayer, S

2006-11-01

To determine whether authors of scientific publications in molecular biology declare patents and other potential financial interests. Survey of a 6-month sample of papers related to molecular biology in Nature. The esp@cenet worldwide patent search engine was used to search for patents applied for by the authors of scientific papers in Nature that were related to molecular biology and genetics, between January and June 2005. Of the 79 papers considered, four had declared that certain authors had competing financial interests. Seven papers in which no financial interests were declared had authors with patent applications that were based on the research in the paper or were closely related to it. Another paper had two authors with connections to biotechnology companies that were not disclosed. Two thirds of the papers in which authors had patent applications or company affiliations that might be considered to be competing financial interests did not disclose them. Failure to disclose such information may have negative implications on the perception of science in society and on its quality if the possible bias is hidden. Journals should make greater efforts to ensure full disclosure, and scientific institutions should consider failure to disclose financial interests as an example of scientific malpractice. Establishing a register of interests for scientists is one way to increase transparency and openness.

Declaration of patent applications as financial interests: a survey of practice among authors of papers on molecular biology in Nature

PubMed Central

Mayer, S

2006-01-01

Objectives To determine whether authors of scientific publications in molecular biology declare patents and other potential financial interests. Design Survey of a 6‐month sample of papers related to molecular biology in Nature. Methods The esp@cenet worldwide patent search engine was used to search for patents applied for by the authors of scientific papers in Nature that were related to molecular biology and genetics, between January and June 2005. Results Of the 79 papers considered, four had declared that certain authors had competing financial interests. Seven papers in which no financial interests were declared had authors with patent applications that were based on the research in the paper or were closely related to it. Another paper had two authors with connections to biotechnology companies that were not disclosed. Conclusion Two thirds of the papers in which authors had patent applications or company affiliations that might be considered to be competing financial interests did not disclose them. Failure to disclose such information may have negative implications on the perception of science in society and on its quality if the possible bias is hidden. Journals should make greater efforts to ensure full disclosure, and scientific institutions should consider failure to disclose financial interests as an example of scientific malpractice. Establishing a register of interests for scientists is one way to increase transparency and openness. PMID:17074824

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 15)

NASA Technical Reports Server (NTRS)

1979-01-01

Entries for 3632 patents and patent applications for patent citations for the period May 1969 through 1979 are listed. Indexes for subject, inventor, source, number, and accession number, are included.

NASA Patent Abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 21) Abstracts

NASA Technical Reports Server (NTRS)

1982-01-01

Abstracts are cited for 87 patents and applications introduced into the NASA scientific and technical information system during the period of January 1982 through June 1982. Each entry consists of a citation, an abstract, and in mose cases, a key illustration selected from the patent or patent application.

43 CFR 3814.2 - Mineral reservation in patent; conditions to be noted on mineral applications.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 2 2012-10-01 2012-10-01 false Mineral reservation in patent; conditions to be noted on mineral applications. 3814.2 Section 3814.2 Public Lands: Interior Regulations Relating to Public Lands (Continued) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS...

43 CFR 3814.2 - Mineral reservation in patent; conditions to be noted on mineral applications.

Code of Federal Regulations, 2014 CFR

2014-10-01

... 43 Public Lands: Interior 2 2014-10-01 2014-10-01 false Mineral reservation in patent; conditions to be noted on mineral applications. 3814.2 Section 3814.2 Public Lands: Interior Regulations Relating to Public Lands (Continued) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS...

43 CFR 3814.2 - Mineral reservation in patent; conditions to be noted on mineral applications.

Code of Federal Regulations, 2011 CFR

2011-10-01

... 43 Public Lands: Interior 2 2011-10-01 2011-10-01 false Mineral reservation in patent; conditions to be noted on mineral applications. 3814.2 Section 3814.2 Public Lands: Interior Regulations Relating to Public Lands (Continued) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS...

43 CFR 3814.2 - Mineral reservation in patent; conditions to be noted on mineral applications.

Code of Federal Regulations, 2013 CFR

2013-10-01

... 43 Public Lands: Interior 2 2013-10-01 2013-10-01 false Mineral reservation in patent; conditions to be noted on mineral applications. 3814.2 Section 3814.2 Public Lands: Interior Regulations Relating to Public Lands (Continued) BUREAU OF LAND MANAGEMENT, DEPARTMENT OF THE INTERIOR MINERALS...

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 24)

NASA Technical Reports Server (NTRS)

1984-01-01

A subject index is provided for over 4300 patents and applications for patent for the period from May 1969 through December 1983. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, U.S. patent numbers, and NASA assession numbers,

78 FR 4211 - Setting and Adjusting Patent Fees

Federal Register 2010, 2011, 2012, 2013, 2014

2013-01-18

... United States economy depends on high quality and timely patents to protect new ideas and investments for... described in Part III of this final rule, namely, fostering innovation, facilitating effective... recovering revenue from back-end fees, the final fee schedule continues to foster innovation and ease access...

Products with Natural Components to Heal Dermal Burns: A Patent Review.

PubMed

de Melo Costa, Aida Carla Santana; Pereira Ramos, Karen Perez; Serafini, Mairim Russo; de Carvalho, Fernanda Oliveira; Teixeira, Luciana Garcez Barretto; Garcao, Diogo Costa; Shanmugam, Saravanan; de Souza Araujo, Adriano Antunes; Nunes, Paula Santos

2015-01-01

Burns are a global public health problem, and non-fatal burn injuries are a leading cause of morbidity. The scale of the problem has led researchers to seek to develop new prod- ucts (both synthetic and natural) for use in the treatment of burn lesions. The aim of this study was to examine all patents in databases between 2010 and 2015 related to natural prod- ucts for the treatment of burn-related wounds that targeted tissue repair and healing. The search term "burn" and the code A61K36/00 (plant and other natural derivatives used in medicinal prepara- tions) from the international classification of patents were used to identify treatments. The search was performed in the WIPO, ESPACENET and USPTO databases. The highest number of patent ap- plications was found in the WIPO data base (617), followed by ESPACENET(23) and USPTO(6). The USA and China were the countries with the most patent applications, and 2008 was the year that had the highest number of applications. Patent applications written in Spanish, English and Portuguese and that were published between 2010 and 2015 were se- lected. 559 patent applications in other languages, and 63 that did not result in the creation of new products between 2010 and 2015 were excluded and the remaining 13 patents application were selected for full reading of the text. Through this study we were able to identify and summarize the new active natural compounds that can be used in the treatment of burns, both in terms of tissue recovery and analgesia.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 01)

NASA Technical Reports Server (NTRS)

1972-01-01

This issue contains entries for 2202 patent and patent application citations covering the period May 1969 through June 1972. The section contains indexes of subject, inventor, source, patent number, and accession number.

Natural compounds for solar photoprotection: a patent review.

PubMed

Serafini, Mairim R; Guimarães, Adriana G; Quintans, Jullyana S S; Araújo, Adriano A S; Nunes, Paula S; Quintans-Júnior, Lucindo J

2015-04-01

Ultraviolet irradiation has deleterious effects on human skin, including tanning, sunburn, cancer and connective tissue degradation (photoaging). Botanical antioxidants have been shown to be associated with reduced incidence of photocarcinogenesis and photoaging through their photoprotective profile. Here, the authors summarized therapeutic patent applications concerning the employment of medicinal plants on the technological development of a formulation with photoprotective or photoaging application. So, the patent search was conducted in the databases WIPO, Espacenet, USPTO and Derwent, using the keywords - photoaging, photoprotection and the IPC A61K 8/97 (cosmetics or similar cleaning supplies obtained from vegetable origin, for example, plant extracts) and A61K 36/00 (medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, for example, traditional herbal medicines). We found 180 patents, out of which 25 were evaluated using inclusion criteria as application of natural products with photoprotective or photoaging application. We found that some patents related to the cosmetic compositions for improving skin wrinkle and either preventing or reducing the signs of photoaging and sunburn. The cosmetic compositions are manufactured in the form of a lotion, gel, soluble liquid, cream, essence, oil-in-water-type or water-in-oil-type formulation, containing the vegetal extracts as an active ingredient.

Identification of the Key Fields and Their Key Technical Points of Oncology by Patent Analysis

PubMed Central

Zhang, Ting; Chen, Juan; Jia, Xiaofeng

2015-01-01

Background This paper aims to identify the key fields and their key technical points of oncology by patent analysis. Methodology/Principal Findings Patents of oncology applied from 2006 to 2012 were searched in the Thomson Innovation database. The key fields and their key technical points were determined by analyzing the Derwent Classification (DC) and the International Patent Classification (IPC), respectively. Patent applications in the top ten DC occupied 80% of all the patent applications of oncology, which were the ten fields of oncology to be analyzed. The number of patent applications in these ten fields of oncology was standardized based on patent applications of oncology from 2006 to 2012. For each field, standardization was conducted separately for each of the seven years (2006–2012) and the mean of the seven standardized values was calculated to reflect the relative amount of patent applications in that field; meanwhile, regression analysis using time (year) and the standardized values of patent applications in seven years (2006–2012) was conducted so as to evaluate the trend of patent applications in each field. Two-dimensional quadrant analysis, together with the professional knowledge of oncology, was taken into consideration in determining the key fields of oncology. The fields located in the quadrant with high relative amount or increasing trend of patent applications are identified as key ones. By using the same method, the key technical points in each key field were identified. Altogether 116,820 patents of oncology applied from 2006 to 2012 were retrieved, and four key fields with twenty-nine key technical points were identified, including “natural products and polymers” with nine key technical points, “fermentation industry” with twelve ones, “electrical medical equipment” with four ones, and “diagnosis, surgery” with four ones. Conclusions/Significance The results of this study could provide guidance on the development

Extending the market exclusivity of therapeutic antibodies through dosage patents

PubMed Central

Storz, Ulrich

2016-01-01

ABSTRACT Dosage patents are one way to extend the market exclusivity of an approved drug beyond the lifetime of the patent that protects the drug as such. Dosage patents may help to compensate the applicant for the long period where the active pharmaceutical ingredient as such is already under patent prosecution, but not on the market yet, due to lengthy development and approval procedures. This situation erodes part of the time the drug is marketed under patent protection. Dosage patents filed at a later date can provide remedy for this problem. Examples of successful and unsuccesful attempts, and the reasons for the respective outcomes, are provided in this article. PMID:27115842

Internet Patent Databases: Everyone Is a Patent Searcher Now.

ERIC Educational Resources Information Center

Wohrley, Andrew A.; Mitchell, Cindy

1997-01-01

Patent information has never been so available, at such low cost, to so many people. Describes patent databases accessible on the Web (Micropatent, Source Translation and Optimization Questel-Orbit QPAT, Internet Patents/Community of Science, and the U.S. Patent and Trademark Office), lists their strengths and weaknesses, and recommends the best…

Plant biotechnology patents: applications in agriculture and medicine.

PubMed

Hefferon, Kathleen

2010-06-01

Recent advances in agricultural biotechnology have enabled the field of plant biology to move forward in great leaps and bounds. In particular, recent breakthroughs in molecular biology, plant genomics and crop science have brought about a paradigm shift of thought regarding the manner by which plants can be utilized both in agriculture and in medicine. Besides the more well known improvements in agronomic traits of crops such as disease resistance and drought tolerance, plants can now be associated with topics as diverse as biofuel production, phytoremediation, the improvement of nutritional qualities in edible plants, the identification of compounds for medicinal purposes in plants and the use of plants as therapeutic protein production platforms. This diversification of plant science has been accompanied by the great abundance of new patents issued in these fields and, as many of these inventions approach commercial realization, the subsequent increase in agriculturally-based industries. While this review chapter is written primarily for plant scientists who have great interest in the new directions being taken with respect to applications in agricultural biotechnology, those in other disciplines, such as medical researchers, environmental scientists and engineers, may find significant value in reading this article as well. The review attempts to provide an overview of the most recent patents issued for plant biotechnology with respect to both agriculture and medicine. The chapter concludes with the proposal that the combined driving forces of climate change, as well as the ever increasing needs for clean energy and food security will play a pivotal role in leading the direction for applied plant biotechnology research in the future.

76 FR 66283 - Notice of Intent To Grant Partially Exclusive Patent License; BOLD Industries, Inc.

Federal Register 2010, 2011, 2012, 2013, 2014

2011-10-26

... Method for a Mobile Tracking Device.//U.S. Patent Application No. 20110036998 filed on August 14, 2009: Countermeasure Device for a Mobile Tracking Device.//U.S. Patent Application No. 20110113949 filed on May 12, 2010: Modulation Device for a Mobile Tracking Device.//U.S. Patent Application Serial No. 12/778,643...

78 FR 72064 - Request for Comments on Methods for Studying the Diversity of Patent Applicants

Federal Register 2010, 2011, 2012, 2013, 2014

2013-12-02

...] Request for Comments on Methods for Studying the Diversity of Patent Applicants AGENCY: United States... . SUPPLEMENTARY INFORMATION: Section 29 of the AIA charged the Director of the USPTO with ``establish[ing] methods... submit comments on any related issues that they believe are relevant. (1) How and by which methods should...

Impact of Gene Patents and Licensing Practices on Access to Genetic Testing for Cystic Fibrosis

PubMed Central

Chandrasekharan, Subhashini; Heaney, Christopher; James, Tamara; Conover, Chris; Cook-Deegan, Robert

2010-01-01

Cystic fibrosis (CF) is one of the most commonly tested autosomal recessive disorders in the US. Clinical CF is associated with mutations in the CFTR gene, of which the most common mutation among Caucasians, ΔF508, was identified in 1989. The University of Michigan, Johns Hopkins University, and the Hospital for Sick Children, where much of the initial research occurred, hold key patents for CF genetic sequences, mutations and methods for detecting them. Several patents including the one that covers detection of the ΔF508 mutation are jointly held by the University of Michigan and the Hospital for Sick Children in Toronto, with Michigan administering patent licensing in the US. The University of Michigan broadly licenses the ΔF508 patent for genetic testing with over 60 providers of genetic testing to date. Genetic testing is now used in newborn screening, diagnosis, and reproductive decisions. Interviews with key researchers and intellectual property managers, a survey of laboratories’ prices for CF genetic testing, a review of literature on CF tests’ cost effectiveness, and a review of the developing market for CF testing provide no evidence that patents have significantly hindered access to genetic tests for CF or prevented financially cost-effective screening. Current licensing practices for cystic fibrosis (CF) genetic testing appear to facilitate both academic research and commercial testing. More than one thousand different CFTR mutations have been identified, and research continues to determine their clinical significance. Patents have been nonexclusively licensed for diagnostic use, and have been variably licensed for gene transfer and other therapeutic applications. The Cystic Fibrosis Foundation has been engaged in licensing decisions, making CF a model of collaborative and cooperative patenting and licensing practice. PMID:20393308

Enhancing antibody patent protection using epitope mapping information

PubMed Central

Deng, Xiaoxiang; Storz, Ulrich; Doranz, Benjamin J.

2018-01-01

ABSTRACT As the $100B therapeutic monoclonal antibody (mAb) market continues to grow, developers of therapeutic mAbs increasingly face the need to strengthen patent protection of their products and enforce their patents in courts. In view of changes in the patent law landscape, patent applications are strategically using information on the precise binding sites of their mAbs, i.e., the epitopes, to support patent novelty, non-obviousness, subject matter, and a tightened written description requirement for broad genus antibody claims. Epitope data can also allow freedom-to-operate for second-generation mAbs by differentiation from patented first-generation mAbs. Numerous high profile court cases, including Amgen v. Sanofi over rival mAbs that block PCSK9 activity, have been centered on epitope mapping claims, highlighting the importance of epitopes in determining broad mAb patent rights. Based on these cases, epitope mapping claims must describe a sufficiently large number of mAbs that share an epitope, and each epitope must be described at amino acid resolution. Here, we review current best practices for the use of epitope information to overcome the increasing challenges of patenting mAbs, and how the quality, conformation, and resolution of epitope residue data can influence the breadth and strength of mAb patents. PMID:29120697

Identifying the trends in wound-healing patents for successful investment strategies

PubMed Central

Gwak, Jae Ha

2017-01-01

Background Recently, the need for rapid wound-healing has significantly increased because of the increasing number of patients who are diagnosed with diabetes and obesity. These conditions have contributed to a surge in the number of patients with chronic wounds worldwide. Furthermore, many cost-effective wound-healing technologies have been developed in order to keep up with the increased demand. In this paper, we performed a quantitative study of the trends associated with wound-healing technologies using patent data. Methodology We analyzed the trends considering four different groups of patent applicants: firms, universities, research institutes, and individuals using a structural topic model. In addition, we analyzed the knowledge flow between patent applicants using citation analysis, and confirmed the role of applicants in the knowledge-flow network using k-means clustering. As a result, the primary wound-healing technology patents applied for by the four groups varied considerably, and we classified the roles of patent applicants were found in the knowledge-flow network. Conclusions Our results showed the organizations that are leading each area of wound-healing technology. Furthermore, from the results, we identified specific institutions that are efficient for spreading knowledge related to wound-healing technology based on the patents. This information can contribute to the planning of investment strategies and technology policies related to wound-healing. PMID:28306732

Cystic Fibrosis Patents: A Case Study of Successful Licensing

PubMed Central

Minear, Mollie A.; Kapustij, Cristina; Boden, Kaeleen; Chandrasekharan, Subhashini; Cook-Deegan, Robert

2013-01-01

From 2006–2010, Duke University’s Center for Public Genomics prepared eight case studies examining the effects of gene patent licensing practices on clinical access to genetic testing for ten clinical conditions. One of these case studies focused on the successful licensing practices employed by the University of Michigan and the Hospital for Sick Children in Toronto for patents covering the CFTR gene and its ΔF508 mutation that causes a majority of cystic fibrosis cases. Since the licensing of these patents has not impeded clinical access to genetic testing, we sought to understand how this successful licensing model was developed and whether it might be applicable to other gene patents. We interviewed four key players who either were involved in the initial discussions regarding the structure of licensing or who have recently managed the licenses and collected related documents. Important features of the licensing planning process included thoughtful consideration of potential uses of the patent; anticipation of future scientific discoveries and technological advances; engagement of relevant stakeholders, including the Cystic Fibrosis Foundation; and using separate licenses for in-house diagnostics versus kit manufacture. These features led to the development of a licensing model that has not only allowed the patent holders to avoid the controversy that has plagued other gene patents, but has also allowed research, development of new therapeutics, and wide-spread dissemination of genetic testing for cystic fibrosis. Although this licensing model may not be applicable to all gene patents, it serves as a model in which gene patent licensing can successfully enable innovation, investment in therapeutics research, and protect intellectual property while respecting the needs of patients, scientists, and public health. PMID:24231943

The "real world" barriers and solutions to Candida vaccine patent prosecutions

PubMed Central

Wang, Shyh-Jen

2012-01-01

The US Patent and Trademark Office (USPTO) adopts recent patent courts’ opinions (such as KSR In re Fisher and Ariad v. Lilly) in patent examinations, which would certainly create barriers to biotech patent prosecution. To identify the barriers to Candida vaccine patent prosecution, we analyzed 99 US-granted patents from January 2001 to May 2012 related to Candida vaccines. The rejections were based on factors that included obviousness, novelty, indefiniteness, double patenting, enablement, written description and utility. Based on this investigation, we find that some of these rejections were actually avoidable, and then further provide workable solutions to avoid some of the barriers, especially those related to patentability. These principles recited in this study should also be applicable to other fields of vaccines and immunotherapeutics. PMID:22894949

Ethical questions to ponder in the European stem cell patent debate.

PubMed

Curley, Duncan; Sharples, Andrew

2006-01-01

Patents may be refused in Europe on ethical grounds. Whereas in the past this issue has arisen only infrequently, recent developments in human embryonic stem cell research have given rise to conflicting opinions in Europe as to the approach that should be adopted in relation to patents. The United Kingdom Patent Office has adopted a positive policy towards inventions involving human embryonic stem cells, but the European Patent Office has to date refused to grant patent applications involving similar subject-matter. A series of legal questions on the role of ethics in granting European patents is now to be considered for clarification by the European Patent Office. The answers to these questions should eventually resolve the debate on the patenting of human embryonic stem cells throughout Europe.

43 CFR 6.9 - Publication and public use of invention before patent application is filed.

Code of Federal Regulations, 2012 CFR

2012-10-01

... 43 Public Lands: Interior 1 2012-10-01 2011-10-01 true Publication and public use of invention before patent application is filed. 6.9 Section 6.9 Public Lands: Interior Office of the Secretary of the... report, to report forthwith to the Solicitor any publication or use (other than experimental) of an...

14 CFR 1214.204 - Patent and data rights.

Code of Federal Regulations, 2013 CFR

2013-01-01

... 14 Aeronautics and Space 5 2013-01-01 2013-01-01 false Patent and data rights. 1214.204 Section... Substantial Investment in the STS Program § 1214.204 Patent and data rights. (a) When accommodating missions under this subpart, i.e., experimental science or experimental applications missions for ESA, ESA member...

14 CFR 1214.204 - Patent and data rights.

Code of Federal Regulations, 2012 CFR

2012-01-01

... 14 Aeronautics and Space 5 2012-01-01 2012-01-01 false Patent and data rights. 1214.204 Section... Substantial Investment in the STS Program § 1214.204 Patent and data rights. (a) When accommodating missions under this subpart, i.e., experimental science or experimental applications missions for ESA, ESA member...

14 CFR 1214.204 - Patent and data rights.

Code of Federal Regulations, 2010 CFR

2010-01-01

... 14 Aeronautics and Space 5 2010-01-01 2010-01-01 false Patent and data rights. 1214.204 Section... Substantial Investment in the STS Program § 1214.204 Patent and data rights. (a) When accommodating missions under this subpart, i.e., experimental science or experimental applications missions for ESA, ESA member...

Patent review.

PubMed

Roy, Anuradha

2011-05-01

The section on patent review will be focused in the areas of interest to the readers of CCHTS. The search was conducted using the following key words: combinatorial chemistry, high throughput screening, drug repurposing, chemical library, high content screening, drug discovery and natural products. All patents highlighted here are identified by the patent number issued either by the World Intellectual Property Organization or by a regional patent office.

Patent review.

PubMed

Roy, Anuradha; McGee, James E

2011-08-01

The section on patent review will be focused in the areas of interest to the readers of CCHTS. The search was conducted using the following key words: combinatorial chemistry, high throughput screening, drug repurposing, chemical library, high content screening, drug discovery and natural products. All patents highlighted here are identified by the patent number issued either by the World Intellectual Property Organization or by a regional patent office.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 31)

NASA Technical Reports Server (NTRS)

1987-01-01

A subject index is provided for over 4600 patents and patent applications for the period May 1969 through June 1987. Additional indexes list personal authors, corporate authors, contract numbers, NASA case numbers, U.S. patent class numbers, and NASA accession numbers.

International patent analysis of water source heat pump based on orbit database

NASA Astrophysics Data System (ADS)

Li, Na

2018-02-01

Using orbit database, this paper analysed the international patents of water source heat pump (WSHP) industry with patent analysis methods such as analysis of publication tendency, geographical distribution, technology leaders and top assignees. It is found that the beginning of the 21st century is a period of rapid growth of the patent application of WSHP. Germany and the United States had done researches and development of WSHP in an early time, but now Japan and China have become important countries of patent applications. China has been developing faster and faster in recent years, but the patents are concentrated in universities and urgent to be transferred. Through an objective analysis, this paper aims to provide appropriate decision references for the development of domestic WSHP industry.

Recent Patents and Designs on Hip Replacement Prostheses

PubMed Central

Derar, H; Shahinpoor, M

2015-01-01

Hip replacement surgery has gone through tremendous evolution since the first procedure in 1840. In the past five decades the advances that have been made in technology, advanced and smart materials innovations, surgical techniques, robotic surgery and methods of fixations and sterilization, facilitated hip implants that undergo multiple design revolutions seeking the least problematic implants and a longer survivorship. Hip surgery has become a solution for many in need of hip joint remedy and replacement across the globe. Nevertheless, there are still long-term problems that are essential to search and resolve to find the optimum implant. This paper reviews several recent patents on hip replacement surgery. The patents present various designs of prostheses, different materials as well as methods of fixation. Each of the patents presents a new design as a solution to different issues ranging from the longevity of the hip prostheses to discomfort and inconvenience experienced by patients in the long-term. PMID:25893020

Whither ink jet? Current patent trends

NASA Astrophysics Data System (ADS)

Pond, Stephen F.; Karz, Robert S.

1995-04-01

The status and potential of ink jet technology is discernible in its major technical literature forum: worldwide patents. Most ink jet technical activity is focused in commercial research and development laboratories where proprietary considerations make patents the norm for publication. Currently there are about 2,000 ink jet disclosures issued annually with over 200 enterprises represented. Ink jet patent activity is increasing about 25% per year driven by a rapidly expanding base of products, applications, and revenue. An analysis of the ink jet patent literature reveals a few major themes (i.e. continuous ink jet, piezoelectric drop-on-demand, and thermal ink jet) and numerous minor ones (i.e. electrohydro-dynamic extraction, magnetic drop-on-demand, Hertz continuous, acoustic ink printing). Patents bear witness to transformations in the industry as dominant players of the 1970's have given way to new leaders in the 1990's. They also foretell important commercial developments in ink jet's near term future. When studied in aggregate, the patent record reveals patterns for the industry in general as well as for individual companies. It becomes possible to use the patent data base not only to identify technical approaches and problems for specific firms, but also to track progress and monitor changing strategies. In addition, international filing patterns can provide insights into industry priorities. This paper presents an overview of ink jet technology as revealed by the patent literature. It will include a 25 year perspective, a review of trends over the past five years, and a survey of today's most active companies and their technical approaches. With this analysis, it will be shown that the information inherent in the patent record is more than the sum of its individual disclosures. Indeed, by using it, we can outlook whither goes ink jet.

Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review.

PubMed

Dawalbhakta, Mitali; Telang, Manasi

2017-01-01

Saffron (Crocus sativus L.) has a long history of use as a food additive and a traditional medicine for treating a number of disorders. Prominent bioactives of saffron are crocin, crocetin and safranal. The aim of this study was to carry out an extensive patent search to collect information on saffron bioactives and their derivatives as therapeutic and cosmeceutical agents. All patents related to the area of interest published globally till date have been reviewed. Moreover, a recent synthetic biology approach to cost effective and consistent production of saffron bioactives has been highlighted. A patent search strategy was designed based on keywords and concepts related to Crocus sativus L. and its bioactives- safranal, crocin and crocetin in combination with different patent classification codes relevant to the technology areas. This search strategy was employed to retrieve patents from various patent databases. The patents which focused on therapeutic or cosmetic applications and claimed compositions comprising crocin, crocetin or safranal as the main active component were selected and analysed. Maximum patenting activity was noticed towards the use of these bioactives in the treatment of neurological disorders followed by multiple uses of the same compound, use in treatment of metabolic disorders and use as cosmeceuticals. Interestingly, there were no patent records related to use of these bioactives in treating infectious disorders. Our patent analysis points out the populous and less explored uses of saffron bioactives and areas where there is further scope for research and growth. Recently developed synthetic biology approach is contributory in improving availability, consistency and cost effectiveness of saffron bioactives. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Identification and Analysis of Technology Emergence Using Patent Classification

DTIC Science & Technology

2014-01-01

and legal time and capital. The desired payoff for this investment is monopolistic control of a section of the technology space, allowed by present...the claims of their application based on either the prior art cited by the patent examiner or economic reali- ties surrounding the markets for...have been developed, the claims of the patents have been tuned and tested at the respective patent office, and market -driven commercial realities may

Patent reform in the United States.

PubMed

Mills, Ann; Tereskerz, Patti

2010-01-01

The recent financial meltdown has muted the patent reform debate in the United States. But given that President Obama, as well as many members of Congress, support patent reform, we expect the debate to resurface. In this essay, we look carefully at reports from three prestigious organizations which have been enormously influential in the debate. We examine the empirical basis contained in these reports upon which proposed legislative changes are based. We conclude that the empirical data being used to justify the need for reform either has serious methodological limitations or is non-existent.  Moreover, we review recent court decisions which have already altered the patent environment calling into further question whether the limited data that exists is still applicable. The effect of these recent decisions has not been adequately evaluated or assessed. Thus, we recommend other empirical studies are needed to inform public policy as to whether patent reform is necessary.

[Response to US review rules on patent subject matter of traditional Chinese medicine compositions].

PubMed

Liu, Pan; Cao, Ya-di; Gong, Rui-Juan; Liu, Wei

2018-02-01

The United States Patent and Trademark Office(USPTO) issued Interim Guidance on Patent Subject Matter Eligibility on December 16， 2014， bringing certain effects to the review rules on patent application of Chinese medicine compositions. Based on the Interim Guidance， cases analysis was used in this paper to analyze the patent subject matter issues of traditional Chinese medicine compositions in the United States. The researches have shown that the application documents should be properly written in the United States when the patent for Chinese medicine compositions is applied， which can improve the probability of authorization. Copyright© by the Chinese Pharmaceutical Association.

NASA patent abstracts bibliography: A continuing bibliography. Section 2: Indexes (supplement 10)

NASA Technical Reports Server (NTRS)

1977-01-01

Abstracts for 3089 patents and applications for patent entered in the NASA scientific and information system for the period covering May 1969 through December 1976 are indexed by subject, inventor, source, NASA case or U.S. patent number, and accession number in the NASA system.

Are the Brookhill-Wilk patents impediments to market growth in cybersurgery?

PubMed

McLean, T R; Torrance, A W

2008-03-01

In the past, many surgeons could practise their craft with little or no knowledge of patent law. But in the world of robotic and computerized surgery, this is increasingly a myopic approach, because the principle means of protecting high-tech surgical instruments is through the application of patent law. The issue is: does the Brookhill-Wilk patent, which covers the performance of remote robotic surgery, impede the growth of cybersurgery? Review of the Brookhill-Wilk patent and relevant law. Patent law, which first took its form in the Middle Ages, attempts to balance the rewarding of innovation with the stifling of market growth. Using US patent law as a model, it would appear that the Brookhill-Wilk patent, a particular example of a medical process patent, could inhibit the growth of cybersurgery, as potential sums of money could be demanded by the patent holder from anyone who practises cybersurgery. However, two recent US Supreme Court cases appear to have seriously undermined the validity of a number of medical process patents, including the Brookhill-Wilk patent. Based on recent changes in patent law, it is not expected that Brookhill-Wilk patent will hinder the growth of cybersurgery.

Power Law Distributions of Patents as Indicators of Innovation

NASA Astrophysics Data System (ADS)

O'Neale, Dion; Hendy, Shaun

2013-03-01

The total number of patents produced by a country (or the number of patents produced per capita) is often used as an indicator for innovation. Such figures however give an overly simplistic measure of innovation within a country. Here we present evidence that the distribution of patents amongst applicants within many countries is well-fitted to a power law distribution with exponents that vary between 1.66 (Japan) and 2.37 (Poland). We suggest that this exponent is a useful new metric for studying innovation. Using simulations based on simple preferential attachment-type rules that generate power laws, we find we can explain some of the variation in exponents between countries, with countries that have larger numbers of patents per applicant generally exhibiting smaller exponents in both the simulated and actual data. Similarly we find that the exponents for most countries are inversely correlated with other indicators of innovation, such as research and development intensity or the ubiquity of export baskets. This suggests that in more advanced economies, which tend to have smaller values of the exponent, a greater proportion of the total number of patents are filed by large companies than in less advanced countries.

37 CFR 1.704 - Reduction of period of adjustment of patent term.

Code of Federal Regulations, 2013 CFR

2013-07-01

... TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Adjustment and Extension... patent office in a counterpart foreign or international application or from the Office, and this... 37 Patents, Trademarks, and Copyrights 1 2013-07-01 2013-07-01 false Reduction of period of...

37 CFR 1.704 - Reduction of period of adjustment of patent term.

Code of Federal Regulations, 2011 CFR

2011-07-01

... TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Adjustment and Extension... first cited in any communication from a foreign patent office in a counterpart application and that this... 37 Patents, Trademarks, and Copyrights 1 2011-07-01 2011-07-01 false Reduction of period of...

37 CFR 1.933 - Patent owner duty of disclosure in inter partes reexamination proceedings.

Code of Federal Regulations, 2010 CFR

2010-07-01

... UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Inter Partes Reexamination of Patents That Issued From an Original Application Filed in the United States on or After November 29, 1999 Information Disclosure in Inter Partes Reexamination § 1.933 Patent...

Bibliometric trend and patent analysis in nano-alloys research for period 2000-2013.

PubMed

Živković, Dragana; Niculović, Milica; Manasijević, Dragan; Minić, Duško; Ćosović, Vladan; Sibinović, Maja

2015-05-04

This paper presents an overview of current situation in nano-alloys investigations based on bibliometric and patent analysis. Bibliometric analysis data, for period from 2000 to September 2013, were obtained using Scopus database as selected index database, whereas analyzed parameters were: number of scientific papers per years, authors, countries, affiliations, subject areas and document types. Analysis of nano-alloys patents was done with specific database, using the International Patent Classification and Patent Scope for the period from 2003 to 2013 year. Information found in this database was the number of patents, patent classification by country, patent applicators, main inventors and pub date.

Bibliometric trend and patent analysis in nano-alloys research for period 2000-2013.

PubMed

Živković, Dragana; Niculović, Milica; Manasijević, Dragan; Minić, Duško; Ćosović, Vladan; Sibinović, Maja

2015-01-01

This paper presents an overview of current situation in nano-alloys investigations based on bibliometric and patent analysis. Bibliometric analysis data, for the period 2000 to 2013, were obtained using Scopus database as selected index database, whereas analyzed parameters were: number of scientific papers per year, authors, countries, affiliations, subject areas and document types. Analysis of nano-alloys patents was done with specific database, using the International Patent Classification and Patent Scope for the period 2003 to 2013. Information found in this database was the number of patents, patent classification by country, patent applicators, main inventors and publication date.

[A survey and analysis of Chinese patent medicine for outpatients with chronic kidney disease].

PubMed

Su, Guo-bin; Liu, Xu-sheng; Weng, Jun-xiong

2011-08-01

To investigate the current state of oral administration of Chinese patent medicine in treatment of chronic kidney disease (CKD) in the Westem medicine hospitals. Outpatients of Department of Nephropathy, Peking University Third Hospital with diagnosed CKD confirmed by CKD diagnosis standard were surveyed by questionnaire in May 2009. The following patients' information was collected using the Questionnaire of the Current State of Oral Administration of Chinese Patent Medicine at CKD Clinics. (1) The present symptoms, tongue figure, pulse figure were syndrome typed referring to The Diagnosis, Syndrome Typing, and Efficacy Assessment of Chronic Renal Failure 2006 by Chinese Society of Renal Diseases, Chinese Society of Traditional Chinese Medicine. (2) Names of Chinese patent medicines and Western medicines patients use presently, the dose and dosage, names of hospitals responsible for prescriptions. (3) Patients' basic diseases including diabetes, hypertension, hyperuricemia, and so on at present. Irrational applications of Chinese patent medicines were classified according to the drug instruction and Guiding Principle of Clinical Application of Chinese Patent Medicines (issued by State Administration of Traditional Chinese Medicine). The irrationality was analyzed. Correlated factors such as age, sex, deficiency in origin syndrome, sthenia in superficiality syndrome, the nature and grade of hospitals responsible for prescriptions, total numbers of Chinese patent medicines, and primary diseases, etc. were analyzed using Logistic regression model. These factors might result in irrational application of Chinese patent medicines. 102 questionnaires were handed out, with 78 effective ones. Of them, 41 patients (41/78, accounting for 52.6%) were taking Chinese patent medicines. Of the 41 patients, irrational application happened to 24 patients (24/41, accounting for 58.5%), absolute discrepancy of medicines and syndromes to 5 (5/41, accounting for 12.2%), repeated

Patent information retrieval: approaching a method and analysing nanotechnology patent collaborations.

PubMed

Ozcan, Sercan; Islam, Nazrul

2017-01-01

Many challenges still remain in the processing of explicit technological knowledge documents such as patents. Given the limitations and drawbacks of the existing approaches, this research sets out to develop an improved method for searching patent databases and extracting patent information to increase the efficiency and reliability of nanotechnology patent information retrieval process and to empirically analyse patent collaboration. A tech-mining method was applied and the subsequent analysis was performed using Thomson data analyser software. The findings show that nations such as Korea and Japan are highly collaborative in sharing technological knowledge across academic and corporate organisations within their national boundaries, and China presents, in some cases, a great illustration of effective patent collaboration and co-inventorship. This study also analyses key patent strengths by country, organisation and technology.

Bioengineered bugs, drugs and contentious issues in patenting

PubMed Central

2010-01-01

Bioengineered bugs, as is the scope of this journal, have great potential in various practical applications. A corollary to bringing useful products to the market is that such products need protection from copying by other people or businesses. Such government-sponsored protections are legally enforced through a patent, copyright or trademark/trade secret system commonly known as intellectual property rights. A condition for obtaining a patent is that the invention must not be disclosed to public either through seminars, informal public disclosures or publications in journals, although in the United States, there is a one year grace period that is allowed to obtain a patent after public disclosure. This article describes my personal experience in obtaining a patent in 1980 on a genetically manipulated bacterium designed for oil spill cleanup. This patent application went through a series of court cases that finally ended up in the Supreme Court of the United States. I also mention a similar contentious legal issue that is on the horizon and that the readers of Bioengineered Bugs should be aware of. Finally, I have taken the opportunity to describe my current efforts to bring to the market some unique potential multi-disease-targeting candidate drugs from Pseudomonas aeruginosa and gonococci/meningococci that, if found non-toxic and efficacious in humans, will revolutionize the drug industry. To ensure their marketability, we are trying to develop a patent portfolio that will ensure that they will be legally protected and such protections will be broad-based and enforceable. PMID:21327122

Regulation and the circulation of knowledge: penicillin patents in Spain.

PubMed

Romero de Pablos, Ana

2011-01-01

This paper tells the early history of penicillin patenting in Spain. Patents turn out to be useful instruments for analysing the management of knowledge and its circulation in different professional and geographical domains. They protected knowledge while contributing to standardisation. Patents also ensured quality and guaranteed reliability in manufacturing, delivering and prescribing new drugs. They gained special prominence by allowing the creation of a network in which political, economic and business, industrial power, public health and international cooperation fields came together. The main source of information used for this purpose has been the earliest patent applications for penicillin in Spain between 1948 and 1950, which are kept in the Historical Archives of the Oficina Española de Patentes y Marcas. The study of these patents for penicillin shows their role as agents in introducing this drug in Spain.

Relating patenting and peer-review publications: an extended perspective on the vascular health and risk management literature.

PubMed

Mucke, Hermann A M

2011-01-01

This investigation identifies patent applications published under the international Patent Convention Treaty between July 2010 and January 2011 in three significant fields of vascular risk management (arterial hypertension, atherosclerosis, and aneurysms) and investigates whether the inventors have also published peer reviewed papers directly describing their claimed invention. Out of only 48 patent documents that specifically addressed at least one of the above-mentioned fields, 15 had immediate companion papers of which 13 were published earlier than the corresponding patent applications; the majority of these papers were published by noncorporate patentees. Although the majority of patent applications (30 documents) had at least one corporate assignee, 18 came from academic environments. As expected, medical devices dominated in the aneurysm segment while pharmacology dominated hypertension and atherosclerosis. Although information related to hypertension, atherosclerosis, or aneurysms that was claimed in international patent applications reached the public quicker through the corresponding peer review document if one was published, more than two-thirds of the patent applications had no such companion paper in a scientific journal. The patent literature, which is freely available online as full text, offers information to scientists and developers in the fields of vascular risk management that is not available from the peer reviewed literature.

The International Patent Situation

ERIC Educational Resources Information Center

Helliwell, B. F. M.

1974-01-01

Highlights the differences in patent laws in different countries to illustrate the importance of searching foreign patents, indicates how patent searches should be tackled and what assistance is available from patent offices, searching organizations and commercial patent documentation services, and considers the probable effect of the Europatent…

Global Perspective for Protecting Intellectual Property - Patenting in USA and Poland

NASA Astrophysics Data System (ADS)

Grebski, Michalene Eva; Wolniak, Radosław

2018-06-01

Paper addresses the different methods for protecting intellectual property in modern knowledge-based economies. The focus of the paper is a comparison between the procedures for applying for patents in Poland and the United States. The comparison has been made from the perspective of the cost of obtaining and maintaining a patent in Poland, the United States and some other countries. The comparison has also been made from the perspective of the procedures for applying for a patent in different countries based on the Patent Cooperation Treaty. The paper also includes a comparison of the time needed for processing the patent application. Low cost provisional twelve-month patent pending protection available in the United States is also being discussed. The paper also provides some guidance and recommendations for conducting a patent search in order to validate the originality of the invention.

Teaching Chemistry Students How To Use Patent Databases and Glean Patent Information

NASA Astrophysics Data System (ADS)

MacMillan, Margy; Shaw, Lawton

2008-07-01

Patent literature is an important source of chemical information that is often neglected by chemical educators. This paper describes an effort to teach chemistry students how to use patent databases to search for information on applied chemical technology related to the manufacture of industrial and specialty chemicals. Students in a second-year-level organic chemistry class were shown how to search patent literature as part of a group research paper assignment that involved determining the feasibility of starting an industrial chemical operation to manufacture a given industrial chemical. Students who were assigned high value or specialty chemicals were most likely to cite patent literature in their final papers. Students who were assigned plastics or bulk commodity chemicals were less likely to cite patents. It is suggested that students made choices about the usefulness of patent literature and that patents were most useful when current patents existed and provided the patent owner a competitive advantage. For plastics or commodity chemicals, manufacturing technologies tend to be mature and are well described by more accessible information sources. Suggestions are made for effective introduction of patent literature instruction into upper-level chemistry courses.

Research-tool patents: issues for health in the developing world.

PubMed Central

Barton, John H.

2002-01-01

The patent system is now reaching into the tools of medical research, including gene sequences themselves. Many of the new patents can potentially preempt large areas of medical research and lay down legal barriers to the development of a broad category of products. Researchers must therefore consider redesigning their research to avoid use of patented techniques, or expending the effort to obtain licences from those who hold the patents. Even if total licence fees can be kept low, there are enormous negotiation costs, and one "hold-out" may be enough to lead to project cancellation. This is making it more difficult to conduct research within the developed world, and poses important questions for the future of medical research for the benefit of the developing world. Probably the most important implication for health in the developing world is the possible general slowing down and complication of medical research. To the extent that these patents do slow down research, they weaken the contribution of the global research community to the creation and application of medical technology for the benefit of developing nations. The patents may also complicate the granting of concessional prices to developing nations - for pharmaceutical firms that seek to offer a concessional price may have to negotiate arrangements with research-tool firms, which may lose royalties as a result. Three kinds of response are plausible. One is to develop a broad or global licence to permit the patented technologies to be used for important applications in the developing world. The second is to change technical patent law doctrines. Such changes could be implemented in developed and developing nations and could be quite helpful while remaining consistent with TRIPS. The third is to negotiate specific licence arrangements, under which specific research tools are used on an agreed basis for specific applications. These negotiations are difficult and expensive, requiring both scientific and

NASA patent abstracts bibliography: A continuing bibliography. Section 1: Abstracts (supplement 22)

NASA Technical Reports Server (NTRS)

1983-01-01

Entries for over 4000 patents and patent applications citations for the period May 1969 through December 1982 are listed. Subject, invention, source, number, and accession number indexes are included.

14 CFR § 1214.204 - Patent and data rights.

Code of Federal Regulations, 2014 CFR

2014-01-01

... 14 Aeronautics and Space 5 2014-01-01 2014-01-01 false Patent and data rights. § 1214.204 Section... Substantial Investment in the STS Program § 1214.204 Patent and data rights. (a) When accommodating missions under this subpart, i.e., experimental science or experimental applications missions for ESA, ESA member...

Annotated chemical patent corpus: a gold standard for text mining.

PubMed

Akhondi, Saber A; Klenner, Alexander G; Tyrchan, Christian; Manchala, Anil K; Boppana, Kiran; Lowe, Daniel; Zimmermann, Marc; Jagarlapudi, Sarma A R P; Sayle, Roger; Kors, Jan A; Muresan, Sorel

2014-01-01

Exploring the chemical and biological space covered by patent applications is crucial in early-stage medicinal chemistry activities. Patent analysis can provide understanding of compound prior art, novelty checking, validation of biological assays, and identification of new starting points for chemical exploration. Extracting chemical and biological entities from patents through manual extraction by expert curators can take substantial amount of time and resources. Text mining methods can help to ease this process. To validate the performance of such methods, a manually annotated patent corpus is essential. In this study we have produced a large gold standard chemical patent corpus. We developed annotation guidelines and selected 200 full patents from the World Intellectual Property Organization, United States Patent and Trademark Office, and European Patent Office. The patents were pre-annotated automatically and made available to four independent annotator groups each consisting of two to ten annotators. The annotators marked chemicals in different subclasses, diseases, targets, and modes of action. Spelling mistakes and spurious line break due to optical character recognition errors were also annotated. A subset of 47 patents was annotated by at least three annotator groups, from which harmonized annotations and inter-annotator agreement scores were derived. One group annotated the full set. The patent corpus includes 400,125 annotations for the full set and 36,537 annotations for the harmonized set. All patents and annotated entities are publicly available at www.biosemantics.org.

Annotated Chemical Patent Corpus: A Gold Standard for Text Mining

PubMed Central

Akhondi, Saber A.; Klenner, Alexander G.; Tyrchan, Christian; Manchala, Anil K.; Boppana, Kiran; Lowe, Daniel; Zimmermann, Marc; Jagarlapudi, Sarma A. R. P.; Sayle, Roger; Kors, Jan A.; Muresan, Sorel

2014-01-01

Exploring the chemical and biological space covered by patent applications is crucial in early-stage medicinal chemistry activities. Patent analysis can provide understanding of compound prior art, novelty checking, validation of biological assays, and identification of new starting points for chemical exploration. Extracting chemical and biological entities from patents through manual extraction by expert curators can take substantial amount of time and resources. Text mining methods can help to ease this process. To validate the performance of such methods, a manually annotated patent corpus is essential. In this study we have produced a large gold standard chemical patent corpus. We developed annotation guidelines and selected 200 full patents from the World Intellectual Property Organization, United States Patent and Trademark Office, and European Patent Office. The patents were pre-annotated automatically and made available to four independent annotator groups each consisting of two to ten annotators. The annotators marked chemicals in different subclasses, diseases, targets, and modes of action. Spelling mistakes and spurious line break due to optical character recognition errors were also annotated. A subset of 47 patents was annotated by at least three annotator groups, from which harmonized annotations and inter-annotator agreement scores were derived. One group annotated the full set. The patent corpus includes 400,125 annotations for the full set and 36,537 annotations for the harmonized set. All patents and annotated entities are publicly available at www.biosemantics.org. PMID:25268232

Recent advances in therapeutics and drug delivery for the treatment of inner ear diseases: a patent review (2011-2015).

PubMed

Nguyen, Kim; Kempfle, Judith S; Jung, David H; McKenna, Charles E

2017-02-01

Inner ear disorders such as hearing loss, tinnitus, and Ménière's disease significantly impact the quality of life of affected individuals. Treatment of such disorders is an ongoing challenge. Current clinical approaches relieve symptoms but do not fully restore hearing, and the search for more effective therapeutic methods represents an area of urgent current interest. Areas covered: Thirty four patents and patent applications published from 2011 to 2015 were selected from the database of the U.S. Patent and Trademark Office (USPTO) and World Intellectual Property Organization (WIPO), covering new approaches for the treatment of inner ear disorders described in the patent literature: 1) identification of new therapeutic agents, 2) development of sustained release formulations, and 3) medical devices that facilitate delivery of such agents to the inner ear. Expert opinion: The search for effective treatments of inner ear disorders is ongoing. Increased understanding of the molecular mechanisms of hearing loss, Ménière's disease, and tinnitus is driving development of new therapeutic agents. However, delivery of these agents to the inner ear is a continuing challenge. At present, combination of a suitable drug with an appropriate mode of drug delivery is the key focus of innovative research to cure inner ear disorders.

Design by Analogy: Achieving More Patentable Ideas from One Creative Design

NASA Astrophysics Data System (ADS)

Jia, Li-Zhen; Wu, Chun-Long; Zhu, Xue-Hong; Tan, Run-Hua

2018-12-01

A patent is a kind of technical document to protect intellectual property for individuals or enterprises. Patentable idea generation is a crucial step for patent application and analogy is confirmed to be an effective technique to inspire creative ideas. Analogy-based design usually starts from representation of an analogy source and is followed by the retrieval of appropriate analogs, mapping of design knowledge and adaptation of target solution. To diffuse one core idea into other new contexts and achieve more patentable ideas, this paper mainly centered on the first two stages of analogy-based design and proposed a patentable ideation framework. The analogical information of the source system, including source design problems and solution, was mined comprehensively through International Patent Classification analysis and represented in the form of function, behavior and structure. Three heuristics were suggested for searching the set of candidate target systems with a similar design problem, where the source design could be transferred. To systematize the process of source representation, analogs retrieval, idea transfer, and solution generation, an ideation model was put forward. Finally, the bladeless fan was selected as a source design to illustrate the application of this work. The design output shows that the representation and heuristics are beneficial, and this systematic ideation method can help the engineer or designer enhance creativity and discover more patentable opportunities.

Scope of claim coverage in patents of fufang Chinese herbal drugs: Substitution of ingredients

PubMed Central

2011-01-01

Herbal ingredients in a Chinese fufang prescription are often replaced by one or several other herbal combinations. As there have been very few Chinese herbal patent infringement cases, it is still unclear how the Doctrine of Equivalents should be applied to determine the scope of 'equivalents' in Chinese fufang prescriptions. Case law principles from cases in other technical areas such as chemical patents and biological drug patents can be borrowed to ascertain a precise scope of a fufang patent. This article summarizes and discusses several chemical and biopharmaceutical patent cases. In cases where a certain herbal ingredient is substituted by another herb or a combination of herbs, accused infringers are likely to relate herbal drug patents to chemical drug patents with strict interpretation whereas patent owners may take advantage of the liberal application of Doctrine of Equivalence in biopharmaceutical patents by analogizing the complex nature of herbal drugs with biological drugs. Therefore, consideration should be given to the purpose of an ingredient in a patent, the qualities when combined with the other ingredients and the intended function. The scope of equivalents also depends on the stage of the prior art. Moreover, it is desirable to disclose any potential substitutes when drafting the application. Claims should be drafted in such a way that all foreseeable modifications are encompassed for the protection of the patent owner's intellectual property. PMID:21854570

Scope of claim coverage in patents of fufang Chinese herbal drugs: Substitution of ingredients.

PubMed

Wang, Xinsheng; Tian, Jiaher; Chan, Albert Wai-Kit

2011-08-19

Herbal ingredients in a Chinese fufang prescription are often replaced by one or several other herbal combinations. As there have been very few Chinese herbal patent infringement cases, it is still unclear how the Doctrine of Equivalents should be applied to determine the scope of 'equivalents' in Chinese fufang prescriptions. Case law principles from cases in other technical areas such as chemical patents and biological drug patents can be borrowed to ascertain a precise scope of a fufang patent. This article summarizes and discusses several chemical and biopharmaceutical patent cases. In cases where a certain herbal ingredient is substituted by another herb or a combination of herbs, accused infringers are likely to relate herbal drug patents to chemical drug patents with strict interpretation whereas patent owners may take advantage of the liberal application of Doctrine of Equivalence in biopharmaceutical patents by analogizing the complex nature of herbal drugs with biological drugs. Therefore, consideration should be given to the purpose of an ingredient in a patent, the qualities when combined with the other ingredients and the intended function. The scope of equivalents also depends on the stage of the prior art. Moreover, it is desirable to disclose any potential substitutes when drafting the application. Claims should be drafted in such a way that all foreseeable modifications are encompassed for the protection of the patent owner's intellectual property.

Recently Patented Viral Nucleotide Sequences and Generation of Virus-Derived Vaccines.

PubMed

Venkataraman, Srividhya; Ahmad, Tauqeer; Haidar, Mounir A; Hefferon, Kathleen L

2017-01-01

With an increase in comprehension of the molecular biology of viruses, there has been a recent surge in the application of virus sequences and viral gene expression strategies towards the diagnosis and treatment of diseases. The scope of the patenting landscape has widened as a result and the current review discusses patents pertaining to live / attenuated viral vaccines. The vaccines addressed here have been developed by both conventional means as well as by the state-of-the-art genetic engineering techniques. This review also addresses the applications of these patents for clinical and biotechnological purposes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

The patentability of living organisms between science, law and ethics.

PubMed

Frati, L; Foà, R; Frati, P

1999-01-01

The approval on May 1998 of the European Union (EU) directive on the legal protection of biotechnological inventions has aligned Europe to the international trend about the patenting of biotechnologies. Many questions are still unresolved, i.e. the differences between the article 53b of the European Patent Convention (EPC), which prohibits patenting of plants and animal varieties, whereas the directive states that Oinvention whose object are plants or animals may be patented if the practicability of the invention is not technically confined to a particular plant or animal varietyO (article 12). Again, the interpretation of plants or animal species specificity and that on the threatening public order and morality (which inhibits patenting) may have doubtful interpretations, according to the different EU States morality and law (e.g. Denmark does not admit patentability of transgenic animals). Despite difficulties, biotechnology Research and Development for applications to medicine, veterinary sciences, agriculture and foods is continuously growing. Bioethical independent evaluations of the applications of biotechnologies and of their side-effects (risk for biodiversity of plants and animals, safety of procedures to save mankind, respect of human dignity and of fundamental human rights, etc.) are mandatory to link the interests of science and industrial productions together with those of mankind. This is the original meaning given by van Potter to the word bioethics, as a bridge to the future.

75 FR 55576 - Intent To Grant Field of Use Exclusive License to U.S. Government-Owned Patents

Federal Register 2010, 2011, 2012, 2013, 2014

2010-09-13

... grant a field of use exclusive, revocable license for the field of prevention and/or therapeutic... patents and patent applications (PCT/ US2001/04520) to Biofactura, Inc., with its principal place of..., Office of Research and Technology Applications (ORTA), (301) 619-6664. For patent issues, Ms. Elizabeth...

Connecting NSF funding to patent innovation in nanotechnology (2001-2004)

NASA Astrophysics Data System (ADS)

Huang, Zan; Chen, Hsinchun; Li, Xin; Roco, Mihail C.

2006-12-01

Nanotechnology research has experienced growth rapid in knowledge and innovations; it also attracted significant public funding in recent years. Several countries have recognized nanotechnology as a critical research domain that promises to revolutionize a wide range of fields of applications. In this paper, we present an analysis of the funding for nanoscale science and engineering (NSE) at the National Science Foundation (NSF) and its implications on technological innovation (number of patents) in this field from 2001 to 2004. Using a combination of basic bibliometric analysis and content visualization tools, we identify growth trends, research topic distribution, and the evolution in NSF funding and commercial patenting activities recorded at the United States Patent Office (USPTO). The patent citations are used to compare the impact of the NSF-funded research on nanotechnology development with research supported by other sources in the United States and abroad. The analysis shows that the NSF-funded researchers and patents authored by them have significantly higher impact based on patent citation measures in the four-year period than other comparison groups. The NSF-authored patent impact is growing faster with the lifetime of a patent, indicating the long-term importance of fundamental research.

Obstacles to prior art searching by the trilateral patent offices: empirical evidence from International Search Reports.

PubMed

Wada, Tetsuo

Despite many empirical studies having been carried out on examiner patent citations, few have scrutinized the obstacles to prior art searching when adding patent citations during patent prosecution at patent offices. This analysis takes advantage of the longitudinal gap between an International Search Report (ISR) as required by the Patent Cooperation Treaty (PCT) and subsequent national examination procedures. We investigate whether several kinds of distance actually affect the probability that prior art is detected at the time of an ISR; this occurs much earlier than in national phase examinations. Based on triadic PCT applications between 2002 and 2005 for the trilateral patent offices (the European Patent Office, the US Patent and Trademark Office, and the Japan Patent Office) and their family-level citations made by the trilateral offices, we find evidence that geographical distance negatively affects the probability of capture of prior patents in an ISR. In addition, the technological complexity of an application negatively affects the probability of capture, whereas the volume of forward citations of prior art affects it positively. These results demonstrate the presence of obstacles to searching at patent offices, and suggest ways to design work sharing by patent offices, such that the duplication of search costs arises only when patent office search horizons overlap.